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Resumo 
 
Nos últimos anos têm sido desenvolvidas várias ferramentas para permitir o controlo de 
neurónios específicos, possibilitando o estudo da sua função. Estas novas ferramentas superam a 
falta de selectividade e o fraco controlo temporal proveniente do uso de estimulação eléctrica 
no  controlo de actividade neuronal. 
A optogenética refere-se á integração de óptica e genética para obter um ganho ou 
perda de função em eventos bem definidos dentro de células específicas em tecido vivo. A 
capacidade de “ligar” e “desligar” neurónios utilizando luz é de facto uma tecnologia inovadora 
que oferece uma solução para limitações passadas. A optogenética, considerada por vários 
especialistas como ‘’método do ano’’ e ‘’inovação da década’’, em 2010, é utilizada para 
hiperpolarizar ou despolarizar neurónios alvo, de uma forma menos invasiva, utilizando luz e 
usufruindo de uma alta resolução espacial e escala temporal na ordem dos milissegundos. Esta 
técnica tem permitido o mapeamento e estudo de redes neuronais com uma grande eficácia. 
A ‘’Channelrhodopsin-2’’ (ChR2) é um canal catiónico sensível à luz, derivado da 
microalga Chlamydomonas reinhardtii. Na última década, a ChR2 tornou-se o arquétipo central e 
a principal ferramenta da optogenética.  Actualmente, a caixa de ferramentas optogenética está 
em contínua actualização, com contribuições de estratégias de engenharia protéica, tais como 
mutagénese dirigida e a construção de quimeras com troca de domínios de diferentes espécies 
de channelrhodopsin. No entanto, alguns aspectos da forma ‘’wild-type’’ da ChR2 ainda 
requerem atenção e melhoramento. Estes incluem o seu espectro de acção, cinética, níveis de 
expressão, inactivação, condutância e exactidão de pico de absorção. Em termos de 
propriedades espectrais, poucas variantes desta proteína têm sido geradas e completamente 
caracterizadas com sucesso. No entanto, o aprimorar do espectro de activação da ChR2 e do 
formato do respectivo pico de absorção são algumas das propriedades mais desejadas. 
A ChR2 é excitada preferencialmente com comprimentos de onda de luz azul (470nm), 
o que limita o seu uso em material biológico de alta taxa de difusão, tal como o cérebro. Luz de 
excitação com maiores comprimentos de onda diminui a difusão de luz produzida por tecidos 
biológicos, e não é absorvida pela hemoglobina, assim, formas da ChR2 ‘’red-shifted’’, a absorver 
luz vermelha ou mesmo perto de infravermelha, são ferramentas desejáveis para a excitação de 
tecidos profundos. 
Alem disto, variantes ‘’blue-shifted’’ são também ferramentas atrativas para desenvolver, 
	   XXI	  
dado que a combinação de várias ChR2 que apresentem sensibilidades a diversos comprimentos 
de onda permitiriam a estimulação de diferentes populações neuronais sem interferência entre 
si. 
Neste projecto, realizámos um desenho ab-initio para produzir quatro novas variantes de 
ChR2, usando uma abordagem de mutagénese dirigida no ambiente do cromófero da ChR2 
alterando de forma radical os resíduos alvo. As mutações foram selecionadas com a aplicação de 
Time Dependent – Density Functional Theory (TDDFT) para prever o espectro de absorção dos 
mutantes selecionados da ChR2. O ‘’colour tuning’’ da ChR2 foi alcançado em quatro novas 
variantes criadas. Em particular, fomos capazes de gerar três variantes ‘’red-shifted’’ e uma 
‘’blue-shifted’’. Após caracterização espectral, as variantes F217D e F269D apresentaram um 
‘’red-shift’’ significativo de 90nm, a variante L221D apresentou um ‘’red-shift’’ de 180nm, a 
variante F269H apresentou um ‘’blue-shift’’ de 20nm. Apesar dos nossos resultados, é 
necessária uma caracterização protéica adicional, tal como a avaliação do tráfego membranar em 
neurónios e as características electrofisiológicas destes novos mutantes para determinar as 
proriedades cinéticas do canal. 
Neste trabalho, também conseguimos definir e descrever com sucesso a expressão e 
purificação da ChR2 ‘’wild-type’’ e de todas as quatro novas variantes no sistema eucariótico de 
expressão heteróloga - Pichia pastoris. Por fim, o nosso estudo valida as previsões de Time-
Dependent Density Functional Theory e revela que abordagens de simulação biofísica podem 
ser utilizadas com vista à criação de variantes de ChR2 inteligentemente desenhadas. 
O desenho de novas variantes ChR2, seguindo a lógica racional aplicada, é uma 
abordagem poderosa e fiável para obter proteínas optimizadas para estratégias biotecnológicas. 
Os resultados originais obtidos com este trabalho demonstram potential para aplicações futuras, 
já que novas e melhoradas variantes de ChR2 continuarão a desempenhar um papel central no 
desenvolvimento e implementação da optogenética. 
 
Palavras-chave: Optogenética; channelrhodopsin-2; ‘’red-shift’’; ‘’blue-shift’’; TDDFT; Pichia 
pastoris 
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Abstract 
 
Over the last few years, several tools have been developed to allow the control over 
specific types of neuron to enable the study of their function. These novel tools aim to 
overcome the lack of selectivity and the poor temporal control that derives from trying to 
control neuronal activity with electrical stimulation. 
 Optogenetics refers to the integration of optics and genetics to obtain gain or loss of 
function in well-defined events and within specific cells in living tissue. The capacity to turn 
neurons “on and off” using light is indeed a groundbreaking technology that has become a 
solution for past limitations. Considered by many, “method of the year” and “breakthrough of 
the decade”, in 2010, optogenetics is used to hyperpolarize or depolarize specific targeted 
neurons using light in a less invasive manner, with high spatial resolution and a temporal 
resolution on the scale of milliseconds. This technique has allowed the mapping and study of 
neuronal networks with demonstrated efficacy. 
Channelrhodopsin-2 (ChR2) is a light-gated cation channel, derived from the microalga 
Chlamydomonas reinhardtii. In the last decade, ChR2 has become the central archetype and the 
main tool of optogenetics. Presently, the optogenetic toolbox is under continuous update, with 
contributions from protein engineering strategies, such as site-directed mutagenesis and 
construction of chimeras with domain swaps between channelrhodopsins of different species. 
However, some aspects of the wild-type form of ChR2 still require attention and enhancement. 
These include its action spectra, kinetics, expression levels, inactivation, conductance and 
absorption peak sharpness. In terms of spectral properties, few variants of this protein have 
been successfully generated and fully characterized. Nevertheless, tuning of ChR2 activation 
spectra and absorption peak sharpness are one of the most sought after properties. 
ChR2 is optimally excitable at a wavelength of blue light (470nm), which limits its use in 
high light-scattering biologic material, such as the brain. However, long-wavelength excitation 
light decreases the scattering of light produced by biological tissues and is not absorbed by 
haemoglobin. Thus, a red-shifted form of ChR2, absorbing red or even near infrared light would 
be a desirable tool for the excitation of relatively deep tissues. 
Furthermore, blue-shifted variants would also be attractive tools to develop, since the 
combination of ChR2 proteins with well separate wavelength sensitivities, combined with multi-
coloured optics, would permit the stimulation of different neuronal populations with no 
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interference between them. 
In this project, we performed ab-initio design to produce four new ChR2 variants, using a 
radical site-directed mutagenesis approach on target residues in the environment of the ChR2 
chromophore. The mutations were selected with the application of Time Dependent – Density 
Functional Theory (TDDFT) to predict the absorption spectra of ChR2 selected mutants. We 
achieved successful colour tuning of ChR2 with our four newly created variants. In particular, 
we were able to generate three red-shifted and one blue–shifted variant. After spectral 
characterization, the F217D and F269D variants presented a significant 90nm red shift, the 
L221D variant had a 180nm red shift and the F269H variant presented a 20nm blue shift. 
Despite our results, additional protein characterization is needed, such as the assessment of 
membrane trafficking in neurons and an electrophysiological characterization to determine 
channel kinetic proprieties for each of the variants. 
In this work, we were also able to define and describe the successful expression and 
purification of wild type ChR2 and of all the new four variants using the eukaryotic Pichia pastoris 
heterologous expression system. Finally, our study validates Time-Dependent Density 
Functional Theory predictions and reveals that biophysical simulation approaches may be used 
towards the creation of intelligently designed ChR2 variants. 
The design of new ChR2 variants, following our applied rationale, is a powerful and 
reliable approach to obtain enhanced proteins for biotechnological strategies. The original 
output obtained here shows potential for future optogenetic application, as new and improved 
ChR2 variants will continue to play a central role in the development and implementation of 
optogenetics. 
 
 
Keywords: Optogenetics; channelrhodopsin-2; red-shift; blue-shift; TDDFT; Pichia pastoris 
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1.1 – The history of Optogenetics   
 
In 1979, Francis Crick claimed that to study the brain, it would be invaluable to have 
“…a method by which all neurons of just one type could be inactivated, leaving the others more or less 
unaltered” (Crick, 1979) . Since Galvani in the eighteenth century, electrical stimulation has been 
widely used by the scientific community to study tissue and brain activity in regards to 
behavioral outputs. However, it is not possible to do so selectively, since direct electrical 
stimulation unspecifically activates all cells near the insertion site of the device. Furthermore, 
these approaches have other restrictions, such as the inability to hyperpolarize neuron to 
induce silencing (Deisseroth, 2010). Therefore, precise and specific control over the activity of 
neurons submerged in the heterogeneous environment of the brain is a major goal in 
neuroscience.  
It took more than three decades to “invent” Francis Crick’s “method” and to solve the 
issue of selective stimulation of neurons. The technique itself became widespread after Karl 
Deisseroth and his group published seminal papers introducing ‘optogenetics’ (Boyden et al., 
2005; Deisseroth et al., 2006). This new method allowed the manipulation of a specific cells 
using light (‘opto’) after the introduction of an exogenous protein in neurons, (e.g. 
Channelrhodopsin-2), while controlling its expression with the use of specific promoters 
(‘genetic’). Although the term ‘optogenetics’ was created to describe the technique in a way that 
could be easily understood and readily used by the research community (Miesenböck, 2011), it 
should be considered carefully, as this technique itself does not generally involve the direct 
interaction between light and the actual genome (Miesenböck, 2009) – even though this is 
currently also a possibility. More strictly, optogenetics refers to the combination of optics and 
genetic approaches to obtain gain or loss of function for well-defined events within specific cells 
of living tissue, to allow a better understanding of biological systems (Deisseroth et al., 2006; 
Miesenböck e Kevrekidis, 2005). Commonly, optogenetic proteins fall in the category of - 
sensors - such as the Green Fluorescent Protein (GFP) or - actuators - such as 
Channelrhodpsin-2 (ChR2) 
The original aspects and theoretical backdrop for optogenetics started in the 1970s, 
when it was acknowledged that light could be a suitable tool to control neuronal activity - much 
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like what happens in the retina. Neverhteless, no specific knowledge on how to turn cells 
responsive to light was available at the time (Crick, 1979). The experimental implementation of 
optogenetics materialized with the prospect of introducing the relatively simple invertebrate 
photoreceptor siganlling cascade into non-photon sensitive neurons (Zemelman et al., 2002). 
This technique – chARGe – involves the transduction of the Drosophila cascade of 
photoreceptor genes formed by arrestin-2, rhodopsin and the alpha-subunit of G protein 
(Zemelman et al., 2002). However, this approach has several limitations, such as the delay in 
activating target neurons and the variability and complexity involved in recrating a three-protein 
pathway. Therefore, an ideal technique would involve rapid photoactivation, precise temporal 
control, high spatial resolution and simple genetic targetability.  A central aspect towards this 
was the the work performed by microbiologists focusing on understanding the phototaxic 
behavior of algae (Deisseroth, 2011).  The studies performed to purify, identify and clone 
several members of the light-sensitive protein family of rhodopsins was a key aspect in the 
discovery of the tools best suited for optogenetic applications.  
Rhodopsins are membrane proteins from the opsin protein family that are responsible 
for the transduction of light stimulation. One of the best characterized member of this family is 
the Bacteriorhodopsin protein, a single–component ion pump (Oesterhelt e Stoeckenius, 1971), 
and Halorhodopsin, a light-gated chloride pump (Bogomolni e Spudich, 1982; Crick, 1979; Kolbe 
et al., 2000; Matsuno-Yagi e Mukohata, 1977; Schobert e Lanyi, 1982). These two proteins 
Bacteriorhodopsin and Halorhosopsin are the prototypical examples of the rhodopsins largely 
used in optogenetic applications.  
Georg Nagel and collegues, using kidney cell lines first demonstrated that ChR2 was a 
light responsive ion channel (kidney cell lines (HEK293 and BHK)) capable of inducing 
photocurrents (Nagel et al., 2003). Deisseroth and collegues followed up on this study and 
highlighted the possibility of using this tool to control complex neuronal circuits (Boyden et al., 
2005). Neurons are naturally excitable cells with the capacity to respond to changes in 
membrane potential and it was expected that the same molecular instruments that were used 
to change the membrane potential in kidney cell lines, could also be applied to mediate action 
potential activation in neurons or in other types of excitable cells (Palczewski, 2006).  
Nowadays, in a more simple way, it is possible to state that optogenetics uses light 
sensitive proteins that are used to stimulate or to identify neuronal activity when exposed to 
specific wavelengths of light (Deisseroth, 2011). The genetic code of the optically sensitive 
protein is added to the genetic material of a specific type of neuron to make it responsive to 
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light (Lin et al., 2009), thus allowing manipulation of neural activity (Pashaie et al., 2014). 
Exposure to one color, or wavelength, activates the genetically modified cell (Figure 1). This 
procedure is non-invasive and has the advantage of having reduced fatigue and lower tissue 
damage when compared to microelectrode stimulation (Li et al., 2011; Llewellyn et al., 2010). It 
also provides both higher accuracy and precision along with the high speed and targeting 
capabilities that are achieved using molecular genetic techniques (Deisseroth, 2011). Another 
key feature is the ability to affect, with an unparalleled precision, specific neurons at a specific 
time. For these reasons, optogenetics technology has been considered ‘Breakthrough of the 
Decade’ by Science (The News Staff, 2010) and ‘Method of the Year 2010’ by Nature Methods 
(Nat Meth, 2010).  
Nowadays, optogenetics is being used across several fields, such as in neurodegenerative 
brain disorders like Parkinson’s disease (Vazey e Aston-Jones, 2013), in understanding the 
functional analysis of stem-cell derived grafts (Steinbeck et al., 2015) and also as a promising 
future treatment for seizures (Wykes et al., 2012) and blindness (Roska et al., 2013). 
 
 
 
Figure 1 – Electric neural stimulation vs. Optogenetics.	  Electrical stimulation of neurons using 
electrodes, assuming that an electric field radiates outwardly in a uniform sphere any neuron or network within 
that sphere is unspecifically stimulated, including axonal fibers of passage. Optogenetic stimulation (e.g. for ChR2) 
or optogenetic inhibition (e.g. with Halorhodopsin), with specific wavelengths, presents specific and highly accurate 
mechanism for neuronal stimulation and inhibition. Adapted from (Deisseroth, 2011). 
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1.2 - The opsin family 
 
Over time, evolution led organisms to develop the capability to perceive and respond to 
light. More than a century of scientific studies have focused on light sensitivity and how it 
regulate the behavior of organisms in reaction to light (Holmes, 1911). Light can affect single cell 
organisms (e.g. algae) as well as complex organisms like mammals. The perception of light allows 
entire range of organisms to react to environmental signals and to adapt their own behavioral 
responses. The cornestone of photodetection is normally supported throught the absorption of 
light by biomolecules such as chromophore.  
Opsins belong to the retinylidene protein family and are one of the most studied, 
abundant and conserved protein families involved in this process. This family of light sensitive 
membrane receptors is characterized by its seven transmembrane helix structure (7TM) that 
features an internal pocket where a covalently linked retinal residue (vitamin-A aldehyde) works 
as a chromophore. The molecular complex of opsin bound to retinal is known as rhodopsin. 
Most known opsin genes come from bacterial or algal genomes, where they accomplish their 
roles as light-activated membrane ion channels.  
Different members of opsins exist in prokaryotic and eukaryotic organisms. Therefore, 
the protein family can be divided into two large groups that share a certain degree of sequence 
homology. These two groups are type I opsins (microbial opsins) and type II opsins (animal 
opsins).  
Type I opsins genes are expressed in prokaryotes, algae and funghi, and are responsible 
for distinctive functions such as energy storage, phototaxis and retinal biosynthesis (Spudich, 
2006). Type I rhodopsins directly affect the cell or organelle membrane potential acting as direct 
light-gated channels.  Type II opsins are primarily present in higher organisms; in humans, they 
are responsible for visual perception in a specialized subset of retina cells (Shichida e Yamashita, 
2003). They also seem to be involved in processes like the circadian rhythm and pigment 
regulation (Hattar et al., 2003; Terakita, 2005), detection of ambient light, season adaptation and 
phototaxis.  Type II proteins indirectly influence transmembrane ion current throught coupling 
to G-protein based signal transduction pathways. This is a key difference between type I and II 
rhodopsins; type I proteins are not coupled to G-protein based signal transduction pathway but 
include in their structure direct-light-activated regulators of transmembrane ion conductance, 
such as the light-driven ion pumps or light-driven ion channels. The different types of microbial 
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rhodopsins will be analyzed later in this chapter. Retinal-binding proteins are the most effective 
light switches that have been used so far in optogenetics (Nogly e Standfuss, 2015).  
The binding of retinal is one of the significant differences among type I and type II opsins. 
Type I opsin genes encode for proteins that use retinal in all-trans configuration, after photon 
absorption, retinal changes its conformation to a 13-cis configuration. Following activation, 
retinal returns to the all-trans state without dissociation from the protein.  
On the other hand, type II opsin genes encode for G-protein coupled membrane 
receptors and retinal binding occurs in 11-cis state (Figure 2). With isomerization, retinal 
returns to the all-trans form resulting in changes to protein structure, allowing the initiation of a 
transducing cascade. This process results from conformation changes that allow protein-protein 
connections with their downstream protein, transducin. 
 
 
Figure 2 – Opsins structure.	  Chemical structure of different processes of isomerization between type I 
and type II opsin. In type I, light induction enables conformation of all-trans retinal to 13-cis retinal. In type II, 
protein chromophore conformation changes from 11-cis retinal to the general form all-trans retinal. Adapted from 
(Zhang et al., 2011). 
 
The light-driven proton pump bacteriorhodopsin is the best studied example of type I 
rhodopsins, and it provides a central reference for the study of other proteins in this class 
(Wickstrand et al., 2015). In this case, light induces the isomerization of retinal from the all-trans 
to the 13-cis conformation, leading to the translocation of protons from the protonated Schiff 
base link to a hydrophilic pathway further across the proteins. In contrast, in a hyperpolarization 
protein like halorhodopsin, the inward transport of the negatively charged chloride is enabled by 
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stabilization of the positively charged protonated Schiff base, and retinal isomerization promotes 
its translocation along the hydrophilic path. This difference in the isomerization processes 
results in a difference in the mechanism through which the two types of rhodopsins induce 
downstream signaling (Figure 3).   
 
 
Figure 3 – Single-component optogenetics tool families.	  Illustrations of some members of type 
I and type II opsins with respective transported ions and signalling pathways indicated. Bacteriorhodopsin (BR), the 
haloarchaeal proton pump, was the first rhodopsin to be identified and the best studied type I protein. Its function 
is related to low-oxygen conditions, where BR is highly expressed in haloarchaeal membranes, and acts as part of 
an alternative energy production system, pumping protons from the cytoplasm to the extracellular medium to 
generate a proton-motive force to drive ATP synthesis. Halorhodopsin (HR) is a light-activated chloride pump. In 
contrast to BR, halorhodopsin (HR) direction of transport is done from the extracellular to the intercellular space. 
Channelrhodopsin (ChR) is a channel that conducts cations across the membrane along with the electrochemical 
gradient. The effective cation channel pore is opened, implying that an ion flux turns independently of retinal 
isomerization and rather depending on the kinetics of channel closure. OptoXR is a type II opsin, derived from 
protein chimera and used to hijack common signalling pathways, providing a precise control through light 
manipulation. G proteins, such as endocannabinoid and dopaminergic receptors, can be paired with optoXRs, 
simplifying the casual impact of intracellular signalling in the brain. Adapted from (Yizhar et al., 2011). 
 
1.3 Microbial rhodopsins 
 
Bacteriorhodopsin (BR) was the first characterized microbial rhodopsin after being 
identified in the archeon Halobacterium salinarum (Oesterhelt e Stoeckenius, 1971). BR pumps 
one proton out of the cell per photocycle and the resulting electrochemical gradient is used to 
	   9	  
drive the synthesis of ATP. This protein is a light-activated pump specialized in proton 
translocation from intercellular to extracellular cellular environment, and in maintaining a 
proton gradient across the membrane and, therefore, ATP synthesis and energy recovery in 
adverse conditions (e.g. low-oxygen) (Michel e Oesterhelt, 1976). For instance, using Xenopus 
laevis oocytes, it was possible to characterize the light induced photocurrent of this rhodopsin 
pump using a voltage-clamp technique (Nagel et al., 1995). Bacteriorhodopsin transition states 
during retinal isomerization were also analyzed by real-time spectroscopy (Kobayashi, Saito e 
Ohtani, 2001). Bacteriorhodopsin research was crucial to the development of better tools for 
optogenetics and it remains a focus of interest.  
Subsequent to bacteriorhodopsin, other rhodopsins were found and characterized in 
Halobacterium salinarum, these include halorhodopsin (HR) (Matsuno-Yagi e Mukohata, 1977) 
and sensory rhodopsin (Bogomolni e Spudich, 1982; Wolff et al., 1986). Halorhodopsin is an 
inward-directed chloride pump with the ability to hyperpolarize the cell membrane first 
discovered in archaebacteria. This protein can be used to silence neuronal activity in response 
to yellow light. The operating principles of halorhodopsin are similar to those of 
bacteriorhodopsin (Essen, 2002); nonetheless, halorhodopsin pumps chloride ions and the 
direction of transport is from the extracellular to the intracellular space (Schobert e Lanyi, 
1982). Consistently, specific amino acid residues have been shown to underlie the differences 
between halorhodopsin and bacterirhodopsin in directionality and preferred cargo ion (Sasaki et 
al., 1995). Sensory rhodopsins are involved in phototaxis, the capability of the organism to sense 
changes in the intensity of light and are responsible for the response to different wavelengths, 
thus enabling movement towards or away from light (Ruiz-González e Marín, 2004; Spudich et 
al., 2000; Spudich e Luecke, 2002).  
Several studies focusing the rhodopsins have generated a substantial understanding on 
the mechanisms controlling the activity of these proteins. Bioinformatics, genome sequencing 
and continuous study of several other organisms also corroborate the new discoveries and the 
extensive presence of homologous rhodopsins in additional domains like Bacteria and Eukarya 
(Jung, Trivedi e Spudich, 2003; Sineshchekov, Jung e Spudich, 2002). Hence, analogues of BR 
with the ability to translocate protons using light have been found not only in Archaea but also in 
many other organisms, such as proteorhodopsin from the γ-Proteobacteria (Béjà et al., 2000). 
Rhodopsin genes are strongly conserved, mainly the amino acid structure in the retinal-binding 
pocket. Their presence has been found in several environments and in a widespread 
phylogenetic array of microbial life, including cyanobacteria and green algae. Interestingly, it was 
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in the soil and fresh wild water that the most important rhodopsin used in optogenetics was 
discovered - the cation conducting channelrhodopsin from Chlamydomonas reinhardtii algae. 
 
 
1.4 – Channelrhodopsins 
 
Ideal light-gated actuators to be used in the “method” idealizd by Francis Crick would 
then be monolithic proteins, rather than multicomponent signalling cascades. The most useful of 
these tools were to be found in branches of biology far removed from neuroscience: the study 
of phototropism in unicellular algae and research on light-driven ion transport in halophilic 
archaebacteria.  
Phototaxis in algae was first considered four centuries ago when several species were 
analysed for their behaviour when exposed to light (Hegemann e Nagel, 2013). Organisms can 
move towards or away from a light source, and this is defined as positive or negative phototaxis, 
respectively. Following this research topic, it was found that, after illumination, many algae 
changed their swimming direction and stood parallel to the direction of light. This led to the 
suggestion that this behaviour could be significant and pertinent (Schaller, David e Uhl, 1997) 
(Figure. 4). 
The interference of cations, such as calcium, as essential components in this mechanism 
have been addressed (Foster e Smyth, 1980). Also, it was found that when recording 
photocurrents in Chlamydomonas reinhardtii algae there is negligeble delay between 
photostimulation and the observed currents, leading to the notion that light sensitive proteins in 
this process are probably connected and functioning as a protein complex or even a singular 
monolithic protein, with the photoreceptor and the channel forming a single structure, 
permeable to some kind of ions when illuminated (Harz e Hegemann, 1991). Additionally, in 
Schaller’s experiment (Figure 4), a strain expressing a channelrhodopsin defective mutant 
presented no phototactic response at all. In fact, a key moment in optogenetics was when the 
structure of this microbial channel opsin was resolved, allowing further engineering methods 
and experimentation (Berndt et al., 2014; Kato et al., 2012; Wietek et al., 2014).  
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Figure 4 – Phototaxis in Chlamydomonas reinhardtii algae.	   (a) Phototactic behaviour of wild 
type strain Chlamydomonas in culture, when briefly exposed to high light intensity (first row). No phototactic 
behaviour is observed in algae expressing a defective mutant of channelrhodopsin (bottom row) (adapted from 
(Hegemann e Nagel, 2013)). (b) Image of microalgae Chlamydomonas reinhardtii in a scale bar of 10 µm. Rhodopsins 
are localized in the orange eyespot (white arrow). Under physiological conditions, Ca2+ ions are transported into 
the cell through light-gated cation channels, thus activating voltage sensitive channels in the flagella membrane (black 
arrow). The subsequent influx of Ca2+ into the flagella leads to a switch in movement (phototaxis) (Kateriya et al., 
2004) (adapted from (Kreimer, 2009)).  
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Chlamydomonas has long been a favourite organism for genetic and biochemical studies of 
flagellar motility and assembly, photosynthesis and organelle genomes. In particular, this specific 
strain, as well as other green algae species, show two main motility responses to light: 
phototaxis and photophobic response (Witman, 1993). Phototaxis is characteristic of algae and 
can be defined as the oriented swimming of cells along the direction of a light source, whereas 
the photophobic response is expressed as the reorientation of swimming cells, induced by an 
abrupt or strong increase of light intensity (Hegemann, 1997). This specific behaviour in these 
unicellular flagellated organisms is only achievable due to the presence of a system of 
photoreception inside the eyespot structure of algae (Hegemann, 1997).   
Perception of light generated by this photoreceptive organelle helps the cells find an 
environment with optimal light context for photosynthesis. Eyespots can be considered the 
simplest, most common and primordial ‘’eyes’’ established in nature, with its own structure 
composed by photoreceptors and areas of pigment granules (Kreimer, 2009). They are directly 
coupled to the algae flagella, and a phototactic response is generated by signals that, when 
transmitted from the eyespot photoreceptors, result in an alteration of the movement patterns 
of the flagella (Hegemann, 1997). In normal conditions, algae have a specific rotational 
movement around their own axis, however, when the eyespot perceive light, it disturbs flagella 
to adjust their swimming position from perpendicular to parallel to light (Schaller, David e Uhl, 
1997). Initial studies had shown that calcium is involved in the regulation of the flagella 
characteristic beating (Schmidt e Eckert, 1976). Later, Hegemann’s group elucidated this natural 
apparatus and proposed that there are two different photocurrents activated by calcium: one in 
the eyespot (photoreceptor current) and the other in the flagella (flagellar current). Hence, 
calcium and H+ (Ehlenbeck et al., 2002) mediate both photocurrents, whereas Ca2+ inhibitors 
supress the last ones. This suggest that the photoreceptor and flagellar currents are carried out 
by this component and that they mediate the single transduction chain regulated by rhodopsin, 
that is responsible for the cellular conduction under diverse light environments (Holland et al., 
1997; Nonnengässer et al., 1996). Altogether, these different studies support the idea that 
photocurrents are mediated by rhodopsins with a photoreceptor role.  
With a noticeable growing interest on this topic and following the use of cDNA libraries 
and DNA sequencing in more recent studies, new sequences encoding for microbial rhodopsins 
have been proposed using bioinformatics and information assembled from known opsins. 
Channelrhodopsin-1 (ChR1) (Nagel et al., 2002) and Channelrhodopsin-2 (Nagel et al., 2003) are 
two major examples of all the effort put together in this area. The nucleotidic sequences of 
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ChR1 and ChR2 were revealed in a large scale sequencing project in C. reinhardtii and were 
submitted to GenBank by the Hegemman’s group, as well as by two other groups 
(Sineshchekov, Jung e Spudich, 2002; Suzuki et al., 2003). Analysis of the C. reinhardtii genome 
database revealed two new cDNA sequences encoding apoproteins with a certain homology to 
microbial opsins and high conservation of amino acid residues forming the retinal-binding 
pocket: channelopsin-1 (Chop 1) and channelopsin-2 (Chop 2) (Nagel et al., 2002). This study 
also showed that the expression of Chop 1 in oocytes of X. laevis produced a light-gated 
conductance that was highly selective for protons, implying that channelrhodopsin-1 (ChR1= 
Chop 1 + retinal) was the photoreceptor system that mediated the H+ carried photoreceptor 
current (Nagel et al., 2002). Moreover, it has been observed that both ChR1 and ChR2 (ChR2= 
Chop 2 + retinal) contribute to the photoreceptor currents, in an electrical cell population 
assay monitoring the differential response of cells facing light versus cells facing away from light 
(Sineshchekov, Jung e Spudich, 2002). ChR1-deprived cells photocurrents at high lash intensities 
were reduced, whereas ChR2-deprived cells photocurrents at low flash energies were reduced. 
Based on these findings, it was determined that ChR1 mediates the high-intensity response, 
whereas ChR2 is accountable for low-intensity photocurrents (Sineshchekov, Jung e Spudich, 
2002). Later, antibodies against Chop1 and Chop were generated, boosting the creation of a 
model structure and enabling intracellular localization with specific membrane protein detection 
and recognition of its respective size in enriched eyespot membranes (Suzuki et al., 2003).  
Differently from the previously mentioned microbial opsins that work as light- driven ion 
pumps, channelrhodopsins act as light-driven channels. ChR1 is a light-gated proton channel, 
while ChR2 is a channel with particular ion selectivity, a single-protein membrane channel 
receptive to blue light. In 2005, the latter was recognized as a tool for genetically targeted 
optical remote control of neurons, neuronal circuits and behaviour. Karl Deisseroth’s lab 
showed that ChR2 could be expressed to control mammalian neurons in vitro, achieving 
temporal precision on the order of milliseconds (Boyden et al., 2005). This was a key finding, as 
all opsins demand retinal as the light-sensing co-factor and it was uncertain whether central 
mammalian nerve cells would contain enough retinal levels. Hence, it was demonstrated that 
ChR2 expressed in mammalian neurons could be used in the precise and reliable control of 
action potential firing in response to light pulses in vertebrate systems, without the necessity of 
exogenous retinal (Boyden et al., 2005). Subsequent observations from the Nagel (Nagel et al., 
2005) and Hegemann groups (Li et al., 2005) additionally established the ability of ChR2 to 
control the activity of vertebrate neurons.   
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Upon light stimulation, ChRs work as inward, nonspecific cation channels that can 
support neural depolarization (Nagel et al., 2002), thus they were quickly adapted to 
neuroscience research, as expression of ChRs in neurons can support action potentials 
following millisecond pulses of blue light (Nagel et al., 2003). Nagel’s lab also expressed ChR2 in 
human kidney and other mammalian cells, showing large light-induced membrane depolarization 
and suggesting that, when expressed in cells of other organisms, ChRs could enable the use of 
light to control electrical excitability, intracellular acidity, calcium influx and other cellular 
processes.  
Besides ChR2, other channelrhodopsins were discovered and successfully used in 
mammalian neurons, like VChR1 from Volxox carteri (Zhang et al., 2008) and MChR1 from 
Mesostigma viride (Govorunova et al., 2011). However, at the moment, ChRs are the only known 
protein channels directly gated by light, which renders them a very useful tool for optogenetic 
manipulation of the nervous system.  
The key features of the structure of the ChR protein and its own specific mechanism of 
action, related to several engineered variants of ChRs, are going to be addressed and explored 
in the following section. 
 
 
1.4.1 – Protein architectural design 
 
Rhodopsins share similar structural features, composed by an opsin apoprotein and a 
retinal chromophore (Spudich et al., 2000), and channelrhodopsin is no exception. 
Channelrhodopsins are protein channels expressed throughout the cell membrane, with a 
structure of seven-transmembrane α-helix topology.  
The retinal chromophore molecule is covalently linked to an amino acid residue that 
works as a Schiff base connected to the protein backbone by a N=C bond. This vitamin A 
aldehyde is accountable for the absorption properties of the protein in the visible range of the 
electromagnetic radiation spectra. Modification of the opsin absorption spectra, by modulation 
of the electronic environment around the retinal molecule, represents an appealing target for 
protein engineering tactics.   
Channelrhodopsin-2 is an 80 kDa protein, consisting of 737 amino acids, localized in the 
cell membrane. The protein has two domains: a membrane-spanning N-terminal portion 
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(nChR21-307) and a cytosolic C- terminal portion (cChR2307-737) (Figure 5). 
 
 
 
Figure 5 – Channelrhodopsin-2 end-terminals.	  Schematic view of the structure of the native ChR2 
from C.reinhardtii. The left part represents the N-terminal (nChR2), with its 7TM helices at their respective site, in 
line to the X-ray structure of the ChR1-ChR2 chimera C1C2 by (Kato et al., 2012). The right part of the figure 
represents the 430 amino acids that constitute the cytosolic cChR2 domain of the protein (from (Introduction, 
[s.d.])).  
 
The nChR2 domain has similarities to certain regions of type I rhodopsin, both at the 
structural and sequence levels, such as the proton pump bacteriorhodopsin. It also has seven 
transmembrane helices, a feature that is characteristic of the ChR2 group of proteins. These 
seven transmembrane domain form an internal pore where the retinal molecule can bind, 
enabling the light-gated properties of the channel.  
The cChR2 domain has shown no similarity with any known protein families so far, and it 
does not influence the channel function of the protein (Nagel et al., 2005, 2003). For this reason, 
the amino acids of the cChR2 domain are usually removed in most ChR2 variants created and 
used for optogenetics.  
Most research groups work with a humanized and truncated version of ChR2 (Figure 6). 
The light-absorbing chromophore is embedded within the hydrophobic center of the 7TM and 
the retinal molecule is connected to a conserved lysine via Schiff base linkage, which is 
protonated to shift the absorption into the visible range of the spectrum. The resulting color of 
this protonated retinal Schiff base (RSB) is fine-tuned by the distance of the negatively charged 
counter ion that together form the active site and also by the location of some polar residues 
nearby the retinal polyene chain (Figure 6).  
When retinal absorbs light, isomerization of this molecule occurs, resulting in a specific 
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protein conformational change, opening the ion pore, as discussed in section 1.2. (Figure 2). 
These structural changes also include the closure of the conducting pore and the return to the 
dark state. The pathway for this opposite reaction differs from the initial opening path, and 
kinetics of dark state recovery are significantly slower (Hegemann e Nagel, 2013). Internal and 
external pH are known to influence the closure of the ChR2 channel, as well as the recovery 
after desensitization (Nagel et al., 2003). Moreover, the OH-cluster and the residues C128 and 
D156 (DC-pair) have a central importance in both the opening and closing of the pore.  
Bovine rhodopsin (Okada et al., 2004) and BR (Nishikawa, Murakami e Kouyama, 2005) 
had their crystal structures identified first, allowing preliminary approaches to comprehend the 
structure of ChR2 based on sequence comparison, homology models and bio-computational 
techniques. Hence, it is considered that channelrhodopsin pioneering structural information was 
first obtained from homology modeling studies based on already known structures of other 
microbial rhodopsins (Plazzo et al., 2012; Watanabe et al., 2012). Regarding ChR2 engineering, 
mutation of any of these residues could result in a dramatic increase of the open state lifetime.  
Remarkably, it was also found that isolating both retinal and the protein, each one 
absorbs primarily in the beginning of the UV range spectra (~380 nm) but, when bound 
together, forming the retinal binding pocket, they induce a red-shift in the retinal absorption 
spectrum. This outcome is known as ‘’opsin shift’’ (Watanabe et al., 2012) and is assumed to 
result from the conformational manipulation of the chromophore, the direct electrostatic 
interfaces settled between the adjacent protein residues and the retinal molecule (Wang et al., 
2012).  
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Figure 6 – Channelrhodopsin structure.	    Illustration of the seven transmembrane fragment of ChR 
highlighting the chromophore pocket. The c-terminal of ChR2 extends into the intracellular space and can be 
replaced by fluorescent proteins without affecting channel function. Hence, most used ChR2 forms are truncated in 
relation to the original protein recognized in C. reinhardtii, such that only the N-terminal part of protein is present. 
The structure and aminoacid numbering is represented according to the C1C2 chimera proposed by (Kato et al., 
2012). Key residues are shown in colour: voltage sensor E123 (cyan), residues of the access channel (magenta), 
central gate (blue) and inner gate (orange), OH-cluster (green), and finally the retinal Schiff base (RSB) is seen in red 
colour (adapted from (Hegemann e Nagel, 2013)). 
 
Notwithstanding all collected knowledge on the structure of ChR2, more precise and 
accurate models are still needed. Elegant techniques such as the approach presented in this 
work, the Ab initio design using Time-dependent Density Functional Theory can be a conceivable 
methodology towards improved models.  
In 2011, a projection of ChR2 structure was determined for the first time, using electron 
crystallography at 6Å resolution. This projection map, when compared to the one from BR 
confirmed that ChR2 was indeed formed by seven transmembrane helices, as all other known 
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microbial rhodopsins (Müller et al., 2011). Next, the first crystal structure of a ChR2 was 
described (Kato et al., 2012), based on a chimeric form of ChR1 and ChR2 (C1C2 chimera). 
This study reported the conformation of the ChR2 light-gated channel underlying the structural 
features of the C1C2 chimera. This primary ChR sequence can be considered similar to BR 
structure (Figure 7), with the end part of the 7TM being shifted to the central axis of the 
monomer (Kato et al., 2012).  
There are additional differences between BR and ChRs, such as the extracellular ends of 
TM1 and TM2 in C1C2 being tilted outwards. These tilts result in the enlargement of the cavity 
formed by the transmembrane domains, allowing water influx for the transport of cations (Kato 
et al., 2012). The crystal structure of C1C2 revealed also the presence in the N-terminal domain 
of β-sheets that might contribute to dimer stabilization (Kato et al., 2012). 
 
 
Figure 7 – C1C2 vs. BR structure.	   Side view (a) and extracellular view (b) of the superimposed TMs of 
C1C2 (green) and BR (orange). The yellow-paired arrows specify the shifts of the extracellular parts of TM1 and 
TM2 (adapted from (Kato et al., 2012)). 
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1.4.2 Retinal binding pocket 
 
The retinal molecule links covalently to the protein structure, working as its 
chromophore. This feature is shared by all rhodopsins, as all-trans retinal is covalently bound to 
Lys 296 (257) on TM7 (to refer to ChR2 numbering sequence it is subtracted 39 from the 
C1C2 residue number sequence), establishing the Schiff base connected to the protein through 
a N=C bond). Interestingly, the TM7 is highly conserved in type I rhodopsin.  
Furthermore, five aromatic residues (Trp 163, Phe 217, Trp 262, Phe 265 and Phe 269) 
are positioned nearby the polyene chain and the β-ionone ring, forming a hydrophobic pocket 
for all-trans retinal (Figure 8 d). Moreover, the residues Cys 167 (128), Thr 198 (159) and Ser 
295 (256) form a less-hydrophobic pocket (Figure 8 d), and could be responsible for the  ‘’opsin 
shift’’, and contribute some specific kinetic properties of the channel (Hegemann e Möglich, 
2011; Kato et al., 2012; Watanabe et al., 2012).  
As mentioned above, the C1C2 chimeric protein conserves the same arrangement as BR 
where a water molecule receives a proton from the protonated Schiff base and donates this 
same proton to an amino acid near the retinal binding pocket. Moreover, a specific residue was 
also identified, Asp 292, as the primary proton acceptor to the Schiff base, resulting from its 
proximity to Lys 296, and consistent with the abolished photocurrents derived from mutations 
in the C1C2 chimera (Kato et al., 2012).  
The retinal binding pocket structure is the light sensing foundation of the channel, and is 
responsible for the distinctive absorption properties of the protein. In the previous section, we 
discussed the ‘’opsin shift’’, a process that enables a change in retinal absorption depending on 
the environment around the molecule. This effect is not yet completely understood, but it 
seems that the shift in the absorption spectra and the wavelength regulation is a result of the 
conformational manipulation of the chromophore and of the electrostatic interactions that 
occur in the retinal binding pocket (Welke et al., 2011). Hence, changes in the protein 
properties targeting this same chromophore pocket will be discussed in the following sections. 
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Figure 8 – The retinal-binding pocket. The structure of the C1C1 chimera consists on the five 
transmembrane domains of ChR1 and the last two of ChR2 (the ~400 a.a. C-terminal part was excluded).  a–
c, Crystal structure of the C1C2 dimer, viewed parallel to the membrane from two angles (a, b), and viewed from 
the extracellular side (c). The C1C2 truncated chimera consists of the N domain, the seven transmembrane helices 
(TM1–TM7) connected by extracellular loops (ECL1–ECL3) and intracellular loops (ICL1–ICL3), and the 
intracellular C domain. Disordered regions are represented as dotted lines. The all-trans retinal (ATR) is indicated 
in pink. d, Close-up on the structure of the retinal-binding pocket of C1C2, with an omit map of ATR at 3σ and of 
D                                  
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the surrounding residues (subtract 39 from the C1C2 residue number to obtain ChR2 numbering) at 3.5σ (adapted 
from (Kato et al., 2012)). 
 
1.4.3 The Ion-Conducting pore  
 
Channelrhodopsins allow a precise control of neuronal activity using light, but a 
complete and exhaustive understanding on how the protein channel is gated is lacking. 
Channelrhodopsins have seven transmembrane domains organized to form an inner pore, and 
that is stabilized by electrostatic interactions (Catterall, 1995). This pore is more permeable to 
cations than anions, which suggests that a highly electronegative region must form the pore 
structure. 
Several studies have identified specific residues that may contribute to the formation of 
the ion pore (Watanabe et al., 2012). These identified residues are Glu 90 (Eisenhauer et al., 
2012), Glu 97, Glu 101 (Watanabe et al., 2012), Asp 156, Asp 253, His 134 and Glu 123 
(Hegemann e Möglich, 2011), and are all considered vital for the kinetic proprieties of the 
protein, as part of the ion channel.  
Based on the C1C2 structure model proposed by H. Kato, an electronegative 
region/pore was found to be constituted by TM1, TM2, TM3, and TM 7, rich in twelve charged 
and polar residues (Gln 56, Thr 59, Ser 63, Glu 83, Glu 90, Lys 93, Glu 97, Glu 101, Glu 123, 
Thr 246, Asp 253 and Asn 258), with the main contribute to the pore formation coming from 
five glutamic acid residues of the TM2 (Glu82, Glu83, Glu90, Glu97 and Glu101) (Watanabe et 
al., 2012). These residues are positioned in the interior part of the protein and seem to connect, 
align and establish a tough hydrophilic and electronegative surface that might be included in the 
stabilization of cation species. This was supported by mutagenesis studies in which some of the 
identified residues were swapped, resulting in a loss of conductance and ion selectivity (Kato et 
al., 2012; Ruffert et al., 2011).  
Besides the aforementioned electronegative side chains, other polar residues were 
found, located in the central part of the pore (Q56, T59, S63, E83, K93, T246, N258 and Y70). 
These residues form two constriction sites in the cytoplasmic side of the channel and are 
responsible for the gating of the channel, through their interactions (Kato et al., 2012). Other 
studies combining bioinformatics, ChR2 and mutant forms of this protein suggested that, besides 
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the Gln 56 and Ser 63 residues, other residues, such as Asn 258 and Thr 250, could have a role 
in channel selectivity (Plazzo et al., 2012).  
The X-ray structural model in the closed state, proposed in 2012 (Kato et al., 2012) 
marks an important step in understanding channelrhodopsin structure and mechanism, and has 
served as a basis for several studies in this area. More recently, the early formation of the ion-
conducting pore of ChR2 was revealed. Indeed, the open state structure is presented and the 
early formation of the ion-conducting pore is clarified in atomic detail using time-resolved FTIR 
spectroscopy (Kuhne et al., 2015). Photoisomerization of the retinal-chromophore causes a 
downward movement of the highly conserved E90, which opens the pore. Molecular dynamic 
simulations show that water molecules invade through this opened pore, Helix 2 tilts and the 
channel fully opens within milliseconds. As E90 is a highly conserved residue in the ChR2 
structure, the proposed E90-Helix2-tilt model (Figure 9) could describe a general activation 
mechanism, providing a new path for additional mechanistic studies and protein engineering 
focusing on mutation of the amino acid E90 to control the properties of the protein in a 
targeted manner (Kuhne et al., 2015). 
 
Figure 9 – The E90-helix 2-tilt model of action of ChR2.  Water molecules are shown in colour, 
protein transmembrane helixes are shown in grey and protonated (a) and deprotonated (b) E90 residue is 
presented in purple in both centre of left and right image; The pore of the ion channel is opened by detaching the 
amino acid E90. Water molecules are transported and tilt Helix 2, therefore opening the continuous channel. The 
light-sensitive retinal is twisted under incidence of light. This twist then continues in the protein and opens rapidly a 
pore, which is closed by amino acid E90 in the dark. E90 marks the narrowest place in the pore and opens it 
through a downward move, similar to the motion of a ‘’swing door’’, so that water can enter an empty vestibule 
above the narrowest place in the pore. The entering water then tilts the protein helix H2, which eventually triggers 
a protein-traversing open ion channel (adapted from (Kuhne et al., 2015)). 
A B 
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1.4.4 Channelrhodopsin-2 photocycle 
 
A few years before the discovery and publication of the crystal structure of ChR2, 
several studies had already focused on the specific mechanisms of the protein (Hegemann, 
Ehlenbeck e Gradmann, 2005; Nikolic et al., 2009). Channelrhodopsin-2 has specific properties 
such as the ability to change its conformation to become permeable to a wide range of ionic 
species (Nagel et al., 2003). Upon light stimulation, the mechanisms affecting the channel and all 
its structural modifications if called a ‘’photocycle’’ (Watanabe et al., 2013).  
One of the most important questions about light-gated ion channels is related to the 
coupling between light activation, protein action, and the way the spectral properties can be 
associated with the opening and the closing of the channel (Bamann et al., 2008). Recently, the 
photocycle of ChR2 has been widely studied using specific techniques as absorption and 
vibrational spectroscopy (Bamann et al., 2008; Radu et al., 2009; Ritter et al., 2008; Verhoefen et 
al., 2010). The known triggering event of this cycle is the absorption of a photon, which leads to 
light-induced isomerization of retinal from all-trans to 13-cis and its thermal isomerization to the 
initial all-trans state (Hegemann e Möglich, 2011). This cyclic reaction comprises several 
thermally unstable intermediates and the complete reaction is determined by light energy 
absorption and storage of a portion of this energy in the protein. Part of this energy is used to 
drive the photocycle, whereas the other part is transformed in energy that is essential for ion 
transport (Haupts et al., 1997). Hence, this process is initiated by light absorption associated 
with electronic excitation and polarisation of the existing retinal chromophore.  
In general, the chromophore relaxes by isomerising, most likely from all-trans to 13-cis 
resulting in the first intermediate P500 which is slightly red-shifted compared to the dark state 
D470 (the numbers represent the absorption maximum) (Nack et al., 2009). As mentioned 
above, the retinal molecule is covalently linked to a lysine in helix VII via a Retinal Schiff Base 
(RSB) and embedded within the helices in the retinal binding pocket. Within microseconds, the 
RSB is deprotonated upon formation of the UV-absorbing P390 intermediate, which is also 
connected to structural changes of the protein backbone. P390 is in equilibrium with the 
conducting P520 state where the RSB is again reprotonated.  
Alongside the passive transport of cations, that, under physiological conditions, is 
directed towards the intracellular side of the membrane, ChR2 has been proposed to act as a 
weak proton translocator where the proton on the RSB leaves on the extracellular side and 
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upon formation of P520 state, takes up on the intracellular side (Feldbauer et al., 2009; Nack et 
al., 2012). The closing of the channel (in milliseconds) involves the two intermediates P480a and 
P480b with absorptions similar to D470, and adaption of the structural rearrangements of the 
protein helixes, enabling the conduction of cations. The photocycle is complete after roughly a 
minute, which is considerably slower than proton-pumping rhodopsins like bacteriorhodopsin.  
Several models for this mechanism have been suggested, one example is the two-cycle 
model based on ChR2 photocurrents, involving two open states of the channel with different 
ion selectiveness (Berndt et al., 2010; Gradmann et al., 2011; Stehfest e Hegemann, 2010). 
However, the model that gained more support in the scientific community is the six-state 
photocycle model (Ritter et al., 2008)  (Figure10, a). This model suggests that it is possible to 
identify three different states of ChR2: the non-conductive excitable state, the active or 
conductive state, and the non-conductive desensitized state. Specifically, this model proposes 
that ChR2, when in the dark, exists as a non-conductive and excitable form with a maximum 
absorption peak of 470nm (D470) (Ritter et al., 2008). This state is then rapidly converted, in 
approximately 1ms (Bamann et al., 2008), to a conducting state with peak absorption at 520nm 
(P520). Between these two states, two other quick intermediates, without measurable currents, 
are present: P500, consequence of the very fast photoisomerization of retinal, and P390, which 
is a product of the Schiff base deprotonation. After this deprotonation, the protein suffers 
severe conformation changes acquiring the P520 conducting state. P390 and P520 states are in a 
pH-dependent equilibrium. It is also known that the open state of ChR2 wild type protein lasts 
for around 10ms, after which the protein decays into a P480 state (under special circumstances 
the P520 can be directly converted to D470) (Ritter et al., 2008). Since this is the slowest step 
of the cycle, under continuous light conditions these intermediates are accumulated and give 
rise to light-adapted forms of ChR2. The P480 state can be further divided into two sub-states 
that differ in their excitability to light. P480a is created from P520 and cannot be directly 
“reactivated” by light. On the other hand, the ‘’a’’ state is in equilibrium with the ‘’b’’ state, this 
last one activated by light of 480nm (P480àP500).  
Though widely studied, the ChR2 photocycle is still not fully understood and some 
features remain undetermined. Certain steps can be skipped under defined light conditions with 
some shortcuts, such as the conversion of P480b directly in P500 without the reformation of 
the D470 or even the direct formation of the dark state from P520 (Bamann et al., 2008; Ritter 
et al., 2008). These shortcuts, loops and different kinetics (Figure 10, b) have been manipulated 
towards the modification of the cycle, enabling the prospect of developing ChR2 new variants 
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and mutants. ChETA variants are one example where there is a faster recovery from the P520 
to P480 state, resulting in a considerable speedier reactivation that permits better temporal 
resolution and faster channel kinetics (Stehfest et al., 2010). Another example are the SFO 
(step-function opsins) mutants that are able to remain in the P520 state for longer time periods, 
up to thirty minutes long in some variants. Consequently, this intermediate can maintain steady 
state currents and while engaging in this conformation for longer periods, the P520-D470 
shortcut allows direct cutting of currents using precise and specific optical control (Zhang et al., 
2011). 
                                                   
                   
Figure 10 – Six-state ChR2 photocycle model.  (a) Photocycle of ChR2 displaying the sequential 
order of the photocycle intermediates (P500, P390, P520 and P480a/b) after the retinal absorption of light in the 
dark-state (D470). Adapted from (Ritter et al., 2008). (b) Alternative ChR2 photocycle diagram illustrating specific 
cycle changes with focus on relaxation time constants of protein states; shortcuts and state features of two ChR2 
variants used in optogenetics are also presented in colour (adapted from (Nack et al., 2010)). 
A 
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1.5 – Optogenetic toolbox 
 
A rich toolbox of genetically encoded molecules has been under active development. 
The variety of these tools has increased as they have been improved and combined together. 
Additionally, eventhough these molecules require vitamin A derivative all-trans retinal to 
properly work (its own chromophore), sufficient all-trans retinal existes in mammalian neurons 
in culture and in vivo to support the function of these molecules (Wang et al., 2007) . Hence, 
microbial opsins offer high-speed neural activation and silencing, without the demand for 
chemicals in the mammalian brain. Even for non-mammalian species, like Drosophila, all-trans 
retinal is enough when supplemented in the food supply. There are four major classes of type I 
opsins with an emerging use in neuroscience and optogenetics (Figure 11), these are 
halorhodopsins, bacteriorhodopsin-like proton pumps, channelrhodopsins and other chimeric 
proteins. 
First, halorhodopsins (HR) are light-driven inward chloride pumps from archaea that live 
in high-salinity environments. When expressed in neurons upon illumination, they pump 
chloride ions into the cells (Figure 11, a i). The first HR to be sucessfully used in neurons was 
from the archaeon Natronomonas pharaonis (known as Halo/NpHR) (Zhang et al., 2007). Next, 
an enhanced HR was developed for optogenetic applications (eNpHR). This variant was 
engineered to achieve stronger expression without the cellular side effects, such as intracellular 
accumulations from expression at high levels (Gradinaru, Thompson e Deisseroth, 2008). 
Illuminating halorhodopsins with yellow light directly mediates hyperpolarization, allowing the 
silencing of neural activity (Figure 11, a ii). It is also known that HR is capable of supporting the 
perturbation of specific neurons to study their role in the brain functions in mouse behaviour, 
for example, acute optogenetic silencing of orexin/hypocretin neurons induces sleep in mice 
(Tsunematsu et al., 2011). Halorhodopsins were also effectively expressed in other organisms 
such as the Drosophila, to mediate hyperpolarization in motor neurons (Inada et al., 2011).  
Overall, however, halorhodopsins have poorer neuronal expression than 
channelrhodopsins, and require the addition of trafficking sequences (e.g. from potassium 
channels) to express better at very high levels in mammalian cells (Gradinaru et al., 2010; Zhao 
et al., 2008). They also recover slowly after extended illumination, taking on average tens of 
minutes to achieve maximal photocurrent amplitude after initial activation (Bamberg, Tittor e 
Oesterhelt, 1993; Chow et al., 2010; Hegemann, Oesterbelt e Steiner, 1985).  
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The second class of light-activated proteins are archaerhodopsin. These are light-driven 
outward proton pumps similar to bacteriorhodopsin, which have the feature of expressing well 
in heterologous cells and also to recover rapidly after activation. One subclass of these proton 
pumps is archaerhodopsin-3 (Arch) from Halobacterium sodomense (Chow et al., 2010), which is 
also found in archaeal species.  When these proteins are expressed in neurons and illuminated 
with yellow or green light, they pump positive charged ions outwards hyperpolarizing the cell 
(Figure 11, b i). As an example, Arch permits complete neuronal silencing in the cortex of 
awaked mice (Figure 11, b ii) (Chow et al., 2010). New variants are also emerging, such as 
ArchT from the Halorubrum genus, which is 3.5 times more light-sensitive than Arch (Han et al., 
2011), enabling, for example, the silencing of large brain regions during experiments of 
optogenetic control of brains of nonhuman primates.  
There are also variants of light-driven proton pumps with different absorption 
wavelengths, allowing the optogenetic control of two neuronal populations. This is the case of 
the light-driven outward proton pump Mac (from Leptosphaeria maculans fungus (Waschuk et al., 
2005), that reacts to blue-light to drive neural silencing. Combining the expression of Mac with 
Halo (which reacts to yellow and, to some extent red, light), it is possible to have a two-
coloured neuronal silencing of two separate neural populations expressing Mac and Halo (Chow 
et al., 2010). 
A third class of light-activated proteins are the widely used channelrhodopsins, that, 
when expressed in neurons, are expressed on the cell membrane and, upon illumination, work 
as a channel that allows the entrance of positive charged ions (mainly sodium ions and protons, 
but also potassium and calcium), consequently depolarizing the cell (Figure 11, c i). 
Channelrhodopsin-2 was the first to be successfully expressed in neurons (Boyden et al., 2005), 
quickly responding to brief pulses of blue light, with large enough depolarizing photocurrents to 
mediate action potentials at rates of tens of hertz (Figure 11, f ii). Due to the effectiveness of 
ChR2 to mediate the driving of specific cells or pathways in vivo, several variants of 
channelrhodopsins have been discovered, studied and engineered, with ChR2 as its 
predominantly model. This range of variants includes, for example, the calcium permeability-
enhanced channelrhodopsin CatCh (Kleinlogel et al., 2011), as well as channelrhodopsins that 
exhibit higher amplitude currents, or currents slower to run down than the original. This is the 
case of several channelrhodopsin mutants and chimeras, including ChR2(H134R) and ChIEF (Lin 
et al., 2009), ChR2(T159C) (Berndt et al., 2011), ChRGR (Wen et al., 2010).  
Furthermore, researchers have been developing channelrhodopsins that are faster or 
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slower to turn off after illumination, such as the channelrhodopsin mutants ChETA (Gunaydin et 
al., 2010), SFO (Berndt et al., 2009) and the ChR2 (D156A) mutant (Bamann et al., 2010). 
Moreover, with specific interest to our own project, colour-shifted channelrhodopsins have also 
been designed. Examples of these new tools include VChR1 (Zhang et al., 2008), MChR1 
(Govorunova et al., 2011) and C1V1 (Yizhar et al., 2011), but strategies for new variants are 
under fast development (Chow et al., 2011).  
Finally, another set of optogenetic tools, based on type II opsins (animal opsins), have 
also been developed through the combination of naturally occurring light-driven G protein-
coupled receptors (GPCRs) with other opsins. Based on the published work by Gobind 
Khorana lab (Kim et al., 2005), Karl Deisseroth’s team engineered chimeric receptors by 
replacing the intracellular loops of bovine rhodopsin with those of specific adrenergic receptors 
(Airan et al., 2009), taking advantage of the common structure-function relationships between 
GPCRs. With these tools, it became possible to optically activate the intercellular pathways 
normally recruited by these receptors (the cAMP and IP3 pathways). As suggested by 
Deisseroth’s team (Airan et al., 2009), these tools were denominated as ‘’opto-XRs’’, where X 
specifies  the particular pathway that is being optically ‘hijacked’’ (for example, opto-α1AR for 
α1 adrenergic receptors).  
In the following sections, vital milestones about the specific manipulation of ChR2, and its 
engineering towards colour-tuning variants, are discussed. 
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Figure 11 – Adaptation of microbial opsins from nature as optogenetic molecular 
tools for optical control of neural activity. (a) (i) Illustration displaying the physiological effect of 
expressing Halo/NpHR in neuronal cells after cell illumination and negatively charged chloride ions flow into the 
cell. (ii) Voltage trace (black trace) recorded, using whole-cell current clamp, from a cultured hippocampal neurons 
expressing Halo and illuminated by orange light (orange dashes under trace), showing light-driven action potential 
silencing.  (b) (i) Physiological effect of expressing  archaerhodopsin-3 protein (Arch) in neurons upon cell 
illumination. Positively charged protons flow out of cells. (ii) Neural activity in a representative neurons recorded 
using extracellular electrode recording in an awake mouse before, during and after 5 seconds of yellow light 
illumination, shown as a spike raster plot (top), and as a histogram of instantaneous firing rate averaged across trials 
(bottom). (c) (i) Physiological effect of ChR2 expression in a neuron upon cell illumination. Positively charged ions 
(mainly sodium and protons, but also potassium and calcium in a smaller amount) flow into the intracellular space, 
from the extracellular space. (ii) Raw voltage trace (black trace) recorded, using whole-cell current clamp, from 
cultured hippocampal neurons expressing ChR2, illuminated with brief pulses of blue light (blue dashes under 
trace), showing light-driven action potentials. Adapted from (Bernstein e Boyden, 2011). 
A 
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1.5.1 – Channelrhodopsin-2 engineering  
 
To date, six major channelrhodopsins variants have been discovered: ChR1 and ChR2 
from Chlamydomonas reinhardtii (Nagel et al., 2002, 2003; Sineshchekov, Jung e Spudich, 2002; 
Suzuki et al., 2003), VChR1 and VChR2 from Volvox carteri (Kianianmomeni et al., 2009; Zhang et 
al., 2008) - these four have already been widely studied and characterized -, Mesostigma viride 
ChR (MChR1) (Govorunova et al., 2011), and the most recently identified channelrhodopsin of 
the halophilic alga Dunaliella salina, DChR1 (Zhang et al., 2011), which was discovered less than 
five years ago.  
‘Optotools’ have become indispensable in neuroscience to stimulate or inhibit excitable 
cells by light and channelrhodopsins have become of great interest, mainly because with 
optogenetics they can be used in numerous fields of biomedical research. To date, optogenetic 
application of microbial opsin genes benefited substantially from molecular modifications, such 
as mutating the opsin backbone (site-directed mutagenesis) or creating chimeras by mining 
related algal genomes (chimera approach by combining helices from different channelrhodopsins 
(Lin et al., 2009; Tsunoda e Hegemann, ; Wang et al., 2009)). Through a combination of 
molecular engineering and genomic discoveries of new light-sensitive proteins, the toolkit of 
neuronal modulators is rapidly improving in both specificity and versatility.  
Overall, engineering of channelrhodopsins allows the modification of their spectral and 
kinetic properties and to improve the expression and membrane targeting in host cells.  Up to 
now, a variety of channelrhodopsins emerged through codon optimization and site-specific 
mutagenesis. Related to this, a humanized form of the channelrhodopsin channel (hChR2) was 
created by substituting certain algae specific codons with mammalian codons (Adamantidis et al., 
2007). Since the initial description of ChR2 as an efficient tool to evoke neural activity in a light-
dependent manner, an outbreak of studies have applied ChR2 in a variety of questions related 
with neuroscience.  
There are several relevant parameters to evaluate a particular opsin, including the 
wavelengths of light to witch the opsin respond, the wavelength which generates the largest 
current, the magnitude of the current generated at the optimal wavelength, the rate to achieving 
maximal current, how fast the opsins channels close, and the degree to which cell membranes 
express the opsin. As such, with molecular mutagenesis studies, the function of ChR2 has been 
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engineered to have faster or extended open-state lifetimes, shifted absorption spectra, reduced 
desensitization and increased expression and photocurrent magnitude. 
 One important parameter is the rate of the channel closure (tau off) that corresponds 
to the minimum effective interpulse interval (a low tau off permits control of high spiking rates), 
as well as the length of time one light pulse alters membrane potential (a high tau off consents 
long-lasting effects, up to 30 min per light pulse). Furthermore, various opsins with fluctuating 
characteristics have been developed and particularly studied with multi-comparison.  
A systematic comparison of microbial opsins under matched experimental conditions has 
been performed in order to understand the essential principles of each one, and identify key 
parameters for the design and interpretation of experiments involving optogenetic techniques 
(Mattis et al., 2012). Moreover, a plot of peak wavelength versus rate of channel closure after a 
pulse (tau off) provides one way to organize the many available opsins, revealing the wide 
variety of possibilities for modulating neural function (Figure 12).  
Figure 12 – Kinetic and spectral properties of optogenetic tools variants. Optogenetic 
tools span a large portion of the visible spectrum and a wide range of temporal kinetics. Decay kinetics are 
temperature dependent; all reported values are recorded at room temperature, with <50% decrease in tau off 
expected at 37ªC. Biochemical modulating opsins refer to G-protein-coupled opsins. Its in vivo properties may 
depend on the host cell responses to elevated intracellular calcium. > than 500 nm of peak activation 
predominantly lead to slow kinetic depolarizing variants (50 ms tau off). Red-shifted variants are regularly 
hyperpolarizing pumps.  Adapted from (Yizhar et al., 2011). 
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chARGe was considered an earlier tool for photo stimulation when it demonstrated 
proof of modulating neural fucntion in cultured neurons (Zemelman et al., 2002),  but its use 
was not extensive due to lack of precision (seconds), highly variation rates and the fact that it 
did not allow the control of individual action potentials. Hence, the first and pioneer opsin used 
in mammalian neurons was ChR2 (Boyden et al., 2005; Nagel et al., 2003), which has been 
established as the main prototype channelrhodopsin for optogenetic application.  
It has been demonstrated that ChR2 can be used to control mammalian neurons in vitro 
with temporal precision in the order of the milliseconds (Boyden et al., 2005). This was a 
meaningful finding that boosted ChR2 usage and toolbox expansion, since all opsins require 
retinal as its own light-sensing co-factor and it was unclear whether central mammalian nerve 
cells would contain sufficient retinal levels. Furthermore, it was shown that despite the small 
single-channel conductance, ChR2 has sufficient potency to drive mammalian neurons above the 
action potential threshold. ChR2 was, therefore, the first optogenetic tool with successful 
application. However, despite ChR2 being widely used to photo-stimulate neurons, its own full 
potential as a light-gated ion channel is still under development, with improvements developing 
occurring year by year.  
The wild-type ChR2 presents a rapid on-rate and moderate channel closing rate 
(Ishizuka et al., 2006; Lin et al., 2009; Nagel et al., 2003) but has some drawbacks, such as small 
currents and strong inactivation properties that are not adequate for certain biological 
applications. The wild-type form of ChR2 has a small single-channel conductance, and is 
optimally excitable at a wavelength of 470 nm, naturally not extended over 520 nm, thus limiting 
its use in a high-light scattering medium such as the brain (Hegemann e Möglich, 2011). Long-
wavelength excitation light decreases the light scattering effect produced by biological tissues 
and it will avoid the absorption by haemoglobin. The more red-shifted a channelrhodopsin is the 
more desirable they become to use in relatively deep tissue penetration. In parallel, blue-shift 
protein would also be interesting to develop, given that the use of channelrhodopsins with 
various wavelength sensitivities combined with multi-coloured optics, would enable the 
stimulation of two different neural populations without overlap.  
Channelrhodopsin-2 also has relatively long recovery time, limiting the maximal firing 
rate that can be induced in neurons to 20-40 Hz. However, the main deficiency of ChR2 is the 
high level of desensitisation that reduces the current by ~80 % at physiological pH (Ishizuka et 
al., 2006; Lin et al., 2009; Nagel et al., 2003). The desensitised response fully recovers after 25s 
in the dark (Lin et al., 2009). Furthermore, ChR2 traffics well to the membrane when expressed 
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at low levels, but forms intracellular aggregates when expressed at high levels (Lin et al., 2009). 
Channelrhodopsin-2 can provide both temporal and spatial precision of stimulation in 
mammalian cells and living animals, and is therefore being extensively used for millisecond scale 
photo-control of cellular functions.  
When ChR2 was expressed in mammalian neurons, a brief (1-2 ms) pulse of blue light 
(~470 nm) opens these channels, evoking an action potential in targeted cells. Cation 
conductance appears to depend primarily on the kinetics of channel closure (tau off) rather than 
other molecular events, such as retinal isomerization (Feldbauer et al., 2009).  
A variety of mutations have been introduced to alter these channel kinetics. While the 
kinetics of wild type ChR2 does not permit precise control over 40 Hz, mutations of the 
glutamate 123 residue to a threonine (T) or an alanine (A) created the known ChETA opsins 
with a tau off of approximately 4 ms against the 10 ms from ChR2. This allows evoking spikes 
over 150 Hz using 2 ms light pulses (Gunaydin et al., 2010). Alteration of channel kinetics in the 
other direction, to very slow channel closure, allowed the creation of ‘’step function’’ opsins 
(SFO), which cause prolonged depolarization using light at 470 nm, raising the excitability of 
targeted neurons. SFO is a version of ChR2 with the C128S and D156 mutations and has a tau 
off of almost 30 minutes. Yet, if shorter ‘’on’’ states are experimentally desired, channel closure 
may be induced with light of approximately 600 nm (Yizhar et al., 2011). This controllable long 
‘’on’’ state may be well suited for translation user. First, the stable state allows transduced cells 
to act as photon aggregators, allowing long pulses of light at lower powers to recruit larger 
volumes of tissue (Berndt et al., 2009; Diester et al., 2011). Second, by raising excitability rather 
than directly inducing spikes, the physiological activity patterns of an area may be preserved 
(Berndt et al., 2009; Yizhar et al., 2011). Raising excitability may allow targeted modulation in a 
more physiological manner, with the need of further studies to investigate the complete utility 
of these features.  
Currently, the most prominent of these the red-shifted opsins is C1V1 (E122T/E162T), a 
hybrid of ChR1 and VChR1. Its peak activation occurs at approximately 560 nm, and its 
photocurrents exceed those of ChR2 (Yizhar et al., 2011). A further red-shifted version, C1V1 
(E162T), can consistently elicit action potentials at 630 nm with large photocurrents, however 
with slower off-kinetic (tau off >60 ms) (Mattis et al., 2012; Yizhar et al., 2011). While further 
red-shifts variants, including absorption into the infrared spectrum, may be desirable, C1V1 
(E122T/E167T) has been mostly used in primate models. 
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1.5.2 – Channelrhodopsin-2 color tuning 
 
After a significant amount of research on the unfolding structural features and 
photocycle of the protein, the first study concerning a red-shifted ChR was obtained. Firstly, 
VChR1, a channelrhodopsin presenting a 70 nm shift (Zhang et al., 2008) with a subsequent 
yellow light excitation, was discovered and characterized. VChR1 structural sequence is similar 
to the previously identified ChR1 and ChR2, allowing the selection of residues thought to be 
accountable for the observed colour tuning on the absorption spectra. These specific residues 
are located in the TM5 domain of the protein, in close proximity to the retinal chromophore, 
and consist of a glycine 182 and a cysteine 184 that are substituted by serines, causing an 
increased polar electronic environment on and around the chromophore, which leads to a red-
shifted absorption spectra. These discoveries suggested the possibility of colour tuning being 
based on the adjustment of the primary structure.  
More target residues were identified in further studies, as is the case of C128 in a ChR2 
versus bacteriorhodopsin sequence assessment (Berndt et al., 2009). This residue was 
considered as a likely target for mutation that would result in slower channel kinetics. It was 
predicted that substituting this cysteine by a serine or alanine would create a bi-stable opsin 
capable of being turned on/off with different wavelengths (Berndt et al., 2009). This mutant opsin 
was then upgraded with an additional mutation (D156A) to develope a closing constant of 30 
minutes (Yizhar et al., 2011). This allowed optical control of overall excitation state of a specific 
neuronal population across long periods of time.  
The first high resolution model of a channelrhodopsin, the crystal structure of C1C2 
(Kato et al., 2012) (a chimera of ChR1 and ChR2)), allowed a deeper understanding of the 
architecture of the retinal binding pocket and ion pore of the protein. This achievement 
enhanced new designs methods focusing new variants, based on the protein 3D structure.  
To understand the essential elements that contribute to spectral tuning of a 
chromophore inside the protein cavity, Wang et al. redesigned human cellular retinol binding 
protein II (hCRBPII) to fully encapsulate all-trans-retinal and form a covalent bond as a 
protonated Schiff base (Wang et al., 2012). The hCRBPII is believed to be accountable for the 
transport of retinal in a way related to the mammalian rhodopsins. Hence, mutating several 
residues on the protein resulted in the achievement of peak absorption shifts on the retina 
molecule across a range of 440-644 nm (Figure 13).  
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Furthermore, by studying the structure of the protein relative to the retinal molecule 
they concluded that modifications that isolate the retinal molecule into a hydrophobic 
environment and even the electronic charges in the polyene chain, particularly near the 
protonated Schiff base, caused greater bathochromic shifts than modifications near the β-ionone 
ring, a result contradicting the findings regarding VChR1. However, given the differences 
concerning ChRs and hCRBPII, specifically in the protonated Schiff base motif, it is conceivable 
that these findings may not be completely comparable. 
 
 
 
Figure 13 – Colour tuning of absorption spectra in a modified retinal binding 
protein. Normalized UV spectra of a selected group of hCRBPII mutants, obtained by directed site mutagenesis. 
Modified electrostatic environment surrounding the retinal molecule shown by pigments colour in cuvettes 
generated by incubation of all-trans-retinal with hCRBPII mutants. Adapted from (Wang et al., 2012). 
 
Additionally, the genomic search for new channelrhodopsins extended the palette of 
available variants, resulting in several screenings on algae species. With this search, two new 
opsins were revealed, Chronos (from Stigeoclonium helveticum) and Chrimson (from 
Chlamydomonas noctigama) (Klapoetke et al., 2014).  
Chrimson is the first known variant with yellow peak absorption (590 nm). It also 
presents low kinetics (low spike reliability over 10 Hz) but to overcome that fact, a Chrimson 
mutant was created (Chrimson R- K176R). This variant displays more appropriate kinetics, but 
due to its ChR2 similarity it shows blue light sensitivity overlapping when paired with ChR2. 
This fact also demands the need of blue-shift variants to achieve independent neuronal 
excitation of two different neuronal populations. Also, ChR-dependent photostimulation may be 
	   36	  
used in combination with fluorescent probes of calcium, membrane potential or other cellular 
functions. For instance, the excitation spectrum of Fluo-3, one of the most popular fluorescent 
calcium indicators, overlaps with the absorption spectrum of ChR2. Therefore, it would be 
difficult to measure Fluo-3 fluorescence during ChR2-dependent photostimulation. This will only 
be achievable with blue-shifted variant of ChR2. 
On the other hand, Chronos is a blue-light sensitive high frequency actuator comparable 
to ChETA variants. Regarding this blue-shift, a novel channelrhodopsin has been discovered and 
characterized, the PsChR from the algae Platymonas (Tetraselmis) subcordiformis. This variant has 
~3-fold greater unitary conductance, faster recovery from excitation and higher sodium 
selectivity than ChR2 (Govorunova et al., 2013). Its maximal spectral sensitivity at 445 nm which 
makes PsChR the most blue-shifted channelrhodopsin so far identified (Govorunova et al., 
2013). 
Recently, a new approach based on the atomistic design of microbial opsin-based blue-
shifted optogenetics tools has been published, in which the development of blue-shifts colour 
variants by rational design at atomic resolution, achieved through accurate hybrid molecular 
simulations, electrophysiology and X-ray crystallography, was obtained (Kato et al., 2015). These 
molecular simulation models and crystal structure demonstrated the precisely designed 
conformation changes of the chromophore induced by combinatory mutations that shrink its π- 
conjugated system, alongside with electrostatic tuning, producing large blue shifts up to 100 nm 
(Kato et al., 2015). Photosensitive ion transport activities were maintained, showing that this 
approach may be applicable to other microbial opsins, at least in the context of blue-shifted 
action spectra of recent proteins isolated from natural sources.  
Another kind of ChR2 variants with great interest would be proteins with variable ion 
selectivity, which would enable broader applications. Although the membrane potential is shifted 
to the negative direction in a light dependent manner by the use of a chloride transporting tool 
such as NpHR, its efficiency is limited because only one ion is transported across the membrane 
with the absorption of a single photon rather than allowing many ions per photon to flow 
through a channel pore. Hence, if channelrhodopsins were designed to be selectively permeable 
to Cl−, they would allow the bulk of ions to flow with the absorption of a single photon. 
Therefore, their hyperpolarizing effects would be expected to be much larger than those of 
Cl−/H+ transporters, such as NpHR or Arch. An example of a successful functional conversion 
regarding this topic is the conversion of ChR2 into a chloride channel by replacement of a single 
amino acid (Glu 90 to lysine, a positively charged residue) (Wietek et al., 2014). This functional 
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conversion enables fast optical inhibition of action potentials, thus silencing neurons (Berndt et 
al., 2014).  
Concerning the most recent variants, the last published red-shifted variant is the red-
activated ReaChR (Lin et al., 2013). This variant if optimally excited with orange to red light in a 
range of 590 -630 nm and offers improved membrane trafficking, higher photocurrents and 
faster kinetics compared to the existing red-shifted ChRs(Lin et al., 2013), such as C1V1(E122T) 
(Yizhar et al., 2011) and VChR1 (Zhang et al., 2008) .  
ReaChR is a complete example of ChR engineering, since it was created by both several 
mutations already described in ChR2, combined with mining chimeras of other available variants. 
Succinctly, Lin and collegues used VChR1, which has minimal trafficking to the membrane, as 
well as poor expression in mammalian cells, as a template to engineer an efficient red-light-
activated channelrhodopsin. To improve desired membrane trafficking, they examined the 
superior membrane trafficking of the available variant ChIEF (Lin et al., 2009), known for an 
almost exclusive plasma membrane expression with minimal cytosolic aggregation in mammalian 
cells without the need for additional trafficking signals (unlike many other ChR variants) (Lin, 
2011). Then, the N-terminus of VChR1 before the transmembrane domain was replaced with 
the equivalent ChiEF sequence. To increase the expression level, they followed a known and 
successful strategy previously used to increase the expression level of ChR in ChR1-ChR2 
chimeras (Wang et al., 2009). Such as, replacing one transmembrane domain of VChR1 with the 
corresponding VChR2 helix. They named this red-shifted intermediate variant VComet, 
displaying optimized membrane expression and trafficking and strong responses to light above 
600 nm (Lin et al., 2013). However, the responses at these longer wavelengths were 
desensitizing and did not recover completely in the dark without reconditioning with 410 nm 
light (Lin et al., 2013). Hence, to reduce this desensitization of VComet to light above 600 nm, 
Lin and collegues decided to insert a known point mutation of ChRs. The ChETA mutation 
(Gunaydin et al., 2010) was inserted but it did not red-shifted or reduces the desensitization of 
VComet. The next attempt was the H134 mutation of ChR2 (Nagel et al., 2005) this howerver 
slowed channel kinetics and degraded the temporal fidelity of this variant. Finally, the mutation 
L171I, corresponding to the same position of the ChIEF mutation (Lin et al., 2009), increased the 
amplitude of the photoresponse until 630 nm light through reduced desensitization while 
retaining the optimized membrane trafficking and expression of VComet. This created the 
ReaChR variant, with a spectral red-shifted peak defined at 630 nm (Lin et al., 2013). This new 
variant describes perfectly the use of available engineering and biotechnological approaches 
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related to optogenetic tools and how all information can be helpful and used together to 
achieve higher development in optogenetics. In the same paper, this variant was also found to 
enable transcranial optical activation of neurons in mouse deep brain structures (Lin et al., 
2013).  
Another new variant was presented last year, the ChR2-XXL (ChR2 mutant D156C) 
(Dawydow et al., 2014). The XXL denomination comes from extra high expression and long 
open state, displaying also improved subcellular localization, elevated retinal affinity and 
photocurrent amplitudes greatly exceeding those of all previous ChR variants (Dawydow et al., 
2014). However, this variant was developed to be used in neuronal activity in adult Drosophila 
melanogaster, still lacking further characterization and applicability for example in mammalian 
neurons. Additionally, its maximum excitation wavelength is ~480 nm, which is similar to the 
470 nm value of ChR2, with only a slight red shift.  
A completely different and new approach to modify the spectral and kinetic 
characteristics of ‘optotools’ was conceived using synthetic retinal analogues (AzimiHashemi et 
al., 2014). As an alternative strategy to mutating the opsin backbone or mining related algal 
genomes, synthetic retinal analogues were combined with microbial rhodopsins for functional 
and spectral properties. Dimethylamino-retinal (DMAR), compared with all- trans-retinal, shifted 
the action spectra maxima of some ChR2 known variants (H134R and H134R/T159C) in ~40 
nm. DMAR also decelerates the photocycle of both ChR2 variants, thereby reducing the light 
intensity required for persistent channel activation (AzimiHashemi et al., 2014). These results 
were also corroborated on assays in C. elegans, HEK cells and larval Drosophila. Yet, experiments 
using mammalian neurons are still to be performed. In parallel to more experiment tests and 
characterization, the use of retinal analogues can be a complementary strategy to obtain 
‘optotools’ with modified characteristics as colour tuning, particularly in already existing cells or 
animal lines.  
In summary, optogenetics are experiencing a fast evolution, much due to development of 
variants of existing optogenetics tools. Channelrhodopsin-2 kinetic variants as ChETA and SFO 
are one good example of successful new variants that resulted from protein engineering, and 
VCR1, Chronos, Crimson and ReaChR are examples of genome-mining approaches leading to 
ChR-like proteins.  
However, there still is the necessity of selectively activating more than one neuronal 
population and to red-shift light activation to prevent tissue damage and increase the 
penetration or radiation. To achieve these goals, colour-tuned variants of ChR2 with activation 
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spectra are needed and the recently and growing knowledge about channelrhodopsin structure 
and variants will be on the base of fundamental importance. New variants should be developed, 
optimized and associated with the already existing range of channelrhodopsins to facilitate the 
diffusion and applicability of a groundbreaking technique like optogenetics. 
 
1.6 – Optogenetic applications 
 
In the last decade, optogenetics has been widely used as a method to study brain 
circuitry (Wang et al., 2007), focused on a specific population of neurons, and even more than 
one population at the same time (Han e Boyden, 2007). It has also helped to elucidate pathways 
of many different diseases. For instance, optogenetics has been used in mice D1 and D2 cells 
(dopamine receptors) in the striatum (Kravitz et al., 2010) and sub-thalamic nucleus (Gradinaru 
et al., 2009), as a way to explore their role in Parkinson’s disease. Regarding this 
neurodegenerative disease, halorhodopsin was also used to enable functional analysis and 
validation of human embryonic stem cell-derived grafts differentiating into dopaminergic 
neurons (Steinbeck et al., 2015).  
A substantial amount of data shows the use of optogenetics to find specific cells to be 
manipulated in order to alter fear memories, treat post-traumatic stress disorder (PTSD), as 
well as other illnesses that revolve around conditioned fear responses (Goshen et al., 2011). It 
has also been used to gain insight into the neuronal networks involved in autism (Gunaydin et 
al., 2014), to test the casual link between dopamine expression and positive reinforcement in 
mental health disorders such as addiction (Witten et al., 2011) and depression (Tye et al., 2013), 
to study social stimuli and social interaction (Yizhar et al., 2011) - possibly providing a hint of 
how circuit-level manipulations might be used for the treatment of neuropsychiatric disorders 
(Peça and Feng, 2011) and to control of epilepsy (with acute potent neural silencers) (Tønnesen 
et al., 2009). Also, optogenetics have been useful in the study of the role of specific neurons in 
behaviours such as breathing (using ChR2 to restore breathing in rodent models of spinal cord 
injury) (Alilain et al., 2008; Arenkiel e Peca, 2009), awakening/sleep disorders such as narcolepsy 
(Adamantidis et al., 2007) and appetitive or aversive learning (Schroll et al., 2006).  
However, there has been a scarcity of studies that demonstrate potential translational 
applications, with only a handful of experiments to have implemented optogenetics approaches 
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towards this goal and focusing on arguably less-tractable therapies than that being reviewed 
(Arenkiel and Peca, 2009).  
Probably the best example with the strongest potential for translational applications to 
humans has been achieved by ophthalmology. In 2006, it was observed that it was possible to 
restore light-encoded signals to the visual cortex in mice lacking photoreceptor cells by 
expression and activation of ChR2 in subsets of inner retinal neurons (Bi et al., 2006). This study 
established the groundwork for related manipulations in other cell types of the retina (Lagali et 
al., 2008; Lin et al., 2008).  
More recently, viral delivery of ChR2 has shown to enable safe and effective restoration 
of the visual function in multiple mouse models of blindness (Doroudchi et al., 2011; Macé et al., 
2015; Wyk, van et al., 2015), thus starting the discussion of future perspectives to the use 
optogenetic approaches to retinal prosthesis, aiming for the first optogenetic human trials 
(Barrett, Berlinguer-Palmini e Degenaar, 2014). As such, GenSight Biologicals, a company 
founded by experts in the fields of ophthalmology and optogenetics, is aspiring to use this 
technique to treat blindness caused by diseases resulting from cell loss in the retina, including 
glaucoma and retinitis pigmentosa. The company is currently in pre-clinical development, based 
on a gene therapy product comprising a non-specified ChR2 and a delivery modified AAV2. 
However, it is important to take into consideration the importance of fully understanding the 
mechanism of how retinal maps translate to visual perception (Arenkiel et al., 2007). In theory 
optogenetics could be used as a therapeutic intervention in conditions for which there is a clear 
benefit to be obtained from switching on or off specific cells types (Chow and Boyden, 2013). 
However, there are several problems that must be tackled before this becomes reality, such as 
the need to deliver genetic constructs into the body by means of viral vector, a technology that 
is far from being fully established in humans.  
In summary, great progress has been made in a short period of time and optogenetics 
have made it conceivable to either increase or decrease the activity of specific neural 
populations in multiple brain regions. Mainly based in animal models of human disease, 
optogenetics have delivered new mechanistic insights into a significant range of human 
psychiatric and neurological diseases, with an expectable growing influence in the scientific 
community as new ‘optotools’ are being developed at a rapid pace.  
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1.7 – The Pichia pastoris protein expression platform 
 
The methylotrophic yeast species Pichia pastoris is a widely used heterologous system for 
the expression of a large variety of recombinant proteins, and a remarkable example of a 
developed and settled biotechnologic approach used for biochemical, genetic, biotechnology 
research and industry.  
The P. pastoris system was originally established as a supply for single cell protein used in 
animal feeding, due to its capacity to metabolize methanol as its sole carbon source. Pichia 
pastoris has also been used for the expression of heterologous proteins (Daly e Hearn, 2005; 
Macauley-Patrick et al., 2005).  
The popularity of this recombinant expression system can be attributed to various 
factors, but mainly to the simplicity of techniques that are necessary for the molecular genetic 
manipulation of this species. Also, P. pastoris can produce exogenous proteins intracellularly or 
towards secretion and perform post-translational modifications, such as glycosylation, disulfide 
bond formation and proteolytic processing (Cereghino, 2000).  
The last few years this system has been improved in terms of expression of complex 
proteins, mainly by protein engineering or altering the P. pastoris protein expression 
host (Ahmad et al., 2014). Comparing to other systems Pichia has advantages such as performing 
glycosylation process and presenting a more appropriate lipid membrane composition, thus 
allowing proper folding of proteins – these are not possible in prokaryotic systems (Higgins, 
2001; Ramón e Marín, 2011). In fact, expression of membranar proteins (such as 
channelrhodopsin) is a specific advantage of this system, given that membrane proteins have a 
tendency to aggregate into inclusion bodies in E. coli. However, as a result of the existence of 
eukaryotic folding/targeting machinery, these proteins can be successfully produced in Pichia 
pastoris (Ramón e Marín, 2011). 
The methylotrophic function in Pichia allows methanol or methane as sole carbon and 
energy source for growth. This feature is due to capability of the yeast cell to use its specialized 
organelle – the peroxisome. This organelle works by corralling reactive chemical metabolites, 
thus preventing cellular damage. The peroxisome contains a high concentration of the Alcohol 
Oxidase enzyme that mediats oxidation of alcohol into aldehyde. A specific promoter for this 
enzyme gene (AOX gene) is under tight regulation and behaves much like the E.coli lac promoter 
(Beckwith, 2013).  
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The AOX gene is very selective for methanol, and is activated only when methanol is 
present in the media, and is strongly repressed by alternative carbon sources (e.g. glucose, 
ethanol or glycerol). The AOX promoter is also capable of inducing the expression of very high 
levels of the enzyme, which may reach 5 to 30 % of AOX protein in the total soluble protein 
expressed under methanol induction. Consequently, the AOX1 promoter has been inserted into 
several expression vectors for the tightly regulated methanol-induced expression of genes of 
interest (Ellis et al., 1985; Koutz et al., 1989; Tschopp et al., 1987), and is one of the principal 
promoter used for the heterologous expression of recombinant proteins in Pichia pastoris.  
However, alternative promoters can be selected to drive protein expression. The GAP 
promoter drives the expression the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
enzyme in a constitutively manner and is expressed at high levels in many organisms, including 
Pichia pastoris. Therefore GAP promoter driven expression leads to a constitutive expression in 
Pichia (Qin et al., 2011; Zhang et al., 2009).  
 Budding yeasts such as Saccharomyces cerevisiae and Pichia pastoris are widely used as 
hosts to produce excreted proteins for research and therapeutic purposes (Gasser et al., 2013; 
Hou et al., 2012). Many of these excreted proteins cross the secretory pathway (Barlowe e 
Miller, 2013). Entry into the secretory pathway requires an N-terminal signal sequence that 
directs translocation into the endoplasmic reticulum (ER). A typical signal sequence includes a 
stretch of hydrophobic residues that are exposed following cleavage of the site that is 
recognized by signal peptidases in the ER lumen. After entry into the ER, proteins fold, and may 
undergo additional changes that include disulfide bond formation, glycosylation and 
oligomerization. Finally, the protein is delivered from the ER to the Golgi apparatus and then to 
the extracellular space. For different exogenous proteins expressed in yeasts, the level of 
secreted product varies widely, presumably because specific steps in the secretory pathway can 
be inefficient (Idiris et al., 2010). Hence, in order to secrete proteins for easier purification from 
the extracellular medium, the coding sequence of recombinant proteins is initially fused to the 
Saccharomyces cerevisiae α-mating factor secretion signal leader (Lin-Cereghino et al., 2013). 
Some proteins can be expressed fused to an N-terminal peptide encoding the Saccharomyces 
cerevisiae α-factor secretion signal encoded in a vector containing the AOX promoter sequence. 
A vector like this allows high-level, methanol inducible, secreted expression of the gene of 
interest in Pichia pastoris.  
The AOX promoters are specifically used in the pPICZ vector series, the pPICZα vectors 
are used the secretion signal is included and the pGAPZ vectors display the GAP promoter use.  
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These vectors usually contain a 5’ fragment containing the specific promoter for the 
selected expression type, a resistance gene for selection against Zeocin antibiotic in both E. coli 
and Pichia (Baron et al., 1992; Drocourt et al., 1990), a C-terminal peptide containing a 
polyhistidine (6xHis) tag for further detection and purification of a recombinant fusion protein, 
and three reading frames facilitating in-frame cloning with the C-terminal peptide. Thus, 
approaches for heterologous expression of recombinant proteins involve cloning the desired 
protein into an expression vector. For example, the pGAPZ series vector has a homologous 
arm to the GAP gene. It is thus important to consider that linear DNA can generate stable 
transforming of Pichia pastoris via homologous recombination between the transforming DNA 
and regions of homology within the genome (Cregg et al., 1985, 1989). Hence, upon 
linearization of the vector and insertion into the cell, recombination events occur and the gene 
is inserted at the GAP locus (Figure 15a). Similarly, naturally and spontaneously multiple 
recombination events can occur and multicopy mutants can be found which usually tend to 
produce protein proportionally to the number of gene copies inserted into the genome (Daly e 
Hearn, 2005) (Figure 15b).  
The low cost and high yield, combined with the advantages of a eukaryotic processing 
machinery makes Pichia pastoris an attractive system for small and large scale production of 
integral membrane proteins (Byrne, 2015). 
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Figure 14 – Recombination and integration in Pichia pastoris. (a) Gene insertion at the GAP 
promoter and single copy integration. By homology recombination, the GAP locus promotes the insertion of the 
gene of interest into the Pichia genome normalized. (b) Multicopy gene insertion events and multicopy integration. 
Subsequent to the first integration, the homology sequence persists in the yeast genome and events of homologous 
recombination can occur. Although with a fewer incidence, this leads to generation of multicopy inserts of the gene 
of interest. Zeocin antibiotic resistance cassette is similarly inserted multiple times, creating Zeocin hyper-resistant 
colonies. (adapted from (Invitrogen, 2010)). 
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1.7.1 – Channelrhodopsin-2 and Pichia pastoris  
 
The heterologous system mostly used to produce and purify ChR2 has also been the 
Pichia pastoris yeast (Bamann et al., 2008, 2010). Many studies with channelrhodopsin use this 
expression system, including the first paper reporting the structural features and the photocycle 
of ChR2 (Bamann et al., 2008). Moreover, protein engineering studies focusing on new variants 
and mutations also use this expression system, as demonstrated, using structural approaches, by 
the broadly characterization of the identified mutations C128S and D156A (SFO’s), which 
operate with Pichia pastoris as the chosen model of expression (Nack et al., 2010).  
Interestingly, functional expression of channelrhodopsins, and specifically ChR2, in the 
standard system E.coli has proven to be difficult (Ernst et al., 2008; Sineshchekov et al., 2013). 
However, proton pump microbial rhodopsins can be successfully expressed in E.coli, particularly 
in the genetically modified strain BL21(DE3), which is more suitable for transformation and 
protein expression. This makes sense given that bacteriorhodopsin, the most studied proton 
pump, was originally isolated from prokaryotic Archaea. Insect cells (Sf9) have also been 
sucessefully used to produce active channelrhodospin (Kato et al., 2012, 2015).  
 
1.8 Time-Dependent Density Functional Theory 
 
It is possible to describe quantum-mechanically the electronic dynamics of a particular 
system using the time-dependent Schrödinger's’ equation (SEq). However, a system may be as 
“simple” as a single electron or it may refer to more complex molecules with many electrons, 
such as amino acids, retinal and proteins.  
Despite this equation being well known and developed, its solution is only feasible for 
very small systems. Therefore, a reasonably sophisticated approach to solve this drawback of 
scalability is to use the Density Functional Theory (DFT) (Burke, Werschnik e Gross, 2005). 
Basic ideas of DFT are related to giving importance to density and non-interacting particles. 
That is, any observable of a quantum system can be obtained from the density of the system 
alone and secondly, the density of an interacting-particles system can be calculated as the 
density of an auxiliary system of non-interacting particles. This system is based in a formulation 
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like the Kohn-Sham one-particle equations (Kohn e Sham, 1965), that requires the use of a non-
exact form to account for the electronic correlation and to correct the kinetic energy 
expression, and computational  methods needed for appropriate process of  high amount of 
data. Consequently, this theory stipulates a simple and exact reformulation of SEq for a multiple-
particle system. For such complex molecules as proteins, DFT allows for the derivation of a set 
of equations that depend uniquely on the electron density, that is a function of the 3 space 
variables, instead of depending on many-body wave functions (in SEq), a function of 3 variables 
for each electron. Besides, these electrons with varying variables can be divided into different 
groups such as inert or dynamic ones, leading to simplifications that may drive the output of the 
equation to be somewhat different from what it is observed.   
Furthermore, Time Dependent DFT is a large field of research concerned with many-
electron systems in time-dependent fields, such as different phenomena like absorption spectra, 
energy loss spectra, photo-ionization and photo-emission..  
In general, to achieve an absorption spectra simulation, TDFT role starts by firstly using 
the Kohn–Sham algorithm to have a value of the solution, then solved by a computational 
program that creates a 3D function of the electron density of the molecule as its base. Next, a 
stimulus is settled to the obtained simulation of the electronic cloud of the molecule and it is 
studied how it evolves during a specific time. In the case of ChR2, the interest is mainly on the 
effect of the visible spectra light on the molecule. Hence, the stimulus is a very fast flash of light, 
in the order of 10-17 seconds, and it is known as a ‘’kick’’. It excites the molecule with 
electromagnetic radiation with a very wide spectrum of frequencies. This ‘’kick’’ must be applied 
across the three different axis and later collected into a final effect. After each “kick” the system 
evolves and changes its dipole moment. 
This system has the advantage of not accounting for energy transfers between adjacent 
molecules that may appear in nature, reinforcing the accuracy of the results and limiting the 
stimulus time propagation. After a certain and global amount of runs, it is created an output of 
several absorbance values as a function of wavelength which finally provides the simulated 
absorbance spectra of the studied channelrhodopsins. Hence, this system could be adapted to 
predict the effect of distinct mutations on a molecule, by changing the electron density cloud in 
the simulation and producing a novel hypothetical absorbance for the molecule. 
In summary, the Time-Dependent Density Functional Theory (TDDFT) can be viewed as 
an exact reformulation of time-dependent quantum mechanics, where the fundamental variable 
is no longer the many-body wave function, but the density. This time-dependent density is 
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determined by solving an auxiliary set of non-interacting Schrodinger equations, the Kohn-Sham 
equations (Marques and Gross, 2004). Moreover, TDDFT has established extremely precise 
descriptions of biological chromophores such as fluorescent proteins like GFP (Marques et al., 
2003) and it was already used for the study of the excited state of DNA bases (Varsano et al., 
2006).
 
 
 
1.9 – Objectives 
 
A major challenge facing neuroscience is the need to control one type of cell in the brain while 
leaving others unaltered. Francis Crick’s goal has become a reality in the last decade. 
Optogenetics has emerged as a technique that allows the precise control over genetically 
altered neuronal populations, with a high degree of spatial and temporal resolution. A key 
component in optogenetic strategies is the protein ChR2, a light-gated channel that can be 
controlled with blue light, and that is currently the central paradigm of several improved tools 
driving the evolution of optogenetics.  
Taking advantage of the recently published crystal structure of a model channelrhodopsin 
we applied Time Dependent–Density Functional Theory (TDDFT) to calculate specific point 
mutations predicted to induced red- and blue-shifts in the absorption spectra of ChR2. These 
mutations, if successful, may then be subsequently inserted in other rhodopsins for greater 
effect.   
The relatively short supply of a red-shift alternative handicaps the use of ChR2 for 
deeper tissue stimulation, but also disqualifies its use for the distinct excitation in spatially 
overlapping neuronal population. For this last case, we also aimed to create a a blue-shift 
variant, leading to a separation of the maxima peaks of red and blue shifted mutants, but also 
further validating TDDFT predictions. 
The main goal of the present project is to test the in silico prediction from TDDFT, 
provided by the Center for Computational Physics of University of Coimbra, and to create 
several mutant forms of ChR2 that display compounded red-shifted absorption and other 
characteristics desirable for future biotechnological, neuroscience, pharmaceutical and 
biomedical applications. As such, our goals included the use of site-directed mutagenesis to 
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generate new ChR2 mutants, and then the optimization of their expression and purification 
from two different heterologous systems (E. coli and Pichia pastoris), as well the characterization 
of the absorption spectra of the modified channels.  
Validation of TDDFT will create an original method to produce a platform to requested 
colour-tuned ChR2 mutants towards the development of the optogenetic toolbox, with also a 
contribution to a wide range of previously mentioned scientific applications. We believe the 
same rationale can be applied in the future to create additional colour-tuned molecules.  
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II.1 – Materials 
 
II.1.1 – Organisms 
 
In this work, cultures of bacteria (Escherichia coli), yeast (Pichia pastoris) and primary rat 
cortex neurons were used. Their experimental use and source (table 1) are described in the 
following table. 
 
 
Organisms                              Use                                   Source 
Escherichia coli DH5α  Molecular cloning Invitrogen 
Pichia pastoris X-33 Protein 
expression/purification 
Invitrogen 
Pichia pastoris SMD 1168H Protein 
expression/purification 
Invitrogen 
Table 1 – List of organisms used in the present work. 
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II.1.2 – Vectors 
 
Different vectors were used in this study, for different purposes, such as cloning and 
protein expression. After each molecular cloning experiment, each vector was analyzed by 
restriction enzyme digestion and sequencing, to confirm and validate the cloning process.  
 
Vector name                       Features                             Source 
pcDNA3.1-hChR2 CMV promoter; hChR2-eYFP; 
AmpR 
addgene.org ( from Karl 
Deisseroth) 
pPICZ A AOX1 promoter; c-myc tag; 
6x His tag; ZeoR 
Invitrogen 
pPICZ(alpha) A AOX1 promoter; α-factor 
signal sequence; c-myc tag; 6x 
His tag; ZeoR 
 
Invitrogen 
pGAPZ A GAP promotor ; c-myc tag; 6x 
His tag; ZeoR 
Invitrogen 
   
Table 2 – List of vectors used in the present work. 
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Figure 15 – Maps of vectors used in the present work. (a) The pcDNA3.1 vector includes a 
fusion protein of ChR2 and eYFP, regulated by the CMV promoter, an ubiquitous mammalian promoter. This 
vector was kindly provided by Karl Deisseroth (Stanford University, USA). (b) The pPICZ A vector includes 
AOX1, a specific inducible promoter for expression in P. pastoris and a Zeocin cassette used for positive clones 
selection. (c) The pPICZ(alpha) A vector shares the same features as the pPICZ A vector, but includes an α-factor 
signal sequence that enables the protein of interest to be secreted to the extracellular medium. (d) The pGAPZ A 
vector has a constitutive promoter, GAP, also suitable to be used in P. pastoris. All the vectors underwent 
restriction enzyme digestion and sequencing to confirm the presence of all the described features in each vector.  
 
II.1.3 – Primers  
 
 All primers used in this work were synthesized in Stabvida (Lisbon, Portugal) and its 
name, sequence and purpose of use are described in Table 3, at the end of this chapter. 
A B 
C D 
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III.1.4 – Antibodies 
 
Primary antibodies Application (dilution) Source  
His-Tag                                 WB (1:1000)            Cell signaling technologies (MA,USA) 
Table 4 – Primary antibody used in this study. 
 
 
Secondary antibodies            Application (dilution)             Source 
Anti- rabbit WB(1:10000) Jackson Immunoresearch 
Inc.(PA,USA) 
Table 5 – Secondary antibody used in this study. 
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II.2 – Methods 
 
II.2.I – Channelrhodopsin-2 absorption spectra predictions 
and mutations rationale  
 
 Fernando Nogueira at the Center for Computational Physics at the University of 
Coimbra (C.C.F.U.C), provided the theoretical predictions of wild-type and mutants of 
channelrhodopsin-2 (ChR2) absorption spectra using created based on the Time dependent- 
Density Functional Theory (TD-DFT).  
 To create the ChR2 new variants, numerous aspects related to the choice of the 
residues to be mutated were considered. For instance, to maintain the channel activity of ChR2, 
no mutations were designed for the residues of the ion pore transmembrane sequence. 
Additionally, it was defined that the change of polarization/charge in mutated residues should 
result into larger effects than mutating a residue for a similar amino acid. Final residues choice 
was also complemented with additional information concerning the polarization of the retinal 
molecule, also provided by our collaborators at the C.C.F.U.C. 
 
II.2.2 – Molecular Biology experiments 
 
Site-directed mutagenesis  
 
 To generate the new variants of ChR2, site-directed mutagenesis was performed. Before 
the mutation procedure, the original DNA containing ChR2 (plasmid 20939: pcDNA3.1-hChR2- 
eYFP from addgene.org) was analyzed by enzymatic restriction digestion. This analysis was 
performed using enzymes such as XbaI and BamHi (NEB, MA, USA). The digestion product was 
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then loaded with DNA loading buffer (0,25% Bromophenol blue; 40% sucrose) into a 1% 
agarose gel and separated by electrophoresis in TAE buffer (40mM Tris Acetate; 1mM EDTA), 
until the correspondent bands were observable under UV light. 
 The site-directed mutagenesis strategy includes the use of specific synthesized primers 
(Table 3) (Stabvida, Lisbon, Portugal), designed using the PrimerX algorithm 
(http://www.bioinformatics.org/primerx/). These primers were designed to hybridize with part 
of the original ChR2 except for the nucleotides targeted for mutation. Polymerase chain 
reaction was performed to obtain mutated, linear DNA fragments (PCR) (Table 6). The 
temperatures and number of cycles used in this reaction are indicated in Table 7. 
 Mutagenesis PCR products were then incubated with DpnI enzyme for 2 hours and 30 
minutes to remove parental methylated DNA, in a 1% agarose gel. A DNA recovery kit 
(Zymoclean Research, CA, USA) was used to recover and purify the digested DNA from the 
agarose gel. Of the total purified DNA, 20 uL were used for bacterial transformation. 
 
Reagents       Concentration           Volume 
5X PrimeSTAR buffer 5x 10 µl 
dNTP mix 200 nM 4 µl 
FW primer 200 nM 1 µl 
REV primer 200 nM 1 µl 
Template DNA (pcDNA3.1-
hChR2) 
500 ng 1 µl 
DNA polymerase (PrimeSTAR 
HS DNA Polymerase) 
2,5U/ µl 1 ul 
dH2O  32 ul 
Table 6 –PCR reaction mix for ChR2 directed mutagenesis. 
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Temperature(ºC)     Cycles                      Time(sec)                   ChR2 variants                          
92  30  
 
F217D and L221D 
95   
18 
30 
55 30 
68 510 
 
98  30  
 
F269D and F269H 
98  
18 
30 
65 30 
72 510 
Table 7 – PCR programs for specific ChR2 mutations. 
 
Bacteria transformation 
 
 The E.coli DH5α competent bacteria used for bacteria transformation was prepared with 
standard protocols. Briefly, after inoculation of 150 ml of LB media, cells were allowed to grow 
at 37ºC until O.D.600=0,4 was reached. Cells were then pelleted at 3000 xg for 10 minutes at 
4ºC and the media removed. The pellet was ressuspended in 20 mL of cold 0.1 M CaCl2 and 
incubated for 30 minutes at 4ºC. The suspension was then centrifuged at 3000 xg for 10 
minutes and ressuspended in 3 mL of 0.1 M CaCl2 supplemented with 15% glycerol. The 
competent cells were then aliquoted and frozen in dry ice/ethanol slurry and stored at -80ºC 
until further use.  
 Bacteria transformation was performed by adding plasmid DNA (~ 100ng-1ug) to an 
aliquot of competent cells previously thawed on ice. The suspension was then incubated on ice 
for 30 minutes. Subsequently, a heat shock treatment of 45 seconds at 42ºC was done to the 
suspension, which were then allowed to recover on ice for 5 minutes. Afterwards, 9 volumes of 
LB (Fisher scientific, PA, USA) were added and the suspension was incubated at 37ºC for 1 
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hour. Finally, cells were plated in LB/Agar plates previously prepared with the appropriate 
antibiotic, to allow the growth of only the bacteria expressing the antibiotic resistance cassette, 
present in the vector. 
 
DNA isolation 
 
 Sixteen hours after bacteria transformation, colonies were picked and allowed to grow 
overnight in LB solution supplemented with the appropriate antibiotic. Plasmid DNA was then 
extracted and purified using a NZYMiniprep kit (NZYtech, Lisbon, Portugal), according to the 
manufacturer’s instructions. Purified DNA was eluted with 15 µl of dH20. 
 
 
DNA sequencing 
 
 To confirm the success of the site-directed mutagenesis and all cloning procedures in 
this project, a sample of the obtained DNA was sent to Stabvida (Lisbon, Portugal) for 
sequencing. The primers used for the sequencing procedures are indicated in Table 3. 
 
ChR2 cloning into the pPICZ A vector 
 
 The sequences encoding the wild type and mutant forms of ChR2 were cloned into the 
pPICZ A vector (Invitrogen, PA, USA) in frame with 6x His TAG sequence. A set of specific 
primers (Table 3) were designed to add a 5’ EcoRI and 3’ KpnI restriction sites to the desired 
ChR2 fragment. Furthermore, a yeast Kozac sequence (AAAAATGTCTG) was added to the 5’ 
end to further increase the expression efficacy (Kozak, 1987, 1990, 1991). The final fragment 
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was amplified by PCR reaction (Table 8), performed with the same protocol in Table 6, 
previously established and optimized. After DNA amplification was complete and confirmed in 
an agarose gel, the sample was treated with 1 µl of Proteinase K (NEB) for 30 minutes at 55ºC 
to remove Taq polymerase and possible contaminants and finally digested with KpnI and EcoRI 
(NEB, MA, USA) restriction enzymes for 3 hours. The digestion product was then loaded into a 
1% agarose gel and, after excision of the correspondent band the DNA was purified using the 
Gel DNA Recovery Kit (Zymoclean Research, CA, USA). The vector was also digested with the 
same enzymes, followed by incubation with calf-intestinal alkaline phosphatase (CIP) (NEB) to 
prevent vector re-circularization. The vector was purified using the same kit, and ligation with 
the ChR2 PCR insert was performed in a total volume of 10 uL using T4 Ligase (NEB) according 
to manufacturer’s instructions. Once ligation was completed, the total reaction volume was 
transformed into E.coli DH5α and colonies were grown in LB/Agar plates supplemented with the 
appropriate antibiotic (25 ug/ml Zeocin (Invitrogen). Colonies were then screened by PCR 
reaction (table 9 and 10), using AOX primers (Table 3) and the DNA the from positive ones 
isolated and sent to sequencing to confirm the correct insertion and frame of the different 
variants of ChR2 (wild-type and mutants). 
 
 
Temperature(ºC)     Cycles                      Time(sec)                   ChR2 variants                          
Table 8 – PCR program for ChR2 insert into pPICZ A vector. 
 
 
 
98  30  
 
F217D; L221D; 
F269D; F269H and 
Wild-type 
98   
35 
10 
55 10 
72 120 
72  300  
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Reagents       Concentration           Volume 
FW primer 200 nM 1 µl 
REV primer 200 nM 1 µl 
Template DNA 0.01-0.5 µg Pick colony 
NZYTaq 2x Green Master 
Mix (NZYtech) 
0.2 U/ µl 12,5 
dH2O  10.5 
Table 9 –PCR screening reaction mix for ChR2. 
 
 
Temperature(ºC)     Cycles                      Time(sec)                   ChR2 variants                          
Table 10 – PCR screening program for ChR2.  
 
 
 
 
 
95  120  
 
F217D; L221D; 
F269D; F269H and 
Wild-type 
95  
30 
60 
52 30 
72 60 
72  300  
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ChR2 cloning into pPICZ(alpha) A and pGAPZ A vectors 
 
 Channelrhodopsin-2 was cloned into two suitable vectors for recombinant expression in 
Pichia pastoris, the pPICZ(alpha) A and pGAPZ A vectors (Invitrogen, PA, USA), using a cloning 
strategy similar to the one used for the pPICZA vector.  
In pPICZ(alpha) A vector (Fig. 17) cloning, to amplify the ChR2 insert (from pcDNA3.1-
hChR2- eYFP), a different designed set of primers (Table 3 and 11) was used containing the 
same restriction site sequences used for pPICZ A vector cloning. After digestion of the vector 
and the ChR2 inserts of the wild type and mutant forms of the protein with the same restriction 
enzymes, the screening was performed by PCR with the same primers and reaction mix used in 
the cloning of the pPicZ A vector. In this cloning the ChR2 sequence was fused with the α-
factor signal sequence and in frame with the referred one, with the AOX1 promoter and with 
the 6x His Tag sequence.  
 Cloning the ChR2 forms into the pGAPZ A vector was done with the same protocol 
used for the cloning of the pPICZ A vector, including the primers (Table 3, 6 and 8). However, a 
different forward primer (Gap_Scr_FW) (Table 3, 9 and 12) was designed specifically for the 
screening step. This specific primer makes pair with the AOX REV (Table 3), since this vector, 
despite including a GAP constitutive promoter, still presents the AOX1 promoter terminator. 
Importantly, the sequences for ChR2 were in frame with the GAP promoter, with the added 5’ 
end Kozac sequence and with the Histidine tag.  
 
Temperature(ºC)     Cycles                      Time(sec)                   ChR2 variants                          
Table 11 –PCR program for ChR2 insert into pPICZ(alpha) A vector. 
98  30  
 
 Wild-type 
98  
30 
10 
60 15 
68 120 
68  600  
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Temperature(ºC)     Cycles                      Time(sec)                   ChR2 variants                          
Table 12 –PCR screening program for ChR2 cloning into pGAPZ A vector. 
 
 
Vector linearization 
 
 The efficiency of yeast electroporation is higher when the plasmid DNA is linearized, 
facilitating homologous recombination in the Pichia pastoris genome. As such, all vectors cloned 
with the different ChR2 forms were digested to generate a linear fragment. Briefly, 10 ug of 
each ChR2 DNA (wild-type and mutants) were digested with 5 ul of CutSmart buffer (NEB, MA, 
USA), 2 ul of PmeI enzyme (NEB) in a final volume of 50 ul, for 3 hours. After that, an additional 
1 ul of enzyme was added and the digestion continued for more 2 hours. After digestion, 
linearization was confirmed in a 1% agarose gel. Finally, the digestion product was purified using 
the DNA Clean & Concentrator kit (ZymoClean Research, CA, USA). For the linearization of 
the vectors pPICZ A and pPICZ(alpha) A, specific restrictions enzymes that cleave the 
promoter region once but do not cleave within the ChR2 sequence were chosen. The PmeI 
enzyme was used with the pPICZ A and pPICZ(alpha) A vectors , whereas the  Bsp HI enzyme 
was used with the pGAPZ A vector.  
 
 
95  120  
 
 Wild-type 
95  
29 
60 
60 30 
72 60 
72  300  
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Pichia pastoris electroporation 
 
 The heterologous system chosen for the expression of wild type and mutant forms of 
the ChR2 protein was Pichia pastoris. The integration of the ChR2 protein sequences in the yeast 
genome was obtained with electroporation. Before the procedure, the selected P.pastoris strain 
(X-33 and SMD 1168H) was grown for 48 hours on YPD plates (1% yeast extract, 2 % peptone, 
2% dextrose and 2% agar; from Fisher scientific, PA, USA). Then, a pre-inoculum of 10 mL of 
YPD media (1% yeast extract, 2 % peptone and 2% dextrose) was inoculated from a single 
P.pastoris colony and grew allowed to grow overnight in a 50 mL conical tube (FalconTM; Fisher 
scientific) at 30ºC. On the following day, the culture was used to inoculate a 500 mL YPD 
culture in a 2.8 L Fernbach culture flask to a starting OD600 of 0.01. The culture was allowed 
to grow to an OD600 of 1.0 for 12 hours. Then, cells were harvested by centrifugation at 2000g 
at 4ªC, the supernatant was discarded, and the cells ressuspended in 100 mL of fresh YPD 
medium with HEPES (pH 8.0, 200 mM, Fisher scientific) in a sterile 250 mL centrifuge tube. 
Next, 2.5 mL of 1 M DTT (Fisher scientific) was added to the cells, gently mixed and incubated 
at 30ºC for 15 minutes. After incubation, 150 mL of cold water was added to the culture and 
washed by centrifugation at 4ºC with an additional 250 mL of cold water. At this stage, and from 
here on, the cells were kept on ice and in each step cells were ressuspended with slow 
pipetting, avoiding vortex.  A final wash step was done with 20 mL of cold 1 M sorbitol (Sigma, 
NJ, USA) and then ressuspended in 0.5 mL of cold 1 M sorbitol, resulting in a final volume of 
1.0-1.5 mL, including cells. These cells were used directly and freshly in the electroporation. 
For the electroporation procedure, up to 1 ug of linearized plasmid DNA sample (in no 
more than 5 ul of water) was added to a tube containing 40 ul of fresh competent cells. The 
entire mixture was transferred to a 2 mm gap electroporation cuvette, on ice. The cell 
suspension was pulsed using MicroPulserTM Electroporator’s “Pic” protocol (BioRad, CA, 
USA). Then, 0.5 mL of cold 1M sorbitol and 0.5 mL of cold YPD were added immediately to the 
cuvette and its entire content was transferred to a sterile 2.0 mL mini-centrifuge tube. Cells 
were incubated for 3.5-4 hours at 30ºC with slow shaking (100 rpm). Finally, cells were spread 
onto YPD plates with 0, 100, 1000 and 2000 ug/ml Zeocin plates, to ensure the growth of 
recombinant colonies only. Agar plates were incubated for 2-4 days at 30ºC before screening. 
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II.2.3 – ChR2 expression and purification from P.pastoris 
 
Protein expression and extraction 
 
 Protein expression was first done in small scale, with the objective of screening the best 
colonies expressing ChR2. After choosing the colonies, ChR2 expression was done in a larger 
scale, to obtain higher amounts of protein. 
For the expression of ChR2 in small scale, several single colonies were picked from 
higher resistance plates, 2000 ug/ml Zeocin plates (hyper resistant clones). These colonies were 
re-streaked onto 1000 ug/ml Zeocin plates to obtain isolated colonies and at the same time, to 
evaluate the expression of clones. Each colony was grown in 5 mL of BMGY (1% yeast extract, 
2% peptone, 100 mM potassium phosphate pH 6, 1.45& YNB, 4x10-5 biotin, 1% glycerol) and 
allowed to grow overnight. Then, 100 uL of the culture was added to 10 mL of buffered glycerol 
complex medium (BMGY) and grown overnight again, until a 4-6 OD600 was achieved. The cells 
were harvested by centrifugation at 3000xg for 10 minutes and then ressuspended in buffered 
methanol complex medium (BMMY) (1% yeast extract, 2% peptone, 100mM potassium 
phosphate, pH 6, 1.45% YNB, 4x10-5
 
% biotin; 2.5% MeOH and 10uM all-trans-retinal) in a final 
volume of 50 mL to achieve a final OD600 of 1, with further incubation for 24 hours at 30ºC. 
After induction, cells were harvested again at 3000xg for 10 minutes. Using the cell pellets 
obtained, 15 mL of homogenization buffer (11,3mM NaH2PO4 (Acros, NJ, USA); 100mM NaCl 
(Acros); 5% glycerol (Fisher, PA, USA); 1mM PMSF; 0.1 mg/ml pepstatin; 0.03 mM leupeptin; 145 
mM benzamidine; 0,37 mg/ml aprotinin (Sigma, NJ, USA)) was added to the 50 mL culture pellet. 
To induce cell lysis, a cell pressure French press system was used (Thermo, MA, USA). Each cell 
suspension was run through the French press three times at ~7000 psi. After this step, intact 
cells and unwanted cell debris were removed by centrifugation at 8000 xg for 20 minutes and 
the pellet was discarded. To achieve the enriched membrane fraction, the supernatant was then 
ultra centrifuged at 180000 xg for 1 hour, ressuspended in solubilization buffer A (20 mM 
potassium phosphate pH 7,4 (Acros); 200 mM NaCl; 5% glycerol; 1% (m/v) n-Dodecyl β-D-
maltoside (Calbiochem/Merch, Nottingham, UK); 250 mM l-arginine (Sigma, Buchs, Switzerland); 
3uM all-trans-retinal (Sigma); 10mM imidazole (Sigma); 0,1mM PMSF (Acros)) in a ratio of 500 ul 
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per 50 mL of the initial culture. Ressuspended membrane fraction was then solubilized overnight 
and a new ultra centrifugation at 180000 xg for 1 hour was performed to remove insolubilized 
membrane fraction. 
After the small-scale expression protocol, glycerol stocks were made from the screened 
positive colonies with high expression of ChR2, by diluting 800uL of culture into 500uL of 50% 
glycerol. These stocks were then used to obtain higher amounts of the different forms of 
ChR2cprotein for purification, using the same protocol previously described but now using 
increased volumes of the different solutions, to a final volume of 3 L of BMMY. As such, for the 
larger expression of the ChR2 proteins, a homogenization buffer ratio of 25 mL per 500 mL of 
initial culture was used and the ratio of solubilization buffer was increased to 5 mL per 500 mL 
of starting culture. Importantly, in this case, the EmulsiFlex-C5 system (Avestin, ON, Canada) 
was used to lyse cells, since the higher volume, viscosity and thickness of the cell suspensions 
after large-scale expression renders samples unable to flow properly through the French Press.  
 
Protein purification with nickel affinity chromatography 
 
 Solubilized membrane fractions obtained for the clones expressing wild type and mutant 
forms of ChR2 were diluted 1:10 in solubilization buffer B (20mM potassium phosphate pH 7,4; 
200mM NaCl; 5% glycerol; 0,03%(m/v) n-dodecyl β-D-maltoside; 0,1 mM PMSF; 10mM 
imidazole). This dilution was made to decrease the concentration of protein and DDM to values 
compatible with the columns used during the purification step (1 or 5 mL HisTrap FF Crude; GE 
Healthcare, NJ, USA). By means of peristaltic pump (~0.5 ml/min), 10-15 volumes of 
solubilization buffer B were used to equilibrate the column. Protein extracts were then loaded 
using the same system and samples were collected as flowthroughs. After all the ChR2 protein 
extracts had passed through the column, 10 more volumes of solubilization buffer B were 
loaded to make a re-equilibration and the columns were inserted into an AKT FPLC system (GE 
Healthcare) where OD260 was supervised. This system was set to a flow rate of 0.7 mL/min and 
equilibrated with solubilization buffer B until a stable baseline of OD260 was reached. Next, the 
column was washed with the solubilization buffer B containing 25 mM imidazole and eluted with 
an increased gradient of imidazole concentration, namely 100mM, 250 mM and 500 mM. At the 
	   66	  
end of this process, fraction samples of 1.7 mL were collected and stored. 
 
Protein dialysis and concentration  
 
 After successful purification, samples containing the wild-type and mutant forms of ChR2 
were mixed, dialyzed and concentrated using Amicon® Ultra-15 Centrifugal Filter Units 10kDa 
(Millipore, MA, USA), following the manufacturer’s protocol. The total volume of the dialysis 
unit was replaced at least 5 times. A second and final concentration was done using Vivasping 
500 tubes (Sartorius Stedim Biotech, Aubagne, France), also according to the manufacturer’s 
instructions. 
 
 
Protein quantification 
 
 Protein quantification was achieved using PierceTM BCA Protein Assay Kit (Thermo, MA, 
USA), following manufacturer’s protocols and using the kit supplied 2 mg/ml BSA standard. 
 
Gel electrophoresis (SDS-PAGE) 
 
 Protein samples were run on SDS-PAGE, providing separation of denatured proteins, in 
12% polyacrylamide resolving gel (1.5 M TriS pH 8.8 (Fisher, PA, USA), 40% acrylamide (Fisher), 
20% SDS (Fisher), 10% APS (Acros, NJ, USA) and TEMED (NZYtech, Lisbon, Portugal)) and 4% 
acrylamide stacking gel(0.625 M Tris pH 6.5 , 40% acrylamide, 20% SDS. 10% APS and TEMED). 
Samples were ran in 1x Running buffer (5x running buffer- 15 g of Tris base (Fisher); 72 g of 
glycine (Fisher) and 5 g of SDS (Fisher)) at 50-90 V. Previously, proteins were also diluted into 
4x Laemmli buffer (Biorad, CA, USA) with β-mercaptoethanol and were incubated overnight at 
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4ªC in the denaturing buffer. 
 
Western-blot 
 
 In western blot analysis, proteins were transferred to a PVDF membrane (GE 
Healthcare, NJ, USA) by electrobloting in a Mini-trans blot system (Biorad, CA, USA) with a 1x 
transfer buffer (transfer buffer 5x - 0.025 M Tris base; 0,192 M glycine) plus 5% methanol. The 
transfer ran at 100 V for 2 hours at 4ºC. First, membranes were activated in methanol, and after 
transfer were washed in Tris-buffered saline (137 mM NaCl, 20 mM Tris-HCl pH 7.6) containing 
0,1% (v/v) Tween-20 (TBS-T). After that, membranes were blocked in TBS-T with 5% (w/v) low-
fat milk and probed with His-Tag antibody (Cell signaling technologies, MA, USA) diluted 
(1:1000) overnight in TBS-T with 5% BSA, at 4ªC. Then, it was done another thorough wash in 
TBS-T followed by Ia 2 hour incubation at room temperature with the secondary anti-rabbit 
antibody (Jackson ImmunoResearch Inc., PA, USA) diluted (1:10000). Another wash was done 
and membranes were finally revealed using Pierce ECL Western Blotting Substrate (Thermo 
scientific, MA, USA) according to manufacturer’s instructions. Membranes were scanned with 
Storm 860 scanner (Amersham Biosciences, NJ, USA).  
 
Comassie protein staining  
 
 Gels were incubated for 10 minutes in Comassie staining solution (0.05% Comassie 
Brilliant blue R-250 (Fisher, PA, USA), 25% methanol (Fisher) and 5 % acetic acid (Fisher)). Then, 
the gel was washed in a distaining solution (25% methanol; 5% acetic acid) once for 1 hour and 
then overnight. The gel was imaged with a standard computer scanner. 
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Silver protein staining  
 
 Silver staining of gels containing different fractions and the different forms of ChR2 were 
treated with a solution of 25% Methanol (Fisher) and 5 % acetic acid (Fisher, PA, USA) for 30 
minutes, washed twice, first with 50% ethanol and then with 30% ethanol. Afterwards, gels were 
incubated and sensibilized in Sodium Thiosulfate 0.2 g/L (Acros, NJ, USA) for 1 minute, 
accelerating and enhancing further reaction with silver and reducing background staining. After 
washing twice with water for 20 minutes, gels were incubated in Silver Nitrate 2 g/L (Acros) for 
another 20 minutes. Finally, after another quick wash with water, gels were developed in a 
solution made of 30 g/L Sodium Carbonate (Acros), 10 mg/L Sodium Thiosulfate and 0.02 % 
formalin (Sigma, NJ, USA). The developing reaction was stopped by removing the gels from 
previous solution and incubating them in a solution of Tris 50 g/L and 2,5% acetic acid for 1 
minute. The gels were then washed with water several times, imaged with a standard computer 
scanner and stored at 4ºC.  
 
 
II.2.4 – ChR2 absorption spectra determination 
 
The concentrated and dialyzed forms of the ChR2 protein were inserted in a quartz 
cuvette (Quartz Suprasil; Hellma, Mullheim, Germany) in a final volume of 500 uL and the 
absorbance measured in a spectrophotometer (SpectraMax PLUS 384; Molecular devices, CA, 
USA), using a wide range of UV 200-800 nm. The absorbance of the buffer used to purify the 
different forms of ChR2 was also measured. The absorption spectra curves for ChR2 were then 
achieved by subtracting the absorbance of the buffer to the absorbance values obtained for the 
different ChR2 forms 
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Primers 
 
Primer name       Sequence (5’ to 3’)                                                              Goal 
MutScr_1_F  
 
GAGAACCATGGGACTCCTTGTC  
 
L221D/L217D 
mutation 
screening  
MutScr_1_R  
 
CATACCCCAGCTCACGAAAAAC  
 
L221D/L217D 
mutation 
screening  
L221D_F  
 
GTCATCTTCTTTTGTCTTGGAGATTGCTATGGCGCGAACACATTTTTTC Directed site 
mutagenesis 
L221D_R  
 
GAAAAAATGTGTTCGCGCCATAGCAATCTCCAAGACAAAAGAAGATGAC  
 
Directed site 
mutagenesis  
F217D_F  
 
CGGCTATGTTAAAGTCATCTTCGACTGTCTTGGATTGTGCTATGGC  
 
Directed site 
mutagenesis  
F217D_R  
 
GCCATAGCACAATCCAAGACAGTCGAAGATGACTTTAACATAGCCG  
 
Directed site 
mutagenesis  
yChR2_F  
 
GCCGAATTCAAAAATGTCTGACTATGGCGGCGCTTTGTC  
 
ChR2 fragment to 
pPICZ A and 
pGAPZ A  
yChR2_R  
 
GCCGGTACCGGCGGCCGCTGGCACG  
 
ChR2 fragment to 
pPICZ A and 
pGAPZ A  
AOX1_F  
 
GACTGGTTCCAATTGACAAGC  
 
pPICZ A, and 
pPICZ(alpha) A 
Screening  
AOX1_R  
 
GCAAATGGCATTCTGACATCC  pPICZ A, 
pPICZ(alpha) A 
and pGAPZ A 
Screening  
F269D_mut_FW GTTCCCAATTCTCGACATTTTGGGGC 
 
F269D directed 
site mutagenesis  
 
F269D_mut_REV 
 
GCCCCAAAATGTCGAGAATTGGGAAC 
 
F269D directed 
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  site mutagenesis  
 
F269H_mut_FW 
 
 
GTTCCCAATTCTCCACATTTTGGGGC 
 
F269H directed 
site mutagenesis  
F269H_mut_REV GCCCCAAAATGTGGAGAATTGGGAAC 
 
F269H directed 
site mutagenesis  
Seq_FW CATTTTTTCACGCCGCCAAAGC  
 
F269H/F mutation 
screening 
Seq_REV GGCTTCGTCTTCGACGAGAGTC  
 
F269H/F mutation 
screening 
pPicZ(alpha)_FW GCCGAATTCGACTATGGCGGCGCTTTGTC ChR2 fragment to 
pPICZ(alpha) A 
pPicZ(alpha)_REV GCCGGTACCGTGGCGGCCGCTGGCACG ChR2 fragment to 
pPICZ(alpha) A 
Gap_Scr_FW GGTTTCTCCTGACCCAAAGAC pGAPZ A 
screening 
Table 3 – List of primers used in the present work. 
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Chapter III – Results and Discussion 
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III.1 – Molecular simulations of ChR2 
 
Novel mutations for channelrhodopsin-2 (ChR2) were designed in order to obtain new 
useful variants of the protein, in particular to obtain forms of ChR2 that have a blue or red shift 
in the protein absorption spectra maximal peak. The theoretical prediction of the target 
residues to be substituted in the wild type form of ChR2 was performed in collaboration 
between our lab and the group of Fernando Nogueira at the Center for Computational Physics 
from the University of Coimbra. 
Four mutations were proposed and selected, namely F269D, F269H, F221D and L221D. 
The protein structure used as reference for Time-Dependent Density Function Theory 
(TDDFT) computational calculations was the light-gated cation channelrhodopsin crystal 
structure (Kato et al., 2012). Hence, designated residues were numbered in line with this 
structure (3UG9) that can be found at http://www.rcsb.org/pdb.  
The F269D, F217D and L221D mutations were predicted to induce a red shift in the 
absorption spectra of ChR2, whereas the F269H mutation was expected to result in a blue-shift 
variant of the protein. These absorption spectra predictions were presented as putative shifts 
(Figure 16) and were based on TDDFT calculations for the four chosen mutants.  
With the availability of the crystal structure of ChR2 (Kato et al., 2012), other aspects of 
the fundamental molecular architecture of the channel were analyzed, including the retinal 
binding pocket, the inner pore and the cationic conductance, which enhances protein 
engineering pointed at the design of novel ChR2 variants with improved features. As such, all 
selected residues for mutation are located near the retinal molecule and are involved in the 
formation of the retinal-binding pocket (Kato et al., 2012), but they are also positioned away 
from the hydrophobic ion pore (Figure 17), which further preserves and retains the gating 
properties of the rhodopsin channel. The proximity to the site where retinal binds renders 
these mutations suitable candidates to develop novel ChR2 variants, as corroborated by a study 
using site-direct mutagenesis to alter of the electrostatic environment in the retinal binding 
pocket, inducing several shifts and color tuning in the absorption profile of a protein-embedded 
all-trans retinal (Wang et al., 2012).  
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Figure 16 – Theoretical putative shift in ChR2 mutants achieved from TDDFT. 
Predicted spectral features of ChR2 wild type and four new mutants. ChR2 wild type absorption spectra is 
represented by full light-blue line. F269H (c) mutation induces a blue shift of ~30nm while F269D (b) is expected 
to induce a ~50 nm red shift in the abortion of the retina chromophore. F217D (a) mutation induces a red shift of 
~60nm. L221D (d) mutation also produces a red shift of ~45. Note (*): wavelength output form TDDFT analysis is 
systematically right-shifted, e.g. the experimental absorption peak at pH 6.0 of dark adapted WT-ChR2 is centered 
at 480nm. These results are from Micael J.T. Oliveira, Bruce F. Milne and Fernando M.S. Nogueira (unpublished 
data).  
 
With the aim of generating the biggest conceivable effect on the absorption spectra, the 
charge of each selected residues was changed. Specifically, phenylalanine (F) and leucine (L) have 
no charge in their side chains in physiological conditions, and are highly hydrophobic as a result 
of their non-polar nature. In consequence, both amino acids where mutated to aspartate (D), a 
residue exhibiting a negative charge at physiological pH. Indeed, the key amino acids chosen to 
be mutated in the variants of ChR2 were two phenylalanine residues in positions 269 and 217, 
and a leucine residue in position 221. All these residues were substituted by aspartate. 
According to the predictions, these changes would give rise to differences in the electrostatic 
environment surrounding the protein chromophore, the retinal molecule, and give rise to red-
shifted ChR2 variants.  
 Besides the generation of original ChR2 red-shifted variants, the creation of a blue-
shifted variant of ChR2 was necessary to further validate the TDDFT theory and all the 
A 
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rationale behind these mutations with an opposite logic than the one used for red shift of 
absorption spectra. Furthermore, it would allow the use of a pair of ChR2 variants with non-
overlapping absorption spectra, such as F269F (red) and F269H (blue). Therefore, the identical 
target F269 residue was replaced by a positively charged amino acid, histidine (H), to obtain a 
protein exhibiting a blue shift on the opsin absorption spectra. 
This theoretical approach based on molecular simulation models using TDDFT can be 
considered original, as it has never been done before concerning rhodopsins and optogenetics 
tools such as ChR2. A similar approach done to generate new optogenetics tools consisted in 
an atomistic design of blue shifted ‘’optotools’’. However, this method aims to mutate residues 
far from the retinal molecule environment, a less radical approach than the one we have 
performed in the present work. Furthermore, it uses different theoretical and mathematical 
calculation methods and it still bases its molecular simulations on classic molecular dynamics 
with several varying variables that may be divided into different groups and calculation phase 
steps, leading to simplifications that may drive the output of the simulation to be somewhat 
different from what it is observed. More importantly, our approach created wider predictive 
results, for both red and blue shift new variants, while the appeoach by Kato and collegues 
focused mainly on discovering blue shifted opsins. 
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Figure 17 – Location of selected residues to mutate in ChR2 structure. (a) 3D structure 
of ChR2 light-induced cation channel. The structural seven transmembrane domains (7TM) are represented in 
seven different colours. Retinal molecule is emphasized in blue and F269 residue in green. (b) Alternative 
illustration of ChR2 structure comprising selected residues to mutate. F217 and L221D are represented in blue and 
black. Retinal is represented in pink. Selected residues and protein structures are based on ChR2 crystal structure 
by (Kato et al., 2012). 
 
III.2 – Site-directed mutagenesis of four novel ChR2 mutants 
 
To test the feasibility of the proposed alterations to the ChR2 primary structure, we performed 
directed site mutagenesis on the original pcDNA3.1-hChR2 vector (plasmid with ChR2 wild 
type sequence), using phenylalanine 269 (F269), phenylalanine 217 (F217) and leucine 221 (L221) 
as targets. For one variant, the purpose was to substitute the TTC codon from F269 with a 
GAC codon that codified an aspartate, whereas for the second one, to substitute the same TTC 
for a CAC codon encoding a histidine. For the third mutation, the aim was to replace the TTT 
codon from F217 with a GAC codon codifying an aspartate. Finally, for the fourth mutation, the 
TTG codon from L221 was replaced by GAT, an aspartate codon. Hence, as theoretically 
suggested, all the non-polar targeted residues were substituted by polar amino acids. 
PCR amplification was done using specific sets of primers to insert two mismatched 
based for each mutation. Once the mutants were obtained, sequencing was performed to 
confirm the modified bases (Figure 18).  
The four novel mutations, predicted by TDDFT studies, were sucessfully generated by 
site-directed mutagenesis on the humanized ChR2 sequence (Lin et al., 2009; Yizhar et al., 2011), 
similarly to other channelrhodopsin structural and new variants studies (Berndt et al., 2011; 
Govorunova et al., 2011; Ritter et al., 2008). We aimed to achieve color-tuning of ChR2 with 
single point-mutations, contrarly to the commonly adapted strategy of  inducing several 
consecutive mutations, such as the development of new ChR2 variants like ReaChR  (Lin et al., 
2013) or the nine point-mutations necessary to fully tuned the absortpion spectrum of a protein 
embedded all-trans retinal  (Wang et al., 2012). 
 
	   77	  
 
 
 
Figure 18 – Sequence results of ChR2 new variants induced mutagenesis. Alignment of 
the sequencing products of mutagenesis and respective analysis.  (a) F217D and L221D mutations sequenced with 
specific forward and revers primers, MutScr_1_F and MutScr_1_R (Table 3). (b) F269D and F269H mutations 
sequenced with specific set of primers, Seq_FW and Seq_REV (Table 3). 
 
 
III.3 – Molecular cloning into the pPICZ A vector 
 
The heterologous system mostly used to produce and purify ChR2 is Pichia pastoris yeast 
(Bamann et al., 2008, 2010; Nack et al., 2010). Besides the low cost and high yield, the 
eukaryotic processing machinery renders P. pastoris a viable system for the small and large scale 
production of many integral membrane proteins for structural studies (Byrne, 2015). 
Expressing functional proteins in E.coli system may be standard for some recombinant 
proteins, but it seems to be difficult for channelrhodopsins (Ernst et al., 2008; Sineshchekov et 
al., 2013). We excluded this possible approach predominantly due to the importance of 
similarity to the host, enabling the functioning of the needed post-translation modifications, 
protein targeting and folding. These particular features are not achieved in the prokaryote E.coli 
not capable to adapt to the eukaryotic ChR2. Other options have also been used, such as the 
Sf9 insect cells used in the ChR2 crystal structure experiments (Kato et al., 2012) and in the 
atomistic design of new blue shifted variants based on molecular simulation models (Kato et al., 
2015).  
A 
B 
	   78	  
However, we decided to use the Pichia pastoris model, for the reasons aforementioned. 
Furthermore, Pichia cells have an easier manipulation grow in high-density cultures that can 
possibly enhance higher levels of protein expression. Concordantly, other groups with 
comparable goals to this project already described expression of ChR2 in P.pastoris (Bamann et 
al., 2008, 2010).  
After the validation of the obtained mutations, encoded in mammalian vector pcDNA3.1 
vector, each ChR2 sequence was cloned into a pPICZ series expression vector. This specific 
vector, contrarily to the mammalian vector, is a suitable heterologous expression vector to 
express recombinant protein in the selected Pichia pastoris system. All four mutants were cloned 
into the pPICZ A vector, including the wild type protein to be used as a control. 
Specific primers (Table 3) were designed to shuttle each ChR2 sequence into the pPICZ 
A vector and, to improve expression in yeast, a Kozak sequence (Kozak, 1987, 1990, 1991) was 
included with two new restriction sites. Inserting a Kozak sequence in the Pichia genome along 
with our gene of interest would increase the level of protein expression by improving the 
translation process and facilitating the recognition of the initiator codon by ribosome (Mark 
Cigan e Donahue, 1987). Equally to our approach, other ChR2 variants studies also added 
Kozak sequence to enhance protein expression in Pichia pastoris(Lin et al., 2013). 
All ChR2 DNA sequences to be inserted into the pPICZ A vector were amplified by 
PCR, using as a template the mammalian pcDNA3.1 vector and the described set of primers 
(Table 3), respective for each protein variant. Using these primers, the amplified fragments were 
flanked with EcoRI and KpnI restriction sites, previously added in the primers.  The amplified 
fragments and the original pPICZ A vector were digested both with the same set of enzymes 
and purified. The cut with these restriction enzymes creates “sticky ends” at the extremities of 
both constructs (vector and amplified DNA), ideal for the ligation step. The ligation mix was 
used in transformation of E.coli DH5α competent cells on Zeocin plates. Since the resistance for 
this antibiotic is carried on the pPICZ A vector, only positives clones which incorporate the 
product of the ligation grow on Zeocin plates. The colonies were picked and used directly for 
PCR amplification as screening for positive ligation result. In this PCR screen, AOX_FW and 
AOX_REV primers were used (Table 3). These primers amplify the region in which the mutated 
sequence is inserted. The positive colonies were selected based on the expected weight of the 
bands in an agarose gel and a single colony was sequenced to confirm the presence of the 
formerly created mutation and the insertion of the fragment in frame with the histidine tag 
present in pPICZ A vector (Figure 19). 
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The same rationale was used for all ChR2 protein forms, that is, the four mutations and 
the wild-type control.  
Similarly to other reports of ChR2 mutant structures (Bruun et al., 2011), this approach 
led us to have the possibility of having channelrhodopsin-2 sequences successfully cloned in the 
pPICZ A vector,  allowing to proceed with a methanol inducible expression of ChR2 in Pichia 
pastoris. 
 
 
 
 
 
 
 
 
 
 
Figure 19 – Cloning strategy and sequence results of ChR2 mutants in pPICZ A 
vector. (a) Illustration of final expected fragment from cloning strategy used to transfer ChR2 protein forms 
from pcDNA 3.1 vector to pPICZ A. Aox1 promoter is presented in black, Kozak sequence (K) is shown in dark 
grey, ChR2 inserted sequence is presented on regular grey and 6x histidine Tag is presented in light grey. (b) 
Alignment of sequencing results from screened ligation products of all ChR2 protein forms cloned into pPICZ A 
vector. AOX forward and reverse primers were used for all these sequencing purposes. 
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III.3.1 – Linearization of the pPICZ A vector containing ChR2 
 
Before Pichia pastoris wild type strain (X-33) cells were transformed by electroporation, 
the cloned vector pPICZ A encoding the inserted ChR2 protein forms was linearized. This 
protocol was done due to the fact that integration events occur with a higher probability with a 
linearized vector than with a circular one (Cregg et al., 2009). 
To achieve DNA linearization, the final vector containing ChR2 was digested with PmeI 
enzyme. This enzyme cuts in the AOX1 promoter region. To corroborate the successful vector 
linearization, samples were digested for five hours and ran on an agarose gel in parallel to the 
same, uncut, vector (Figure 20).  
This achieved linearization, before electroporation, proved to be essential to strong 
integration of the plasmid into the Pichia pastoris genome and further effective expression of 
our protein of interest, as reported in several structural studies of ChR2 (Ernst et al., 2008; 
Govorunova et al., 2013; Müller et al., 2015). 
 
 
 
Figure 20 – Linearization of pPICZ A vector containing ChR2 protein forms. Linearized 
vectors against non-linearized vector in 1% agarose gel. (a) ChR2 wild type in pPICZ A vector, linearized and non-
linearized. (b) ChR2 mutants, L221D, F217D, F269D and D269H in pPICZ A vector, linearized and non-linearized. 
Non-digested vector runs at multiple different sizes due coiling of double stranded DNA,  
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III.4 – Heterologous ChR2 expression in Pichia pastoris 
 
The first results are related to the wild type ChR2, from protein induction, small and 
large-scale expression and purification until the expected absorption spectra was achieved. This 
strategy was performed as a control, a first and crucial step to validate TDDFT predictions and 
to further optimize the protocol of induction, expression and purification of wild type ChR2. 
Only after completing this successful optimization, experiments were applied to the ChR2 
mutants.  
We established our experiments on successful preceding approaches to isolate ChR2 
from P. pastoris (Bamann et al., 2010; Ernst et al., 2014; Lórenz-Fonfría et al., 2013; Yizhar et al., 
2011). Nonetheless, we also established and optimized our own protocols directed to ChR2.  
Several studies showed the competence of yeast to integrate multiple copies of the 
expression vector providing fast and improved means to obtain multi-copy expression colonies 
through colony selection on plates with higher concentration of antibiotic. Based on this 
findings, we defined our ChR2 selection method to maximally enhance the probability of 
selecting and picking the best possible colonies expressing ChR2, hyper resistant or ‘’jackpot’’ 
colonies. 
Hence, electroporated cells were plated on YPD-Zeocin plates with different and 
growing concentration of antibiotic (0 µg/ml, 100 µg/ml, 1000 µg/ml and 2000 µg/ml), as direct 
selection of positives recombinants (Figure 21a). The YPD-Zeocin plates were grown for 48 
hours until clones were perceptible (Figure 21b). 
Consequently, X-33 strain colonies were selected based on their growth in high Zeocin 
concentration in YPD plates associated with higher levels of protein expression. Colonies were 
preferentially picked from the 2000ug/ml Zeocin plates. Colony selection from plates with less 
concentrated antibiotic happened only if there were no visible colonies in 2000ug/ml plates and 
as a comparative control to the hyper resistant colonies (from 2000 Zeocin) (Figure 21a).  
In fact, compared to all other plates, highest concentrated plates presented a very 
noticeable reduction in the number of grown colonies, usually with 1-10 colonies. The 100ug/ml 
and 1000ug/ml plates always presented a large number of colonies through all YPD surface, 
being more disperse on 1000ug/ml Zeocin plates. Therefore, hyper resistant colonies can be 
considered the colonies that integrated in their genome more copies of the vector through 
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repeated cycles of homologous recombination. As such, they contain not only multi-copies of 
the mutated DNA sequence but also from the Zeocin resistance cassette. 
First, the 2000ug/ml Zeocin plate positive clones were re-picked to a fresh 2000ug/ml 
Zeocin plate (screening plate) (Figure 21c) and then grown in yeast complex media. Afterwards, 
a small-scale induction was performed (Figure 21d) to find the best possible colony expressing 
ChR2. To do this small scale the widest possible, several colonies were screened and analyzed, 
usually more than 10, from all variable electroporation plates. This small-scale induction was 
implemented with final 50 mL of growth culture. This protocol is original and created optimized 
for the purpose of this project. Each culture volumes, induction time and defined step in this 
protocol were optimized specifically for ChR2.  
Briefly, 1-10 clones were first grown in BMGY, a medium containing glycerol as the 
carbon source, until an O.D.600 between 4 and 6 is reached (usually 5 was used as the optimal 
O.D.). Then, clones grown in BMGY were centrifuged to discard the glycerol medium and 
ressuspended in BMMY, a medium containing 2,5% methanol and also supplemented with retinal 
(Bruun et al., 2011) to induce ChR2 expression (methanol added to the complex medium acted 
as the activator of the AOX1 promoter). The 50 mL cultures were induced for 24 hours and 
then centrifuged to obtain a cell pellet, to further extract and isolate the expressed protein. 
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Figure 21 – Channelrhodopsin-2 expression strategy in Pichia pastoris. (a) ChR2 colony 
selection method based on growing Zeocin concentration. (b) Full range variety of YPD/Zeocin electroporation 
plates. (c) Screening plate with isolated selected colonies from original 2000ug/ml Zeocin plates. (d) 50 ml cultures 
of ChR2 small- scale induction screening in Pichia pastoris X-33. 
 
 
Next, western-blot and silver staining techniques were performed to confirm ChR2 
expression (Figure 22). First, an induction test was done comparing ChR2 expression in Pichia 
pastoris against the same yeast strain with no protein transfected (Figure 22a). This experiment 
confirmed that ChR2 was successfully and exclusively expressed and that the X-33 strain had no 
similar size endogenous protein recognized by his tag antibody. 
Small scale screened colonies expression was also tested using western-blot (Figure 22b) 
and silver staining (Figure 22c). In these cases the protein expression in clarified cell lysate 
(removed of cell debris) was isolated from the membrane fraction and analyzed. It was also 
compared the expression of colonies from 1000ug/ml (control) against the ones in the highest 
2000ug/ml antibiotic plates.  
Analyses of these results showed the presence of ChR2 double band, one with 31 kDa 
and another one with 34 kDa (Figure 22). These bands are known to correspond to a 
glycosylated and non-glycosylated form of the protein (Ernst et al., 2008). However, all the 
positions and amount of glycosylation in ChR2 remain undetermined (Kirsch, 2008). The 
glycosylations have an important role, as they are responsible for proper folding and targeting of 
channelrhodopsins.  
We also observed that ChR2 presented a certain tendency to aggregate (Figure 22), a 
common feature in membrane proteins (Lin e Guidotti, 2009). Many published studies also 
witnessed that most opsins have a high tendency to aggregate in eukaryotic systems (Bamann et 
B C D 
	   84	  
al., 2010; Gradinaru et al., 2010; Lin, 2011). Our decision of adding 2,5% methanol to the yeast 
culture buffered medium, contrarily to the 0,5% methanol commonly used in similar studies 
(Govorunova et al., 2013), also proved to enable a high yield of expressed ChR2. 
These results also corroborate the successful ChR2 expression as we observed stronger 
bands in isolated membrane fractions than in the respective cells lysate (Figure 22 b, c). Hence, 
from this point on, only isolated membrane fraction samples were presented and analyzed in the 
following experiments. Furthermore, it is clear that ChR2 presented stronger bands when 
isolated from 2000ug/ml colonies, compared to colonies from lower antibiotic plates. 
Finally, the results obtained allowed the selection of a single colony (named as ‘’1’’ in 
Figure 22b), the highest expressing one, to express in large-scale induction protocol and to be 
used as a control in the following ChR2 mutants experiments. This chosen hyper resistant 
colony was also tested using silver staining, and showed the same strong double band patterns, 
alongside with the presence of naturally occurring endogenous Pichia proteins (Figure 22c), 
commonly present due to the highest sensitivity of silver staining technique and the lacking of 
protein purification so far. The large-scale experiment included the scale up of the previously 
done small scale, from 50 ml to 3L culture, with each step being proportionally increased in 
terms of quantities. Colony 1 was successfully expressed in large scale (Figure 22d) and its 
membrane fraction was isolated to posterior purification of ChR2.  
It is important to mention that the cell pellet obtained from large-scale induction was 
lysed with a EmulsiFlex-C5 system, instead of the French Press, due to the high amount of pellet 
obtained. The EmulsiFlex-C5 system made it possible to lyse a high amount of cells in large 
sample volumes and to achieve maximum ChR2 recovery. 
We attained a considerable yield of channelrhodopsin using the Pichia pastoris system, as 
reported and established by other groups working on the same protein (Bamann et al., 2008; 
Bruun et al., 2011; Govorunova et al., 2013; Müller et al., 2015; Yizhar et al., 2011), allowing 
further channelrhodopsin-2 purification.  
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Figure 22 – Channelrhodopsin-2 expression tests. (a) Western-blot image for ChR2 wild type 
methanol induction test. (b) Western-blot results from small-scale screening identifying positive hyper resistant 
ChR2 colonies. Used controls are selected colonies from less concentrated YPD/Zeocin plates (1000ug/ml). 1 and 
2 are the two best expressing colonies from previous wider small-scale screening (data not shown). CL represents 
cell lysate and MF represents membrane fraction samples. (c) Image from silver staining gel of CL and MF samples 
of chosen ChR2 wt best expressing clone, designated ‘’colony 1’’ (from (b)). (d) Western-blot result representing 
successful scale up of ChR2 expression through large-scale protocol. (*) All western-blot membranes were 
incubated with rabbit anti-histidine primary antibody and anti-rabbit secondary antibody.  
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III.5 – Channelrhodopsin-2 purification 
 
After ChR2 was isolated from yeast cells, the cell membrane fraction was solubilized 
with n-Dodecyl β-D-maltoside (DDM), a detergent formerly reported to stabilize ChR2 (Bruun 
et al., 2011; Ernst et al., 2008; Govorunova et al., 2013; Kato et al., 2012, 2015; Stehfest et al., 
2010), as well as comparable membrane proteins like type II (animal) opsins (Filipek et al., 2003; 
Palczewski, 2006).  
We then proceeded to the purification of ChR2. Initially, we performed this step using 
‘’in batch’’ purification technique, that is, incubating the protein extract with IMAC resin 
(immobilized metal affinity chromatography), outside a column. After that incubation time, the 
protein/resin mixture was inserted into an empty column and posteriorly eluted. Despite the 
fact that this technique has been used to purify several proteins (Chang, Chen e Ho, 2015; 
Chong et al., 2009), in our hands this technique did not work, given that no specific ChR2 bands 
appeared in silver staining and comassie gels (data not shown). To overcome this obstacle, 
ChR2 was purified using pre-packed nickel columns suitable for nickel affinity chromatography, 
as used in similar experiments for channelrhodopsins (Kato et al., 2012, 2015). 
 Following protein injection in the columns with a peristaltic pump, with a flow of 1 ml 
per minute, the system used for chromatography was the AKTA system. Our initial binding 
buffer composition
 
contained 20 mM sodium phosphate pH 7,4, 200 mM NaCl, 5% (v/v) 
glycerol, 0,03% (w/v) DDM, 10 mM Imidazole and 250mM Arginine. This buffer was also based 
on channelrhodopsin published studies (Ernst et al., 2008; Kato et al., 2012), and was optimized 
to increase the purity of ChR2. After equilibration of the column with binding buffer, the 
protein extract was diluted 1:10 in the same buffer and then transferred in the nickel column, 
containing a resin with selectivity and high affinity for histidine-tagged proteins. In the AKTA 
system, ChR2 was automatically eluted with increasing concentration of imidazole, providing a 
specific chromatogram to indicate where and in which fraction the protein was eluted (Figure 
23a).  
After analysis of the obtained chromatogram UV peak, fractions samples were run on a 
SDS-PAGE. Also, silver staining was performed to the same gel to detect the purified ChR2 
(Figure 23b). The presence of the same double band pattern observed in previous experiments 
showed again the existence of aggregates. Minimum contaminants were also observed in the 
silver staining gel but they were not significant to interfere with the following absorption spectra 
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determination. Samples 16-18 (Figure 23) were selected for the following experiments. 
We achieved successful purification of ChR2 by nickel affinity chromatography, 
analogously to Kato’s channelrhodopsin studies (Kato et al., 2012, 2015) and by other groups 
(Berthold et al., 2008; Bruun et al., 2011; Govorunova et al., 2013). The AKTA purifier system 
that we used to perform the affinity chromatography also proved to be suitable for imidazole 
gradient elution and an accurate final purification, as reported for other channelrhodopsin 
variants development (Bruun et al., 2011). 
 
 
Figure 23 – ChR2 wt purification with nickel affinity chromatography. (a) ChR2 wt 
purification chromatogram. Absorbance at 260 nm is represented in blue, imidazole concentration in green, 
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collected fractions in red and black arrow indicates positive eluted fractions.  (b) Silver staining of collected protein 
samples from imidazole elution range. Positive samples for ChR2 purified are indicated in white box. 
 
 
III.6 – Determination of ChR2 wt absorption spectra 
 
With the successful purification of ChR2, the next step was to determine its absorption 
spectrum. Respective measurements were obtained using a spectrophotometer, as done by 
other groups (Ernst et al., 2008; Kato et al., 2012; Ritter et al., 2008). However, the device that 
we used was somehow less advanced than the ones used in other published studies. For 
example, other devices present more spectral resolution (2 nm (cite) vs. 10nm) and a more 
advanced illumination (with LED).  
To achieve higher concentrations of ChR2 and to generate the most reliable absorption 
spectra, positive samples 16-18 were mixed together and concentrated by centricon 
centrifugation. The selected samples presented high concentration of imidazole (250 nM), 
naturally essential to elute the protein from the column. Before concentration, mixed samples 
were diluted three times to reduce imidazole concentration, detrimental to the centricon 
membrane.  
Additionally, because concentrated protein fractions still presented some imidazole that 
could possibility interfere with the final absorption spectrum, we performed dialysis of the 
samples, in the same centricon used for sample concentration. Centrifuging the concentrated 
sample resulting in a simple salts buffer exchange (dialysis). An additional second concentration 
step was done to a final volume of 500 microliters. Final sample was achieved (Figure 24a), in a 
final buffer similar to the used binding buffer, with less imidazole (5mM).  
After this process, the amount of purified protein was sufficient to produce absorption 
spectra (Figure 24b), similar to what has been observed in other published channelrhodopsin 
structural studies (Ernst et al., 2008; Govorunova et al., 2013; Kato et al., 2012; Muders et al., 
2014; Ritter et al., 2008).  
The wild type of ChR2 presented a very noticeable peak, in the blue light region of the 
spectra, as predicted and expected as a main feature from ChR2. However, the maximal peak 
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was centered at 510 nm, a slight red shift compared to the 470 nm established for wild type 
ChR2 (Nagel et al., 2003; Ritter et al., 2008; Zhang et al., 2010). This may be explained by the 
fact that pH and imidazole, especially the pH, affect the spectral properties of ChR2 (Ernst et al., 
2008; Scholz et al., 2012) and even ChR1 (Berthold et al., 2008), specifically causing red-shifts in 
the final output. In our case, the absorption spectra was measured with wild type ChR2 in a final 
buffer of pH 7, against the 7,4-7,5 pH of other published spectra (Ernst et al., 2008; Ritter et al., 
2008). Additionally, the buffer used in this output also contained imidazole (5mM). 
This first valid absorption spectrum of wild type ChR2 obtained was the primary goal 
and achievement of this work, crucial to the following experiments, as it demonstrated it was 
possible to achieve an absorption output from ChR2 with the strategy we defined. It was also 
used as the main control for experiments using each ChR2 mutant, and the first step to validate 
TDDFT predictions. More importantly, wild type ChR2 successful absorption spectra enabled 
the possibility to compare and determine the predicted and desirable shifts of the new variants. 
Further optimizations are presented below regarding the new ChR2 variants.  
 
 
 
        
Figure 24 – UV-visible spectroscopy of purified ChR2 wild type. (a) Complete steps of 
adopted strategy to achieve final sample of purified and concentrated ChR2 wt. (b) Absorption spectra of purified 
ChR2 wt in dodecyl maltoside solution at pH 7. 
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III.7 – Protocol optimization 
 
After the validation of the spectral properties of wild type ChR2, we proceeded to the 
experiments using the four new ChR2 mutants with the same strategy used for the wild type 
protein. Hence, following the determination of wild type ChR2 absorption spectra, a few steps 
in the protocol were optimized to achieve better results with the mutants, such as higher yields 
of expression for all ChR2 forms.  
Particularly, two main optimizations were tested: the use of a new strain of Pichia pastoris 
and the use of new vectors, suitable for the heterologous protein expression in the yeast 
system. The protein purification protocol was also optimized, as shown below. 
 
 
III.7.1 – Pichia pastoris SMD1168H strain 
 
After the purification of ChR2 from P. pastoris, we aimed at obtaining higher yields of 
ChR2 expression from this system, as superior amounts of extracted protein enhance 
purification and to obtain better and accurate absorption spectra. We therefore used a different 
strain of Pichia pastoris to induce and express ChR2: instead of the X-33 wild type strain 
previously used and that have been shown to present low expression levels in ChR1 (Berthold 
et al., 2008), we followed the identical protocol of protein induction and extraction exploiting 
the SMD1168 strain, a protease-deficient strain lacking key protease activity, described to led to 
a higher expression of recombinant proteins .  
ChR2 expression in P.pastoris have been reported to be enhanced with the use of 
proteinase A (pep4) deficient strains and the SMD1168H strain in particular was already 
successfully used in channelrhodopsin heterologous expression (Govorunova et al., 2013; Hou et 
al., 2012; Yizhar et al., 2011). Hence, to test this new strain and to obtain better results with the 
ChR2 variants, we performed a high-throughput small-scale induction as a wide screening to 
compare X-33 vs. SMD1168H protein expression, but also to select the best ChR2 mutant 
colonies to use in large scale and further purify. 
We electroporated all ChR2 forms, wild type and four mutants, in both X-33 and SMD 
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yeast cells. Afterwards, we picked several colonies from 2000ug/ml antibiotic plates and a few 
ones from 1000ug/ml for additional control. Then, we compared by western-blot all the 
screened isolated membrane fractions, attaining a very expressive output of X-33 vs. SMD 
expression capability. We also used as a control, the ‘’colony 1’’ that was used in the previous 
experiments to achieve our first absorption spectra. These results are shown in Figure 25. 
We obtained positive clones for all ChR2 forms in both Pichia strains. However, as 
reported on published literature (Govorunova et al., 2013; Hou et al., 2012; Yizhar et al., 2011), 
when analyzing these results, it is clear that SMD1168H clones accomplished significantly higher 
expression levels of ChR2 than the ones from X-33. This showed that enhanced expression 
efficiency can be obtained for all protein variants in SMD and even when comparing the oldest 
‘’colony 1’’ to new wild type and mutant clones. SMD clones also tended to present less 
aggregation than X-33 clones.  
The output from these experiments led us to choose SMD1168H strain to express the 
ChR2 mutants in large scale and also the wild type form of ChR2 as an additional and accurate 
control for these new optimizations. The best expressing colonies were selected for each 
protein form based on these results.  
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Figure 25 – SMD1168H vs. X-33 ChR2 expression. (a) Western-blot image of small-scale 
screening of ChR2 wild type and four new variants, expressed in X-33 Pichia pastoris strain. Colony 1 was used as 
control from previous expressed ChR2 wt in X-33. Double control with ran samples of first/old induction and new 
induction in parallel with other presented clones. (b) Western-blot image of mall-scale screening of ChR2 wild type 
and mutants, expressed in SMD1168H Pichia pastoris strain. Same double control with Colony 1, with additional 
control of ChR2 wt expressed in X-33. * Represents selected clones for posterior large-scale induction. All 
western-blot membranes were incubated with rabbit anti-histidine primary antibody and anti-rabbit secondary 
antibody.  
 
The results obtained after small scale screening (Figure 25) allowed the selection of the 
best expressing clones and to perform large scale induction to each one. After lysis of the yeast 
cells and isolation of the membrane fractions, an additional test was done before proceding for 
protein purification. Samples from the large scale induction of each ChR2 variant were 
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compared with the same ones from respective small scale using western blot analysis to confirm 
successful scaling up of protein expression (Figure 26). Three samples were compared for each 
ChR2 variant: one from the 50mL culture small-scale, an intermidate from both scales, 50mL 
removed from the 3L large-scale, representing the exact same amount of pellet from the small-
scale, and a third one, from the 3L large-scale. 
All four channelrhodopsin-2 new mutants presented clear double pattern bands, when 
expressed in large scale culture with Pichia pastoris SMD1168H, corrorobating again the known 
efficacy of this specifc yeast strain for channelrhodopsin expression (Govorunova et al., 2013; 
Hou et al., 2012; Yizhar et al., 2011). The ChR2 specific bands in large-scale samples are clearly 
stronger than the ones resulted from expression in small scale cultures, validating our scale-up 
strategy. 
 
 
 
Figure 26 – ChR2 large-scale induction test. (a) Western-blot image of large-scale vs. small scale of 
selected ChR2 clones to purify. All western-blot membranes were incubated with rabbit anti-histidine primary 
antibody and anti-rabbit secondary antibody. 
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III.7.2 – Alternative expression vectors for Pichia pastoris 
III.7.2.1 – ChR2 constitutive expression 
 
The heterologous Pichia pastoris system presents multiple suitable commercial vectors 
for convenient protein expression. Pichia pastoris harbours several stronger or weaker 
promoters that can be exploited to drive heterologous expression of recombinant genes, both 
in an inducible or constitutive fashion. Our gene of interest, ChR2, was cloned into the pPICZ 
vector, as previously shown. With this vector we achieved successful ChR2 expression. 
However, to achieve higher amounts of expressed protein, we decided to test alternative 
vectors, specifically the pGAPZ vector for constitutive expression.  
With the same cloning strategy used for the pPICZ vector, we cloned wild type ChR2 in 
frame with the GAP promoter, the histidine tag and a Kozak sequence (Figure 27). Cloning was 
successful, as confirmed by PCR screening (Figure 28a) and sequencing (Figure 28b).   
 
 
 
Figure 27 – Cloning strategy for constitutive expression of ChR2 wt. Illustration of final 
expected fragment from cloning strategy used to transfer ChR2 protein forms from pcDNA 3.1 vector to pGAPZ 
A. GAP promoter is presented in black, Kozak sequence is shown in dark grey, ChR2 inserted sequence is 
presented in regular grey and 6x histidine Tag is presented in light grey. 
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Figure 28 – PCR screening and sequence results of ChR2 wt cloning into pGAPZ A 
vector. (a) PCR screening of ligation product of ChR2 wild type cloning into pGAPZ A vector. Expected band of 
~700bp. Used primers on table 3 (Gap_scr_fw and Aox_rev). (b) Alignment of sequencing results from positive 
colony 4. Gap_scr_fw and Aox_rev primers were used to sequencing purposes. 
 
 
Inducible expression is usually the preferred strategy, since it allows a convenient control 
of the experimental conditions applied before expression and is ideally adapted for the 
production of proteins that are toxic to the host. We used the promoter mostly used for the 
alcohol oxidase-encoding gene (AOX1). This promoter is tightly repressed by glucose and 
strongly induced by methanol (Hartner e Glieder, 2006), allowing cells to use methanol as their 
sole carbon source.  
So far, there are no reports of the constitutive expression of channelrhodopsins, which 
increases the interest of our approach. However, there are numerous cases where constitutive 
expression performs as well as inducible expression, in particular when using the strong 
glyceraldehyde-3-phosphate dehydrogenase (GAP) promoter (Cos et al., 2006; Qin et al., 2011; 
Zhang et al., 2009). In addition, constitutive expression is more straightforward to manage since 
no switch in the carbon source is required, which can be particularly convenient when running 
fermentation procedures. 
Constitutive expression eases process handling, omits the use of potentially hazardous 
inducers and provides continuous and slower transcription of the gene of interest. For this 
purpose, the GAP promoter is commonly used and, on glucose, reaches almost the same 
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expression levels as methanol-induced AOX1 (Waterham et al., 1997). Expression levels from 
GAP vectors drop to about one half on glycerol and to one third when cells are grown on 
methanol (Cereghino e Cregg, 2000). However, only reasonable protein levels were reached 
after optimizing cultivation conditions (Várnai et al., 2014), normally less than with inducible 
promoters. 
We electroporated the linearized wild type pGAPZ/ChR2 construct into SMD1168H 
and X-33 yeast cells, proceeding to small scale screening and selecting the best expressing clone, 
the only SMD colony that grew in 2000ug/ml Zeocin plates. 
Afterwards, to optimize ChR2 expression and to compare with the pPICZ vector, a time 
point induction test was performed using that selected colony (Figure 29a). A successful 
constitutive expression of ChR2 wild type was achieved. All samples were normalized, with the 
same amount of loaded protein (250mg), all grown from 50 mL small-scale culture and with the 
same weight of the final cell pellet. After western blot analysis, it is possible to conclude that the 
optimized time for constitutive wild typ ChR2 expression was 36h (Figure 29b). When 
comparing 24h induction (time used for inducible expression) from both vectors, we confirmed 
that, according to the literature, constitutive expression yields less amount of protein than 
inducible expression (Figure 29c). 
Interestingly, when constitutively expressed, ChR2 presents an initial pattern of two 
bands. With the increasing of induction time, after 24 hours, it presents a single band. This 
noticeable fact contrasts with the double band pattern shown after inducible expression. 
Consequently, it is possible to speculate that constitutively expressing ChR2 enhances its 
glycosylation, which becomes more efficient and more complete than with inducible expression. 
As a result, ChR2 is more prevalent at the membrane. This fact is probably due to the simpler 
and slower induction and expression with the GAPZ vector, with no need to change the carbon 
source during the experiment. 
These results allow the comparison between both types of induction. However, to 
achieve even more accurate information, the time point test required further replication and the 
western blot quantification to be performed with a loading control (for example, beta-tubulin). 
Unfortunately, these experiments were not performed due to time constraints. 
Finally, after obtaining higher amounts of expressed protein, the pPICZ vector was used 
in the following experiments with the ChR2 mutants. 
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Figure 29 – Inducible vs. constitutive expression in ChR2. (a) Representative western-blot of 
ChR2 wild type constitutive expression. Inducible expression is presented as a control. All samples were quantified 
and normalized. It was loaded 250mg of protein per well. (b) Relative quantification results of ChR2 wild type time-
point induction test. (c) Relative quantification of protein amount in 24 hours of constitutive expression and 24 
hours of inducible expression.  
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III.7.2.2 – ChR2 secreted expression 
 
Having successfully expressed channelrhodopsin with an inducible and constitutive strategy, the 
next test was to express this protein with a secretion strategy. The secretion of recombinant 
proteins to the culture medium, outside the cell, may present some advantages: soluble protein 
expression may be induced for longer periods of time, since they do not accumulate in the 
limited volume of the cytoplasm where they might become toxic for the host. This can lead to 
an increase in the expression yield. Furthermore, no cell lysis is required and secreted proteins 
can be recovered directly from the culture media, which contains far fewer contaminating 
proteins than the cells, thus simplifying the purification process. One limitation is the frequent 
degradation of the secreted proteins by extracellular proteases and proteases released from 
lysed cells. In addition, proteins that are not naturally secreted, like Ch22, may not be properly 
folded outside the cell. In this regard, intracellular expression is a valuable alternative (Delroisse 
et al., 2005; Fantoni et al., 2007), as successfully proved by our experiments. 
When choosing a secretion strategy, the target protein needs to be recognized for the 
secretion pathway by the presence of a signal sequence. Successful secretion of many proteins 
from P. pastoris has been reported using a range of different signal sequences. These include a 
protein’s native secretion signal, the Saccharomyces cerevisiae α-factor secretion signal. The 
vector that we used for this approach, pPICZ (Alpha) A contains the same AOX1 promoter 
with the additional feature of including this secretion signal. 
In the case of integral membrane proteins, adding a secretion sequence may be highly 
beneficial for expression in P. pastoris. Such an approach has proved highly effective for the 
production of some proteins, such as G- protein coupled receptors (Grünewald et al., 2004; 
Weiss et al., 1995). Interestingly, these proteins are type II opsins, which is a good indicator of 
this type of expression in channelrhodopsins. 
There are no reports of ChR2 being expressed with the pPICZ(alpha) vector. However, 
some structural studies of this protein reported secretory expression with the use of an 
alternative vector, pPIC9K (Govorunova et al., 2013; Scholz et al., 2012). This vector is similar 
to the one we chose, with the same secretory function and with exactly the same secretion 
signal as pPICZ(alpha) vector. The only differences are that pPIC9K does not present the 
Zeocin resistance gene, but resistance to Geneticin. Regarding this antibiotic difference, pPIC9K 
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is genetically modified to enhance multiple plasmid integration into the yeast genome. In other 
words, this permits the use of high antibiotic concentration (until 4mg/m) to select hyper 
resistant clones containing multiple copies of the gene of interest. Interestingly, that is the 
approach we used for selection of a ChR2 clone (2mg/ml) in pPICZ and pGAPZ vectors. 
However, these two vectors are not specifically engineered for this multicopy integration 
strategy, thus it is possible to say that we developed a successful strategy with the vectors used 
in our experiments. 
  To perform this secretory approach, wild type ChR2 was shuttled into the commercial 
pPICZ(alpha) A vector with the cloning strategy (Figure 30) used for pPICZ and pGAPZ 
vectors. We designed a specific set of primers to amplify wild type ChR2 to insert into the 
pPICZ(alpha) vector (Table 3).  
The cloning strategy was effective and the final construct was achieved, as shown by PCR 
screening and respective DNA sequencing (Figure 31). However, due to time constraints, the 
final construct was not linearized and electroporated in Pichia pastoris cells to perform a small-
scale screening.  Thus, it was not possible to confirm if wild type ChR2 was also successfully 
expressed in a secretory way. In the future, the completion of this experiment will make it 
possible to compare the inducible vs. constitutive vs. secretory expression of ChR2.   
 
 
 
Figure 30 – Cloning strategy for secretory expression of ChR2 wt. Illustration of final 
expected fragment from cloning strategy used to transfer ChR2 protein forms from pcDNA 3.1 vector to 
pPICZ(alpha) A. AOX1 promoter is presented in black, white arrow represents alpha-factor secretion signal, ChR2 
inserted sequence is presented in grey and 6x histidine Tag is presented in light grey. 
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Figure 31 – PCR screening and sequence results of ChR2 wt cloning into 
pPICZ(alpha) A vector. (a) PCR screening of ligation product of ChR2 wild type cloning into pPICZ(alpha) 
A vector. Expected band of ~700bp. Used primers on table 3 (Aox_fw and Aox_rev). (b) Alignment of sequencing 
results from positive colony 2. Aox _fw and Aox_rev primers were used to sequencing purposes. 
 
 
 
III.8 – Purification and determination of absorption spectra of 
new ChR2 variants 
 
 
The full and complete optimization of the protocol concerning wild type ChR2, 
described in the previous sections, led us to choose the pPICZ vector and the P. pastoris 
SMD1168H strain to express the four ChR2 mutants as well.  
After establishing the crucial issues and perform large-scale expression (Figure 28), the 
membrane fraction of each ChR2 mutant was isolated and ressuspended before proceeding to 
protein purification and subsequent determination of the absorption spectra.  
Despite the chromatography and absorption spectra of wild type ChR2 were performed 
in the wild type X-33 strain, here we took advantage of the new selected and optimized strain 
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(SMD1168H) of Pichia pastoris in order to improve the rate of expression and obtain higher 
levels of the protein (Govorunova et al., 2013). Also, we optimized the composition of the 
purification buffers and the final dialyzed buffer where purified ChR2 was when its absorption 
spectrum was determined. These optimizations are specific to each ChR2 mutant purification 
and spectral determination. We also aimed to perform a new purification and absorption 
spectra of wild type ChR2, in SMD1168H strain, as a new and accurate control in the same 
conditions as the protein mutants. 
 
 
III.8.1 – ChR2 F217D 
 
After obtaining the first valid results of the wild type ChR2 purification, we started by 
using the same strategy for the first mutant, the F217D. In particular, we used the same 
composition for the binding and elution buffers, and the same flow when injecting the protein 
extract into the 1ml HisTrap column (Bruun, 2013). However, this first attempt to purify the 
mutant protein was not successful and no purified ChR2 F217D protein was observable in any 
eluted fraction, when analysing silver staining gels (data not shown). Therefore, it was obvious 
that an optimization on this purification step was necessary. 
The concentration of glycerol had already been decreased to avoid excessive pressure 
on the column and it has been reported that increasing the concentration of salt and imidazole 
may reduce non-specific protein binding (Block et al., 2009; Bornhorst e Falke, 2000). We then 
decided to increase the concentration of NaCl from 0,2M to 0,3M and sodium phosphate from 
20mM to 50mM. However, we decided not to increase imidazole concentration but instead to 
decrease, from 10mM to 7,5mM. This decrease was included to free the column resin of 
imidazole and render it more available to bind ChR2, since there was poor protein binding. As 
such, these changes were established, the protein membrane fraction was solubilized and 
purification by nickel affinity chromatography was performed. To enable a slower and effective 
protein binding to the resin, we also decreased the flow on protein injection into the column, 
from 1mL/min to 0,5mL/min. Furthermore, from this point on, we started to pass the flow-
through a second time through the column.  
Analysis of the obtained chromatogram (Figure 32, a) and the eluted fractions (Figure 
32b) showed that the protein was successfully purified and eluted in the fractions corresponding 
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to the marked peak/increasing (250mM imidazole) of absorbance at 260nm and presented the 
characteristic double band patterns in the silver staining. Some contaminants, protein 
aggregation or endogenous protein from P.pastoris are seen in the silver staining gel, a natural 
occurring issue probably resulting from the necessary reduction in imidazole that, in an inverse 
way, increased non-specific protein binding. A size exclusion chromatography could be a 
solution to this issue as performed in other channelrhodopsin studies (Kato et al., 2012, 2015); 
however, the probability of these contaminants to interfere with the determination of the 
absorption spectra by presenting meaningful absorbance in the full range of the visible light 
spectrum is very small. In fact, this circumstance was confirmed in the following results. 
A positive sample, with successful purified ChR2 F217D, was also tested by western blot, 
before and after concentration of samples 19-22 (Figure 32 c,d). Once again, these results 
confirmed the successful purification of ChR2 F217D and the efficient concentration procedure, 
after which the protein absorption spectrum was measured. 
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Figure 32 – ChR2 F217D purification with nickel affinity chromatography. (a) ChR2 
F217D purification chromatogram. Absorbance at 260 nm is represented in blue, imidazole concentration in green, 
collected fractions in red and black arrow indicates positive eluted fractions.  (b) Silver staining of collected protein 
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samples from imidazole elution range. Two black arrows indicate positive samples for purified ChR2 F217D. Note: 
Black pattern across both gels are SDS-PAGE buffer contaminant and not specific contaminants from purification 
procedure. (c) Western-blot of ChR2 F217D positive and negative samples. FT is flow-through and W is wash. (d) 
Western blot of ChR2 F217D positive mixed samples after concentration. 1 and 2 represent first and second 
concentration, respectively. Mix represents all positive samples mixture before concentration; dil 3x is the mix 
sample diluted 3 times to reduce prejudicial imidazole; FTc, FTd and FTc2 are flow-through from first 
concentration, dialysis and second concentration, respectively. 
 
 
 
We observed a clear spectral absorbance of ChR2 F217D, with a noticeable red-shifted 
peak around 600 nm (Figure 33). Hence, observe that TDDFT prediction was confirmed, as this 
mutant presented a clear red-shifted comparing to the spectrum of wild type ChR2. This was 
the first step to a complete corroboration of TDDFT predictions and the characterization of 
our first ChR2 red-shifted mutant.  
We also observed that the final concentrated sample containing ChR2 F217D presented 
a very strong yellowish colour (Figure 33), which is an additional confirmation that ChR2 F217D 
was present in the sample. This has been previously shown by other groups as proof of a 
successfully ChR2 purification (Li, 2013).  
However, to achieve the most accurate absorption spectrum possible, we decided to 
investigate and test the final concentrated and dialysed buffer, where the protein was when the 
absorption spectra was measured. This decision was also based on the fact that, in short 
wavelengths measurements (from 300nm), protein absorption is highly saturated (Figure 33). 
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Figure 33 – UV-visible spectroscopy of purified ChR2 F217D. (a) Absorption spectra of 
purified ChR2 F217D in dodecyl maltoside solution at pH 7. (b) Absorption spectra of purified ChR2 wt in dodecyl 
maltoside solution at pH 7. 
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III.8.1.1 – Channelrhodopsin buffer test 
 
To study the influence of the final buffer on the absorption spectra output for all the 
ChR2 variants, we measured the absorption of different buffer compositions.  
The final buffer composition used so far contained sodium phosphate, NaCl, DDM, 
retinal, glycerol and PMSF. The imidazole was only present in the first spectrum for wild type 
ChR2. Based on the previously mentioned fact that imidazole affects spectral properties of 
ChR2 (Scholz et al., 2012), this component was removed for experiments concerning ChR2 
F217D as well as the remaining variants. 
There is a theoretical explanation for the initially saturated and high absorbance values 
and the strong yellowish color in the final purified, concentrated and dialyzed sample. DDM is a 
micelle-forming detergent that has been shown to maintain many membrane proteins in a stable 
state over prolonged periods of time (Gutmann et al., 2007) and is widely used to stabilize our 
protein (Bruun et al., 2011; Kato et al., 2012). It is known that DDM stabilizes ChR2, forming a 
protein-detergent complex with a micelle around the protein. The retinal is covalently linked to 
ChR2 structure, working as its chromophore, and in solution presents a yellow color. However,  
after observing high lower wavelength absorption we questioned if free retinal and free DDM, 
unbounded from protein, formed a similar micelle complex with each other. We hypothesize 
that the retinal-DDM complex would not able to pass through the Centricon membrane device, 
and thus concentrate with ChR2 and enhance the yellowish color and the saturated absorbance 
in the beginning of the spectrum. 
To test this, we measured the absorption spectrum of the final buffer, protein free, with 
four different compositions: final buffer without imidazole (Figure 34a), without imidazole and 
without retinal (Figure 34b), without imidazole and without DDM (Figure 34c) and finally 
without imidazole, without DDM and without retinal (Figure 34d). Each buffer composition was 
concentrated and the absorption spectra were measured before and after this process, with 
samples from non-concentrated buffer and from the centricon membrane and flow-through. 
In fact, when analyzing the output of this different absorption spectrum, it is possible to 
confirm that, in the buffer with retinal and DDM together (no imidazole, Figure 34a), there is a 
large peak of saturated absorbance around 350nm. This peak is initially present before 
concentration and it is even higher in the sample from the centricon membrane (the membrane 
turned yellow), contrarily to the flow-through sample where there is no peak anymore. These 
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results suggest that retinal in the presence of DDM is not able to pass through the membrane 
and was therefore concentrated. Additionally, none of the other buffers, when retinal and DDM 
were not mixed together, presented the same issue.  
Taken together, these results validate our hypothesis of a retinal-DDM complex that 
interferes with the protein absorption spectra in the 350-400 nm range.  
Thus, to achieve more accurate ChR2 absorptions spectra, we decided to remove retinal 
from the final buffer, since DDM can be considered to have a more crucial role as it stabilized 
ChR2. The retinal useful for ChR2 was already bound to the protein structure, with the free 
one being considered unessential. Consequently, for the rest of our experiments, the binding 
buffer added to the columns in protein purification was the last step where vitamin-A aldehyde 
was added. 
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Figure 34 – UV-visible spectroscopy of different candidates to final buffer to 
measure ChR2 absorption spectra. Each graphic presents samples from pre-concentration and after 
concentration (membrane and flow-through). (a) Absorption spectra of final buffer without imidazole (b) 
Absorption spectra of final buffer without imidazole and without retinal. (c) Absorption spectra of final buffer 
without imidazole and without DDM. (d) Absorption spectra of final buffer without imidazole, without retinal and 
without DDM. (e) Absorption spectra of all four final buffers in pre-concentration. All measurements were 
performed in solution at pH 7. 
 
 
 
III.8.2 – ChR2 wild type (2) 
 
A second set of identical experiments was performed to obtain new absorption spectra 
for wild type ChR2. Similarly to other channelrhodopsin studies, our protein of interest was 
purified again by nickel affinity chromatography (Govorunova et al., 2013; Kato et al., 2012, 
2015), concentrated and dialyzed (Berthold et al., 2008; Ernst et al., 2008; Kianianmomeni et al., 
2009; Ritter et al., 2008) to finally measure its absorption spectrum. These results were 
obtained after expression of wild type ChR2 in the Pichia pastoris SMD1168H strain, with the 
optimized buffers, as an additional and more accurate control to the absorption spectra of all 
E 
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the ChR2 mutants.  
The purification results are presented in wild type ChR2 (2) chromatogram (Figure 35a) 
and in silver staining of eluted fractions (Figure 35b). As in previously obtained purifications, the 
protein was eluted in fractions corresponding to the absorbance peak noticed in 250 mM 
imidazole elution.  
To confirm the presence of the purified protein (samples 21-23), before (Figure 35c) and 
after concentration (Figure 35d) we used western blot analysis. In both cases, the wild type 
ChR2 characteristic double band pattern was clearly visible (*even after 20 days at 4ºC), which 
validates the purification and concentration processes. 
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Figure 35 – ChR2 wt (2) purification with nickel affinity chromatography. (a) ChR2 wt 
purification chromatogram. Absorbance at 260 nm is represented in blue, imidazole concentration in green, 
collected fractions in red and black arrow indicates positive eluted fractions.  (b) Silver staining of collected protein 
samples from imidazole elution range. Black arrow indicates positive samples for purified ChR2 F217D. Note: Black 
pattern across the gel are SDS-PAGE buffer contaminant and not specific contaminants from purification 
procedure. (c) Western-blot of ChR2 wt positive and negative samples. FT is flow-through and W is wash. (d) 
Western blot of ChR2 F217D positive mixed samples after concentration. Mix represents all positive samples 
mixture before concentration; dil 3x is the mix sample diluted 3 times to reduce prejudicial imidazole; FTc, FTd and 
flow-through from concentration and dialysis, respectively. 
 
 
The absorption spectrum was determined and once again it was possible to see the 
absorption peak around 510 nm (Figure 36a), in line with the first absorption spectra of wild 
type ChR2 (510nm) and the known published peak (470nm) (Nagel et al., 2003). As previously 
mentioned and discussed, this difference in the peak is a result of pH variation (Ernst et al., 
2008; Scholz et al., 2012) (470nmà pH 7,5; 510nmà pH 7). 
A second valid and clear spectral absorbance of wild type ChR2 was also observed. This 
control was another step to further compare and complete validate TDDFT predictions.  
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Figure 36 – UV-visible spectroscopy of purified ChR2 wt (2). (a) Absorption spectra of 
purified ChR2 wt (2) in dodecyl maltoside solution at pH 7. (b) Absorption spectra of purified ChR2 wt in dodecyl 
maltoside solution at pH 7. 
 
 
III.8.3 – ChR2 F269D 
 
The second mutant we tested was ChR2 F269D. All experiments for this variant were 
done in parallel with the wild type ChR2 (2) control, with the exact same conditions. 
Concordant with the previous successful and validated outputs for wild type ChR2 (1 
and 2) and ChR2 F217D, the ChR2 F269D purification results are presented in the respective 
chromatogram (Figure 37a) and in silver staining of eluted fractions (Figure 37b). The protein 
was eluted in fractions corresponding to the noticed absorbance peak, but contrarily to the 
other purifications, elution of this mutant occurred in 100 mM imidazole elution. This fact is 
explained by the re-use of a 1mL HisTrap column (Bruun, 2013), which created a poorly binding 
of the protein to the resin. 
We also used western blot analysis to confirm the presence of the purified protein 
(samples 7-9), before (Figure 37c) and after concentration (Figure 37d). In both cases, the wild 
type ChR2 characteristic double band pattern was clearly visible, which corroborates the 
purification and concentration processes.  
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Figure 37 – ChR2 F269D purification with nickel affinity chromatography. (a) ChR2 
F269D purification chromatogram. Absorbance at 260 nm is represented in blue, imidazole concentration in green, 
collected fractions in red and black arrow indicates positive eluted fractions.  (b) Silver staining of collected protein 
samples from imidazole elution range. Black arrow indicates positive samples for purified ChR2 F269D. Note: Black 
pattern across the gel are SDS-PAGE buffer contaminant and not specific contaminants from purification 
procedure. (c) Western-blot of ChR2 wt positive and negative samples. FT is flow-through and W is wash. (d) 
Western blot of ChR2 F269D positive mixed samples after concentration. Mix represents all positive samples 
mixture before concentration; dil 3x is the mix sample diluted 3 times to reduce prejudicial imidazole; FTc, FTd and 
flow-through from concentration and dialysis, respectively. 
 
 
 
After determination of the ChR2 F269D absorption spectrum, it was possible to see a 
clear red shifted absorption peak around 600 nm (Figure 38a). Compared to the absorption 
C 
 
D 
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spectrum of the wild type protein (Figure 38b), this had a red-shift around 100 nm, similar to 
the previous validated ChR2 F217D. Both of these two novel red-shifted variants have their 
spectral peak close to the red-shifted variant Chrimson (Klapoetke et al., 2014). However, the 
kinetic parameters of Chrimson are undesirable when compared to ChR2 and it is also activated 
at 470nm on a fraction of its peak currents (Klapoetke et al., 2014). Consequently, our new red-
shifted variants, F217D and F269D will need characterization in neuronal tissue to evaluate their 
kinetic properties in comparison to published red-shifted variants. 
Taken together, these results support a second valid red-shifted ChR2 mutant, as 
predicted by TDDFT. This output was another crucial step towards the complete validation of 
the physics theory, and the creation of one more new desired variant of ChR2.  
 
 
 
 
Figure 38 – UV-visible spectroscopy of purified ChR2 F269D. (a) Absorption spectra of 
purified ChR2 F269D in dodecyl maltoside solution at pH 7. (b) Absorption spectra of purified ChR2 wt in dodecyl 
maltoside solution at pH 7. 
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III.8.4 – ChR2 L221D 
 
At this point we obtained successful absorption spectra of wild type ChR2 (two 
independent experiments), ChR2 F217D and ChR2 2F69. Hence, our strategy to achieve these 
outputs was successful. However, we aimed at achieving higher amounts of purified protein and 
clearer absorption spectra. Consequently, we decided to scale up our purification strategy, using 
new 5mL HisTrap columns (Bruun et al., 2015) instead of the 1mL columns. This way, we 
increased the binding surface with five times more available resin.  
The third mutant to be studied was ChR2 L221D and we applied the same strategy used 
so far, with the aforementioned change. The purification results are again presented in the 
respective chromatogram (Figure 39a) and in silver staining of eluted fractions (Figure 39b). The 
protein was eluted in fractions corresponding to the very noticed absorbance peak, in the 
elution gradient of imidazole 250mM. Analyses of the silver staining showed that, when using the 
5mL columns, the amount of purified protein was higher than all the previous ones, where 1mL 
columns were used. However, it is clear that the increased amount of purified protein was 
proportional to the increase of endogenous protein and contaminants, as shown by the visible 
unspecific bands in this ‘’dirtier’’ gel.  
In the silver staining gel it was possible to identify the same double band pattern, as in 
the previous western blots and staining, with some contaminants. However, due to the nature 
of the assays needed to be performed after the purification, the absorption spectra 
measurements, it was not necessary to execute any further optimization, since the chances that 
these contaminants present significant absorbance in the 300-800nm window is negligeble. This 
fact was confirmed in the following measurements of the absorption spectra. 
Positive purified samples were also confirmed by western blot (samples 23-25), before 
(Figure 39c) and after concentration (Figure 39d). In both cases, the wild type ChR2 
characteristic double band pattern was visible, corroborating the purification and concentration 
processes. In this particular case, the double band pattern was less visible than on the same test 
to the other ChR2 variants. We ascribe this discrepancy to deficient primary antibody 
incubation during western blot, regardless; this result will require future investigation. 
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Figure 39 – ChR2 L221D purification with nickel affinity chromatography. (a) ChR2 
L221D purification chromatogram. Absorbance at 260 nm is represented in blue, imidazole concentration in green, 
collected fractions in red and black arrow indicates positive eluted fractions.  (b) Silver staining of collected protein 
samples from imidazole elution range. Black arrow indicates positive samples for purified ChR2 L221D. Note: Black 
pattern across the gel are SDS-PAGE buffer contaminant and not specific contaminants from purification 
procedure. (c) Western-blot of ChR2 L221D positive and negative samples. FT is flow-through and W is wash. (d) 
Western blot of ChR2 L221D positive mixed samples after first and second concentration. Mix represents all 
positive samples mixture before concentration; dil 3x is the mix sample diluted 3 times to reduce prejudicial 
imidazole; FTc, FTd and flow-through from concentration and dialysis, respectively. 
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After measurement of the ChR2 L221D absorption spectrum, it was possible to observe 
the most significant red shift from all of the ChR2 mutants. This absorption peak was visible 
around 690 nm (Figure 40a), a 190 nm red shift when compared to the wild type protein (Figure 
40b). ChR2 L221D absorption peak is significantly more red-shifted than the characteristic peak 
in ReaChR, the most red-shifted available variant thus far (Lin et al., 2013). Furthermore, 
ReaChR spectral shift resulted from several known point mutations combined with swapping of 
different chimeras domains (Lin et al., 2013) . With these present results, we achieved a bigger 
red shift with an original single point mutation in the wild-type ChR2 sequence.   
We also note that the present shift is more accentuated and clear than the previous 
ones (leading to absorbance scale adjustment). This can be a consequence of the purification 
scale up, from 1mL to 5 mL column. However, the increased ‘’dirtiness’’ of the analyzed silver 
staining, and the fact that this was an output from the first time we used 5mL columns, led us to 
conclude that an optimization to these columns was needed. This optimization will be discussed 
in the next sections for the ChR2 mutant.  
Importantly, ChR2 L221D was the third red-shift variant of ChR2 created, and the one 
with the superior shift. Once again, this validates the TDDFT prediction 
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Figure 40 – UV-visible spectroscopy of purified ChR2 L221D. (a) Absorption spectra of 
purified ChR2 L221D in dodecyl maltoside solution at pH 7. (b) Absorption spectra of purified ChR2 wt in dodecyl 
maltoside solution at pH 7. 
 
 
III.8.5 – ChR2 F269H 
 
The fourth and last ChR2 mutant that we studied was ChR2 F269H. This specific 
mutation has the same target residue, phenylalanine (F) 269, as the previously validated red-
shifted ChR2 F269D. However, rather than substituting the non-polar target residue for a 
negative amino acid like aspartate (D), in this mutation the F269 is substituted by the positively 
charged amino acid histidine.  
The TDDFT theory predicts that this opposite rationale results into a blue-shifted ChR2. 
Hence, ChR2 F269H experiments were fundamental to completely validate the putative physics 
predictions that already demonstrate to be accurate with the three new and Ab-iniitio designed 
ChR2 red-shifted variants. 
Once again, we aimed at further achieving higher amounts of purified protein, to reach 
even clear abortion spectra. Accordingly, we maintained the previous scale up in our purification 
strategy, using new 5mL HisTrap column (Bruun et al., 2015) instead of the regular 1mL column. 
However, it became clear that we needed to optimize the use of 5mL columns to purify 
this protein. More precisely, we needed to reduce non-specific binding and increase the 
concentration of salts and imidazole, that are known to produce that desired effect (Block et al., 
2009; Bornhorst e Falke, 2000). The concentration of salts was already increased in the previous 
purifications but the imidazole concentration was reduced to enhance general binding. Thus, for 
this purification with five times scale-up, we increased the concentration of imidazole from 
7.5mM to 12,5mM. 
The ChR2 F269H purification results are displayed in the respective chromatogram 
(Figure 41a) and in silver staining of eluted fractions (Figure 41b). The protein was eluted in 
fractions corresponding to the elution step gradient of imidazole 250mM. An earlier peak in the 
elution step on 100 mM was observed, corresponding to unspecific protein, as demonstrated in 
silver staining (Figure 41b). The silver staining results turned it possible to see that, when using 
the 5mL columns, the amount of purified columns is in fact superior than all the past ones 
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where 1mL columns was used. In this case, the purification was more efficient than before, with 
strong and clear bands showing in the silver staining gel. The imidazole ratio balance should be 
optimized and settled depending on the used column volume and the binding capacity of our 
protein of interest.  
Hence, it was observed that the increasing imidazole concentration led to reduced non-
specific binding and we also settled the most optimized purification for the protein, with 5mL 
HisTrap columns with high concentration of salts (50mM sodium phosphate and 0,3M NaCl) 
and 12,5mM of imidazole.  
Positive purified samples were also confirmed in western blot (samples 23-25), before 
(Figure 41c) and after concentration (Figure 41d). In both cases, the wild type ChR2 
characteristic double band pattern was visible, corroborating the purification and concentration 
process. In this particular case, the double band pattern was again less visible than on the same 
test to the other ChR2 variants 
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Figure 41 – ChR2 F269H purification with nickel affinity chromatography. (a) ChR2 
F269H purification chromatogram. Absorbance at 260 nm is represented in blue, imidazole concentration in green, 
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collected fractions in red and black arrow indicates positive eluted fractions.  (b) Silver staining of collected protein 
samples from imidazole elution range. Black arrows indicate positive samples for purified ChR2 L221D. Note: Black 
pattern across the gel are SDS-PAGE buffer contaminant and not specific contaminants from purification 
procedure. (c) Western-blot of ChR2 F269H positive and negative samples. (d) Western blot of ChR2 F269H 
positive mixed samples after concentration. Mix represents all positive samples mixture before concentration; dil 
3x is the mix sample diluted 3 times to reduce prejudicial imidazole; FTc, FTd and flow-through from concentration 
and dialysis, respectively. 
 
 
After measurement of the ChR2 F269H absorption spectrum, it was possible to see the 
strongest and clearest peak so far, specifically in the blue light zone of the spectrum. ChR2 
F269H absorption peak was visible around 490 nm (Figure 42a), a 20 nm blue shift when 
compared to the wild type protein (Figure 42b).  
Interestingly, when mutating the non-polar F269 residue for a positive amino acid 
(histidine), it enables a blue shift on the ChR2 absorbance spectrum. Mutating the exact same 
residue for a negative charged amino acid (aspartate) leads to a very noticeable red shift 
absorption. These outputs validate TDDFT predictions as an original and noteworthy rationale 
to apply to ChR2 sequence in the creation of novel desirable mutations. Furthermore, our new 
variants, ChR2 F269D and F269H, have the potential to form a pair of ChR2 that have non-
overlapping absorption spectrum, for optical excitation of distinct neural populations. This 
specific goal was already achieved by expressing both Chronos and Chrimson, two red-shifted 
channelrhodopsins, in mouse brain slice (Klapoetke et al., 2014). These two actuators present a 
gap of 90nm between its respective absorption spectra (Klapoetke et al., 2014), while our new 
variants ChR2 F269D and F269H display an absorption difference of 110nm between each 
other. Consequently, these results highlight the potential of our novel ChR2 variants. This 
potential can be further increased it if we consider ChR2 L221D to form pair with ChR2 F269H, 
resulting in an interesting absorption difference of 200nm. 
For ChR2 L221D, the accentuated absorbance peak was now proved to be a 
consequence of the purification scale up, from 1mL to 5 mL column. These results also 
corroborate the efficacy of increasing the imidazole concentration in the purification process, 
leading to more purified protein with less contaminants and non-specifying binding. The 
optimization used in this respective mutant was the most suitable for our goal of attaining clear 
and accurate ChR2 absorption spectra. 
Finally, ChR2 F269H was the fourth and last variant of ChR2 created and the first blue 
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shift protein. This was a crucial result since it fully and extensively validates the TDDFT 
predictions, and supported the possibility of creating red and blue shifted variants of ChR2. We 
successfully designed and produced three red-shifted and one blue-shifted new ChR2 variants. 
 
 
 
 
 
 
 
Figure 42 – UV-visible spectroscopy of purified ChR2 F269H. (a) Absorption spectra of 
purified ChR2 F269H in dodecyl maltoside solution at pH 7. (b) Absorption spectra of purified ChR2 wt in dodecyl 
maltoside solution at pH 7. 
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III.9 – Ab-initio designed new ChR2 optogenetic toolbox 
 
In this project, we successfully designed and created four new ChR2 variants: ChR2 
L221D, ChR2 F217D, ChR2 F269D and ChR2 F269H. We next normalized the absorption 
spectra of all these proteins and plotted them together in the same graphic (Figure 43). 
 
 
 
Figure 43 – UV-visible spectroscopy of purified new ChR2 optogenetic toolbox. 
Absorption spectra of four purified ChR2 new variants in dodecyl maltoside solution at pH 7. All measured 
absorbance values were normalized. 
 
 
We were able to produce three red-shifted variants and one blue-shifted protein. Our 
wild type protein absorption peak was established at 510 nm, at pH 7.  
The ChR2 F269D and F217D mutants present their own peaks at 600nm, consequently 
presenting very substantial red shift absorption of 90 nm. Both these variants presented even 
higher red shift output than the shifts predicted by TDDFT. Particularly, the F269D mutation 
resulted in an increased shift of 40nm relatively to TDDFT predictions, 90nm vs. 50nm, 
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respectively. The ChR2 F217D was predicted to induce a significant shift of 60nm, 30nm less 
than our scrutinized outputs of 90nm shift. 
The substitution of the non-polar leucine residue 221 by the negative charged aspartate 
turned ChR2 L221D in our highest red-shifted variant, with a characteristic absorption peak at 
690nm. This variant grants a shift of 180 nm when compared to the wild type ChR2, rendering 
ChR2 L221D the protein with the biggest potential to achieve desirable red-shifted absorptions, 
higher than any published variant so far. Once again, the TDDFT prediction was smaller than the 
final output, 45nm and 180nm respectively. 
The ChR2 L221D 180nm red shift is higher than the two most red-shifted depolarizing 
variants so far, Chrimson (Klapoetke et al., 2014) and ReaChR (Lin et al., 2013), with 120nm and 
160nm, respectively.  
Wild type ChR2 has a small single-channel conductance and is optimally excitable at a 
wavelength of 470 nm, naturally not extended over 520 nm, limiting in this way its use in high-
light scattering medium as the brain (Hegemann e Möglich, 2011). Long-wavelength excitation 
light decreases the scatter produced by biological tissues and it will avoid the absorption by 
haemoglobin. The more red-shifted channelrhodopsins absorbing red or even near infra-red 
light would be more desirable for relatively deep tissue penetration. Hence, our three new 
ChR2 red-shifted variants can be good candidates to solve this issue. 
Finally, the fourth mutant we created presents an absorption peak at 490nm. Hence, 
F269H displays a 20nm blue shifted variance respectively to wild type ChR2. The theoretical 
physics output predicted a shift of 30nm, against our experimental 20nm shift. ChR2 F269H is 
just less 5nm than the biggest channelrhodopsin blue shift published so far (Govorunova et al., 
2013).  
The ChR2 F269H blue-shift variant can be interesting to use in combination with red 
shifted variants, leading to the separation of the maxima peaks of the two mutants. This will 
generate two distinct peaks of absorption and avoid the overlapping of neuronal activation. This 
can enhance the possibility of a distinct activation of two ChR2 mutants with different light, and 
if expressed in two different classes of neurons, it will result in the distinct excitation of specific 
types of neurons. Particularly, this combination brings the possibility of controlling a defined 
subset of cells intermixed in the multitudes of neuronal tissue, as already exhibited through the 
combination of ChR2 and NpHR, activated with blue and yellow light, respectively (Zhang et al., 
2007). However, this published approach led to parallel depolarization and hyperpolarization 
(NpHR). As such, we propose that an optogenetic approach using a pair of mutants obtained in 
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our work, for instance ChR2 F269H and L221D, would enhance the possibility of depolarizing 
two different populations of neurons with non-overlapping (Klapoetke et al., 2014) blue and red 
lights, respectively. This possible application may show great interest in optogenetics, based on 
the inexistence of protein variants with distinct absorption spectrum. 
There is still room for improvement and optimization for future experiments, such as 
the study of the effect of pH in the absorption spectra of the proteins we obtained, as 
performed in a similar study (Scholz et al., 2012). It is also possible to increase the number of 
outputs to enhance the accuracy of the protein characterization, in a more sensible 
spectrophotometer. 
Although we designed single mutations, it would be interesting to combine modifications 
and produce a double mutant with a potential synergistic effect. This approach could achieve 
even bigger shifts than the outputs resulting from single mutations.  
TDDFT rationale has full and wide applicability to produce new variants of ChR2, the 
main protein used in optogenetics and potentially other optogenetic proteins such as Halo or 
ArchT. The basis for the four new ChR2 variants could also result in a method to generate, on 
demand, a platform of colour-tuned ChR2 and other rhodopsin mutants with scientific and 
biomedical applications. A creation of a viral vector encoding the created variants for animal 
delivery could also be a following step. 
We successfully completed protein production and purification, as well as the initial and 
crucial biophysical characterization of the engineered mutants. However, an enhanced study of 
the new proteins is still required, such as the analysis of the kinetic properties of the channel 
using electrophysiology experiments and protein membrane trafficking in neurons. 
In fact, we have already started experiments concerning membrane trafficking in cortical 
neurons transfected with the four proteins cloned into a mammalian vector fused with YFP 
(intracellularly on the protein c-terminal).  
With the approach of changing non-polar residues by polar ones in the retinal 
environment, the colour-tuned mutations could affect the kinetics properties of the ChR2 
channel. Hence, the determination of the functional properties of these mutations is crucial, as it 
is known that, concerning depolarizing tools, there is a tradeoff between kinetics and peak 
activation (Berndt et al., 2011; Mattis et al., 2012; Pan et al., 2014) . Besides, this fact it is still not 
fully understood and explained, as there is a noted deficiency of depolarizing optogenetics tools 
with fast kinetics and red-shifted absorption.  
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The present study revealed that biophysical and biomolecular simulation predictions, 
based on Time-dependent Density Functional theory, accomplished accurate creation of novel 
ChR2 variants. This specific protein design and rationale can be a powerful and reliable approach 
to engineer several biotechnological protein tools that compel detailed control of the protein 
molecular structure by mutations. Our original and final outputs presented in this thesis show 
high potential for future optogenetic application. 
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Chapter IV – Conclusions and Future 
Perspectives  
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Channelrhodopsin-2 is a light-gated cation channel initially isolated from the microalgae 
Chlamydomonas reinhardtii. For the last decade, ChR2 has become the central paradigm of 
optogenetics and its main tool, with wide biomedical and neuroscience applications.  
The relevance of ChR2 in neuroscience arose from discorering that its heterologous 
expression in mammalian brain allows a millisecond precise and selective control of specific 
genetically targeted neurons, without the need to add exogenous factors. Hence, the 
optogenetics technique allowed that, for the first time, it is conceivable to depolarize and/or 
hyperpolarize a specific group of neural cells to map and study the brain complexity, with a 
breakthrough efficacy.  
With honours like “method of the year” and “breakthrough of the decade,” it’s 
comfortable to assume that optogenetics, and its ability for turning neurons on and off using 
light, is indeed, a game-changing technology.  
The optogenetic toolbox is being under continuous development, based on protein 
engineering with strategies as site-directed mutagenesis and chimeras construction with domain 
swapping between different channelrhodopsin species. However, there are still opportunities for 
further enhancements in channelrhodopsin action.  
Despite the broad application and development of optogenetics and ChR2, there are still 
some limitations precluding the required effect of channelrhodopsin in the depolarization of 
neurons, such as unsuitable kinetics, low expression levels, rapid inactivation, small conductance 
and undesired absorption peak light sensitivity. In fact, in terms of spectral properties, few 
variants were successfully generated and fully characterized.  
In this present work, based on biophysical computational theory predictions, we 
established the successful creation of color-tuned variants of ChR2, by radical directed-site 
mutagenesis on target residues on the electrostatic environment of the protein chromophore. 
Four new mutants were effectively Ab-initio designed, produced and characterized. We 
originally created three red-shifted variants. F217D and F269D were characterized with a 90nm 
red-shifted absorption peak, relatively to the wild type protein. L221D protein presents even a 
higher red-shifter, of 180nm. We were also proficient to create a fourth new variant, F269H, a 
20nm blue-shifted ChR2.  
Although we designed single mutations and achieved very significant shifts, it is possible 
to try the use of combined modifications and challenge to produce a double mutant with a 
potential synergistic effect between. This approach could achieve even bigger shifts than the 
outputs from single mutations. 
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To achieve our final fruitful outputs, we completed a series of molecular biology 
designed constructs, in both mammalian and yeast suitable vectors. Furthermore, we entirely 
settled and optimized the laboratory production of recombinant protein in the heterologous 
system of Pichia pastoris. More precisely, we were able to generate ChR2 by inducible and 
constitutive expression in two different strains, X-33 and SMD1168H. We selected and defined 
the combination of inducible expression in SMD1168H strain as the one with higher yields of 
ChR2. Molecular constructs aimed at secretory expression were also completed, but required 
experimental investigation.  
Protein purification by nickel affinity chromatography was also achieved and continuously 
optimized, in both 1 mL and scale-up 5 mL columns. Protein concentration and spectral 
characterization of all ChR2 variants and wild type was also fully achieved.  The study of pH 
effect on our proteins absorption spectra is a future optimization process. It can also be 
possible to increase the number of wavelength points to enhance the accuracy of the protein 
characterization, using a more sensitive spectrophotometer. 
The electrophysiological characterization of our new proteins is the following step of this 
project. This characterization includes analysis of the kinetic properties of the channel and the 
efficacy of protein trafficking in neurons. A creation of a viral vector encoding our created 
mutants for in vivo delivering could also be a next step. 
The functional purification and spectroscopic characterization of our four novel ChR2 
variants we report on this dissertation signifies a significant step towards a detailed structural 
and functional exploration of ChR2. 
Concluding, we were able to produce a successful colour tuning of ChR2, to create four 
new desired ChR2 mutants and validate theoretical TDDFT predictions. The continuous study 
of our proteins will be essential for its development and potential optogenetic implementation. 
 The present study open the prospect of tailoring channelrhodopsins for biomedical and 
neuroscience applications, based on biophysical and biomolecular simulation predictions, based 
on Time-dependent Density Functional theory. The creation of intelligently designed ChR2 
variants using protein design can be a consistent method to engineer other numerous 
biotechnological proteins, based on a reliable control of the protein molecular structure.  
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